;indicatorAnalyzingName;missingDatasPercent;ig
0;Ambient air pollution  attributable DALYs per 100'000 children under 5 years;0.0;
1;Household air pollution attributable deaths-Both sexes;20.0;0.8500382123485997
2;Household air pollution attributable deaths-Male;20.0;0.8500382123485997
3;Household air pollution attributable deaths-Female;20.0;0.8500382123485997
4;Household air pollution attributable deaths;20.0;-9767.385363438818
5;Household air pollution attributable deaths in children under 5 years-Both sexes;20.0;0.18073896689988977
6;Household air pollution attributable deaths in children under 5 years-Male;20.0;0.18073896689988977
7;Household air pollution attributable deaths in children under 5 years-Female;20.0;0.18073896689988977
8;Household air pollution attributable deaths in children under 5 years;20.0;-9767.385363438818
9;Household air pollution attributable deaths per 100'000 capita;0.0;
10;Household air pollution  attributable deaths per 100'000 children under 5 years;0.0;
11;Household air pollution attributable DALYs-Both sexes;20.0;0.9510208778942935
12;Household air pollution attributable DALYs-Female;20.0;0.9510208778942935
13;Household air pollution attributable DALYs-Male;20.0;0.8500382123485997
14;Household air pollution attributable DALYs;20.0;-9767.385363438816
15;Household air pollution attributable DALYs in children under 5 years-Female;20.0;0.18073896689988977
16;Household air pollution attributable DALYs in children under 5 years-Both sexes;20.0;0.18073896689988977
17;Household air pollution attributable DALYs in children under 5 years-Male;20.0;0.18073896689988977
18;Household air pollution attributable DALYs in children under 5 years;20.0;-9767.385363438816
19;Household air pollution attributable DALYs (per 100 000 population)-Both sexes;20.0;0.9510208778942935
20;Household air pollution attributable DALYs (per 100 000 population)-Female;20.0;0.9510208778942935
21;Household air pollution attributable DALYs (per 100 000 population)-Male;20.0;0.8500382123485997
22;Household air pollution attributable DALYs (per 100 000 population);20.0;-9767.385363438818
23;Household air pollution  attributable DALYs per 100'000 children under 5 years;0.0;
24;Household air pollution attributable DALYs (per 100 000, age-standardized)-Female;20.0;0.9510208778942935
25;Household air pollution attributable DALYs (per 100 000, age-standardized)-Male;20.0;0.8500382123485997
26;Household air pollution attributable DALYs (per 100 000, age-standardized)-Both sexes;20.0;0.9510208778942935
27;Household air pollution attributable DALYs (per 100 000, age-standardized);20.0;-9767.385363438818
28;Ambient air pollution attributable deaths in children under 5 years-Both sexes;18.66666666666667;0.18682458066441443
29;Ambient air pollution attributable deaths in children under 5 years-Male;18.66666666666667;0.18682458066441443
30;Ambient air pollution attributable deaths in children under 5 years-Female;18.66666666666667;0.18682458066441443
31;Ambient air pollution attributable deaths in children under 5 years;18.66666666666667;-9757.285138704374
32;Ambient air pollution attributable deaths-Female;18.66666666666667;0.8770888482281727
33;Ambient air pollution attributable deaths-Male;18.66666666666667;0.8770888482281727
34;Ambient air pollution attributable deaths-Both sexes;18.66666666666667;0.8770888482281727
35;Ambient air pollution attributable deaths;18.66666666666667;-9757.285138704374
36;Ambient air pollution attributable death rate (per 100 000 population, age-standardized)-Male;18.66666666666667;0.8770888482281727
37;Ambient air pollution attributable death rate (per 100 000 population, age-standardized)-Female;18.66666666666667;0.8770888482281727
38;Ambient air pollution attributable death rate (per 100 000 population, age-standardized)-Both sexes;18.66666666666667;0.8770888482281727
39;Ambient air pollution attributable death rate (per 100 000 population, age-standardized);18.66666666666667;-9757.285138704374
40;Ambient air pollution attributable DALYs-Both sexes;13.777777777777771;1.4773312010965283
41;Ambient air pollution attributable DALYs-Male;13.777777777777771;1.512225172039832
42;Ambient air pollution attributable DALYs-Female;13.777777777777771;1.4773312010965283
43;Ambient air pollution attributable DALYs;13.777777777777771;-8777.582707465433
44;DALYs attributable to ambient air pollution (age-standardized);13.777777777777771;-9730.299526273535
45;Ambient air pollution attributable YLLs-Male;18.66666666666667;0.8770888482281727
46;Ambient air pollution attributable YLLs-Female;18.66666666666667;0.8770888482281727
47;Ambient air pollution attributable YLLs-Both sexes;18.66666666666667;0.8770888482281727
48;Ambient air pollution attributable YLLs;18.66666666666667;-9757.285138704374
49;Ambient air pollution attributable death rate (per 100 000 population)-Female;18.66666666666667;0.8770888482281727
50;Ambient air pollution attributable death rate (per 100 000 population)-Male;18.66666666666667;0.8770888482281727
51;Ambient air pollution attributable death rate (per 100 000 population)-Both sexes;18.66666666666667;0.8770888482281727
52;Ambient air pollution attributable death rate (per 100 000 population);18.66666666666667;-9757.285138704374
53;Ambient air pollution attributable deaths (per 100 000 population, age-standardized);18.222222222222214;-9730.299526273535
54;Household air pollution attributable death rate (per 100 000 population)-Female;20.0;0.8500382123485997
55;Household air pollution attributable death rate (per 100 000 population)-Male;20.0;0.8500382123485997
56;Household air pollution attributable death rate (per 100 000 population)-Both sexes;20.0;0.8500382123485997
57;Household air pollution attributable death rate (per 100 000 population);20.0;-9767.385363438818
58;Household air pollution attributable death rate (per 100 000 population, age-standardized)-Female;20.0;0.8500382123485997
59;Household air pollution attributable death rate (per 100 000 population, age-standardized)-Both sexes;20.0;0.8500382123485997
60;Household air pollution attributable death rate (per 100 000 population, age-standardized)-Male;20.0;0.8500382123485997
61;Household air pollution attributable death rate (per 100 000 population, age-standardized);20.0;-9767.385363438818
62;Ambient air pollution  attributable deaths per 100'000 children under 5 years;0.0;
63;Ambient air pollution attributable DALYs-Both sexes;13.777777777777771;1.4773312010965283
64;Ambient air pollution attributable DALYs-Male;13.777777777777771;1.512225172039832
65;Ambient air pollution attributable DALYs-Female;13.777777777777771;1.4773312010965283
66;Ambient air pollution attributable DALYs;13.777777777777771;-8777.582707465433
67;Ambient air pollution attributable DALYs  in children under 5 years-Male;18.66666666666667;0.18682458066441443
68;Ambient air pollution attributable DALYs  in children under 5 years-Both sexes;18.66666666666667;0.18682458066441443
69;Ambient air pollution attributable DALYs  in children under 5 years-Female;18.66666666666667;0.18682458066441443
70;Ambient air pollution attributable DALYs  in children under 5 years;18.66666666666667;-9757.285138704374
71;Ambient air pollution attributable DALYs  (per 100 000 population)-Female;13.777777777777771;0.8582652965045132
72;Ambient air pollution attributable DALYs  (per 100 000 population)-Male;13.777777777777771;0.8770888482281727
73;Ambient air pollution attributable DALYs  (per 100 000 population)-Both sexes;13.777777777777771;0.8582652965045132
74;Ambient air pollution attributable DALYs  (per 100 000 population);13.777777777777771;-9757.285138704374
75;Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized)-Female;13.777777777777771;0.8582652965045132
76;Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized)-Male;13.777777777777771;0.8770888482281727
77;Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized)-Both sexes;13.777777777777771;0.8582652965045132
78;Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized);13.777777777777771;-9757.285138704374
79;Functioning national AMR surveillance plan;0.0;
80;Establishment of National Coordination Centre (NCC);0.0;
81;Nomination of National Focal Point (NFP);0.0;
82;Establishment of national reference laboratory (NRL);0.0;
83;EQA provided to the national reference laboratory (NRL);0.0;
84;EQA provided for bacterial identification and AST;0.0;
85;EQA provided to local laboratories participating in GLASS;0.0;
86;GLASS pathogens testing covered by EQA;0.0;
87;Types of AST standards followed by countries;0.0;
88;Number of national surveillance sites in each country providing data to GLASS: hospital category;0.0;
89;Number of National surveillance sites in each country providing data to GLASS: outpatient facility category;0.0;
90;Number of local clinical laboratories in each country performing AST to support national AMR surveillance sites;0.0;
91;Antenatal care coverage - at least one visit (in the two or three years preceding the survey) (%;49.77777777777778;-8286.17213964863
92;Antenatal care coverage - at least one visit (in the five years preceding the survey) (%);67.55555555555556;-9207.171570210921
93;Antenatal care coverage - at least four visits (in the two or three years preceding the survey) (%);50.666666666666664;-8469.075375883307
94;Antenatal care coverage - at least four visits (in the five years preceding the survey) (%);65.77777777777777;-9175.812910017055
95;Adolescent fertility rate (per 1000 women aged 15-19 years);59.11111111111111;-8813.14565350725
96;Prevalence of met need of assistive products (%)-Male;90.22222222222223;0.004986605785878062
97;Prevalence of met need of assistive products (%)-nan;90.22222222222223;0
98;Prevalence of met need of assistive products (%)-Female;90.22222222222223;0.004986605785878062
99;Prevalence of met need of assistive products (%)-Both sexes;90.22222222222223;0.004986605785878062
100;Prevalence of met need of assistive products (%);90.22222222222223;-10748.371323297852
101;Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate)-Male;15.555555555555557;1.520255863707316
102;Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate)-Female;15.555555555555557;1.474171827729052
103;Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate)-Both sexes;15.555555555555557;1.4733186674237797
104;Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate);15.555555555555557;-628.2890663814575
105;Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate)-Male;15.555555555555557;1.4647537631423608
106;Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate)-Female;15.555555555555557;1.5722774453141741
107;Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate)-Both sexes;15.555555555555557;1.4738787569251812
108;Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate);15.555555555555557;-628.2677114229327
109;Mean systolic blood pressure (crude estimate)-Male;20.0;1.0495958158064038
110;Mean systolic blood pressure (crude estimate)-Female;20.0;1.0970562103986188
111;Mean systolic blood pressure (crude estimate);20.0;-2939.9633848518683
112;Mean systolic blood pressure (age-standardized estimate)-Male;15.555555555555557;1.398691732418916
113;Mean systolic blood pressure (age-standardized estimate)-Female;15.555555555555557;1.491239660618695
114;Mean systolic blood pressure (age-standardized estimate);15.555555555555557;-628.519922843003
115;Process evaluation was employed to assess implementation;0.0;
116;Formative research was conducted;0.0;
117;Outcome evaluation was employed to assess effectiveness;0.0;
118;Campaign was part of a comprehensive tobacco control programme;0.0;
119;Campaign was pre-tested;0.0;
120;Campaign utilized media planning;0.0;
121;At least one national mass media campaign ran during the survey period;0.0;
122;Earned media/public relations were used to promote the campaign;0.0;
123;Campaign aired on television and/or radio;0.0;
124;Children aged < 5 years with pneumonia symptoms taken to a health facility (%)-nan;53.333333333333336;0
125;Children aged < 5 years with pneumonia symptoms taken to a health facility (%)-Female;53.333333333333336;0.4008771648048257
126;Children aged < 5 years with pneumonia symptoms taken to a health facility (%)-Male;53.333333333333336;0.40263665456069786
127;Children aged < 5 years with pneumonia symptoms taken to a health facility (%);53.333333333333336;-8785.863650588191
128;Congenital syphilis number of reported cases;0.0;
129;Cataract surgical coverage of adults aged 50 and over (%)-Male;84.88888888888889;0.04574597608151221
130;Cataract surgical coverage of adults aged 50 and over (%)-Both sexes;84.88888888888889;0.04956939097053814
131;Cataract surgical coverage of adults aged 50 and over (%)-Female;84.88888888888889;0.04836696964036502
132;Cataract surgical coverage of adults aged 50 and over (%);84.88888888888889;-10493.88307497098
133;Effective cataract surgical coverage of adults aged 50 and over (%)-Both sexes;86.66666666666667;0.043343609509503
134;Effective cataract surgical coverage of adults aged 50 and over (%)-Male;86.66666666666667;0.041129663654616344
135;Effective cataract surgical coverage of adults aged 50 and over (%)-Female;86.66666666666667;0.043534506314962584
136;Effective cataract surgical coverage of adults aged 50 and over (%);86.66666666666667;-10525.756672180662
137;Climate change attributable deaths;0.0;
138;Climate change attributable DALYs ('000);0.0;
139;Climate change attributable deaths per 100'000 capita;0.0;
140;Climate change attributable DALYs per 100'000 capita;0.0;
141;Climate change attributable deaths ('000) in children under 5 years;0.0;
142;Climate change  attributable deaths per 100'000 children under 5 years;0.0;
143;Climate change attributable DALYs ('000) in children under 5 years;0.0;
144;Climate change  attributable DALYs per 100'000 children under 5 years;0.0;
145;Composite coverage index (%);56.888888888888886;-8725.572697911777
146;Composite coverage index (%);56.888888888888886;-8725.572697911777
147;Poverty headcount ratio at $1.25 a day (PPP) (% of population);53.333333333333336;-10018.077298399965
148;Human development index rank;17.777777777777786;-8789.567406928027
149;Gender inequality index rank;30.666666666666657;-9034.73931431694
150;Mortality rate for 5-14 year-olds (probability of dying per 1000 children aged 5-14 years);13.333333333333329;-15.690730251534664
151;Number of reported cases of cholera;68.44444444444444;-9274.107667111413
152;Number of reported deaths from cholera;0.0;
153;Cholera case fatality rate;68.44444444444444;-9308.784555413851
154;Contraceptive prevalence - modern and traditional methods (%);49.77777777777778;-8275.768429050515
155;Births by caesarean section (in the two or three years preceding the survey) (%);50.22222222222222;-8524.591796966588
156;Births by caesarean section (in the five years preceding the survey) (%);65.77777777777777;-9195.396231868564
157;Total density per 100 000 population: Hospitals;39.11111111111111;-10053.677697683906
158;Total density per 100 000 population: Health posts;50.666666666666664;-9575.933526324796
159;Total density per 100 000 population: Health centres;50.22222222222222;-9575.174393173873
160;Total density per 100 000 population: District/rural hospitals;44.44444444444444;-9426.86626495054
161;Total density per 100 000 population: Provincial hospitals;43.111111111111114;-9480.094024065666
162;Total density per 100 000 population: Specialized hospitals;43.111111111111114;-9439.170874059982
163;Availability of national standards or recommended lists of medical devices;28.888888888888886;-9902.151023863555
164;Existence of dementia training for legal professionals;0.0;
165;Types of lists recommending health technology for high burden diseases;29.33333333333333;-9922.496991335342
166;Total density per million population: Magnetic Resonance Imaging;40.888888888888886;-9384.814177858669
167;Total density per million population: Computed tomography units;39.55555555555556;-9313.404212302396
168;Total density per million population: Positron Emission tomography;47.55555555555555;-9547.880997951126
169;Total density per million population: Gamma camera or Nuclear medicine;47.111111111111114;-9504.146351934063
170;Total density per million population: Linear Accelerator;24.0;-9047.89650963228
171;Type of nomenclature system;28.0;-9888.626040399899
172;Use of nomenclature system;87.11111111111111;-10616.305158998483
173;Health technology (medical device) national policy;25.77777777777777;-9858.620153457248
174;Unit in the Ministry of Health responsible for the management of medical devices;26.22222222222223;-9864.47241033036
175;Procurement of medical devices carried out at the national level;27.555555555555557;-9884.916229271237
176;Availability of national list of approved medical devices for procurement or reimbursement;26.22222222222223;-9864.47241033036
177;National guidelines, policies or recommendations on the procurement of medical devices;27.555555555555557;-9893.108028421757
178;Availability of technical specifications of medical devices to support procurement or donations;28.444444444444457;-9897.059833062702
179;Total density per million population: Telecobalt Unit;24.0;-9058.638956750607
180;Total density per million population: Radiotherapy units;23.111111111111114;-9005.57287059911
181;Total density per million females aged from 50 to 69 years old: Mammography units;44.888888888888886;-9454.933494325196
182;Enforcing bans on tobacco advertising, promotion and sponsorship;13.333333333333329;-4713.288996464848
183;Compliance of ban on advertising on national TV and radio;42.22222222222223;-10100.934324500462
184;Ban on advertising: National TV and radio;0.0;
185;Compliance of ban on promotional discounts;63.55555555555556;-10350.915641663632
186;Ban on promotional discounts;0.0;
187;Ban on non-tobacco goods AND services identified with tobacco brand names;0.0;
188;Compliance of ban on non-tobacco goods AND services identified with tobacco brand names;68.44444444444444;-10403.286730970169
189;Ban on brand name of non-tobacco products used for tobacco product;0.0;
190;Compliance of ban on brand name of non-tobacco products used for tobacco product;77.77777777777777;-10487.249043637046
191;Ban on appearance of tobacco brands in TV and/or films (product placement);0.0;
192;Compliance of ban on appearance of tobacco brands in TV and/or films (product placement);58.666666666666664;-10312.315312968603
193;Compliance of ban on appearance of tobacco products in TV and/or films;87.11111111111111;-10587.452586843023
194;Appearance of tobacco products in TV and/or films;0.0;
195;Ban on appearance of tobacco products in TV and/or films;0.0;
196;Requirement to present prescribed anti-tobacco ads before, during or after the broadcasting or showing of any visual entertainment media product that depicts tobacco products, use or images;0.0;
197;Compliance of ban on sponsored events;67.55555555555556;-10403.207726262199
198;Sponsored events;0.0;
199;Complete ban on sponsorship;0.0;
200;Ban on any form of contribution (financial or other support) to any event, activity or individual;0.0;
201;Banning the publicity of financial or other sponsorship or support by the tobacco industry of events, activities, individuals;0.0;
202;Ban on tobacco companies/tobacco industry publicizing their “Corporate Social Responsibility” activities;0.0;
203;Ban on entities other than tobacco companies/tobacco industry publicizing the Corporate Social Responsibility activities of the tobacco companies;0.0;
204;Ban on tobacco companies funding or making contributions (including in-kind contributions) to smoking prevention media campaigns, including those directed at youth;0.0;
205;Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images;0.0;
206;Ban on advertising: International TV and radio (broadcast from abroad, including satellite);0.0;
207;Complete ban on tobacco vending machines;0.0;
208;Subnational bans on tobacco advertising, promotion and sponsorship;0.0;
209;Subnational advertising, promotion and sponsorship bans - at least one jurisdiction has a comprehensive ban in place;0.0;
210;Ban on internet sales of tobacco products;0.0;
211;Ban on display of tobacco products at points of sale;0.0;
212;Law requires fines for violations of direct advertising bans;0.0;
213;Law requires fines for violations of indirect advertising bans;0.0;
214;Compliance of ban on advertising on local magazines and newspapers;46.22222222222222;-10158.31933485373
215;Ban on advertising: Local magazines and newspapers;0.0;
216;Existence of dementia training for community workers;0.0;
217;Ban on advertising: International magazines and newspapers;0.0;
218;Ban on advertising: Billboards and outdoor advertising;0.0;
219;Compliance of ban on advertising on billboards and outdoor advertising;48.0;-10172.817719400347
220;Compliance of ban on advertising at point of sale;72.44444444444444;-10433.747495210822
221;Ban on advertising: Point of sale;0.0;
222;Ban on display of tobacco products at points of sale;0.0;
223;Ban on advertising: Internet;0.0;
224;Compliance of ban on free distribution of tobacco products in the mail or through other means;56.888888888888886;-10269.252678900886
225;Ban on free distribution of tobacco products in the mail or through other means;0.0;
226;Compliance with bans on direct advertising;33.33333333333334;-8693.354165571316
227;Compliance with bans on promotion and sponsorship;39.11111111111111;-8925.308472151717
228;Electric field (kV/m);0.0;
229;Electric field (kV/m);0.0;
230;Electric field (V/m);0.0;
231;Magnetic flux density (microT);0.0;
232;Power density (W/m^2);0.0;
233;Power frequency (Hz);0.0;
234;Specific absorption rate (SAR) (W/kg);0.0;
235;Existence of standards;0.0;
236;Legislative status;0.0;
237;Availability of estimates on large  health expenditures as a share of total expenditure or income;42.666666666666664;-8565.983812422857
238;Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, estimated data) (millions);0.0;
239;Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, estimated data) (%);0.0;
240;Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, reported data) (%);30.222222222222214;-6916.724415567458
241;Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, estimated data) (millions);0.0;
242;Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, estimated data) (%);0.0;
243;Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, reported data) (%);30.666666666666657;-6921.004347791601
244;Total population  pushed below the $1.90 a day  poverty line by household  health expenditures (millions);0.0;
245;Total population  pushed below the $1.90 a day  poverty line by household  health expenditures (%);0.0;
246;Total population  pushed below the $3.10 a day  poverty line by household  health expenditures (millions);0.0;
247;Total population  pushed below the $3.10 a day  poverty line by household  health expenditures (%);0.0;
248;Population  pushed below the $1.90 a day  poverty line by household  health expenditures (%);34.66666666666667;-7101.675614978564
249;Population  pushed below the $3.10 a day  poverty line by household  health expenditures (%);35.111111111111114;-7113.8158111015755
250;Increase in poverty gap due to household  health expenditures, expressed as a proportion of the $1.90 a-day poverty line (%);35.111111111111114;-7147.488573782283
251;Increase in poverty gap due to household  health expenditures, expressed as a proportion of the 3.10 a-day poverty line (%);35.55555555555556;-7159.662192971935
252;Availability of estimates on impoverishment due to out-of-pocket health expenditures;42.666666666666664;-8565.977091827765
253;Demand for family planning satisfied - modern and traditional methods (%);52.88888888888889;-8486.619181262105
254;Demand for family planning satisfied - modern methods (%);60.888888888888886;-9333.625963206001
255;Age-standardized DALYs (per 100,000);23.555555555555557;-8822.193411985752
256;National regulator approval of anti-dementia medication;0.0;
257;Availability of generic anti-dementia medication;0.0;
258;Availability of at least one anti-dementia medication approved for on-label use reimbursement;0.0;
259;Availability of atleast one adult hygiene products for people with dementia;0.0;
260;Availability of atleast one housing adjustment for people with dementia;0.0;
261;Availability of  atleast one assistive technology for people with dementia;0.0;
262;Existence of dementia national nongovernmental organization;0.0;
263;Dementia nongovernmental organization equipped with office;0.0;
264;Dementia nongovernmental organization office branches (Sub-national);0.0;
265;Dementia nongovernmental organization office branches (Local);0.0;
266;Dementia nongovernmental organization office branches (National only);0.0;
267;Dementia nongovernmental organization staff primarily salaried/volunteer;0.0;
268;Policy;0.0;
269;Provision of governmental funding to dementia nongovernmental organization for activities/services;0.0;
270;Dementia nongovernmental organization's involvement in policy development;0.0;
271;Existence of dementia carer support services;0.0;
272;Implementation level [national/subnational] of dementia carer support services;0.0;
273;Existence of dedicated resources for dementia carer support services;0.0;
274;Existence of implementation plan for dementia carer support services;0.0;
275;Existence of psycho-social supports for dementia carers;0.0;
276;Existence of respite care for dementia carers;0.0;
277;Existence of information on legal rights for dementia carers;0.0;
278;Existence of financial benefits/social protection for dementia carers;0.0;
279;Accessibility of dementia carer training and education [Capital/capital and main cities/capital, main cities, rural areas];0.0;
280;Majority provider of dementia carer training and education (NGO);0.0;
281;Majority provider of dementia carer training and education (Private sector);0.0;
282;Majority provider of dementia carer training and education (Public sector);0.0;
283;Accessibility of psycho-social supports for dementia carers [Capital/capital and main cities/capital, main cities, rural areas];0.0;
284;Majority provider of psycho-social supports for dementia carers (NGO);0.0;
285;Majority provider of psycho-social supports for dementia carers (Private sector);0.0;
286;Majority provider of psycho-social supports for dementia carers (Public sector);0.0;
287;Accessibility of respite care for dementia carers [Capital/capital and main cities/capital, main cities, rural areas];0.0;
288;Majority provider of respite care for dementia carers (NGO);0.0;
289;Majority provider of respite care for dementia carers (Private sector);0.0;
290;Majority provider of respite care for dementia carers (Public sector);0.0;
291;Accessibility of information on legal rights for dementia carers [Capital/capital and main cities/capital, main cities, rural areas];0.0;
292;Majority provider of information on legal rights for dementia carers (NGO);0.0;
293;Majority provider of information on legal rights for dementia carers (Private sector);0.0;
294;Majority provider of information  on legal rights for dementia carers (Public sector);0.0;
295;Accessibility of financial benefits/social protection for dementia carers [Capital/capital and main cities/capital, main cities, rural areas];0.0;
296;Majority provider of information on financial benefits/social protection for dementia carers (NGO);0.0;
297;Majority provider of information on financial benefits/social protection for dementia carers (Private sector);0.0;
298;Majority provider of information  on financial benefits/social protection for dementia carers (Public sector);0.0;
299;Estimated number of dementia carers receiving training and education;0.0;
300;Estimated number of dementia carers receiving psycho-social supports;0.0;
301;Estimated number of dementia carers receiving respite care;0.0;
302;Estimated number of dementia carers receiving information on legal rights;0.0;
303;Estimated number of dementia carers receiving financial benefits/social protection;0.0;
304;Existence of at least one functioning dementia awareness campaign;0.0;
305;Implementation level [national/subnational] of dementia awareness campaign;0.0;
306;Existence of at least one functioning risk reduction campaign;0.0;
307;Implementation level [national/subnational] of dementia risk reduction campaign;0.0;
308;Availability of dementia-friendly initiatives that improve accessibility;0.0;
309;Existence of dementia-friendly initiative to improve accessibility of public spaces;0.0;
310;Existence of dementia-friendly initiative to improve accessibility of public transportation;0.0;
311;Existence of dementia-friendly initiative for assistance with home modification;0.0;
312;Existence of dementia-friendly initiative with assistive technology for loss of capacity;0.0;
313;Existence of dementia-friendly initiative supporting community places for older people;0.0;
314;Existence of dementia-friendly initiative supporting social opportunities;0.0;
315;Inclusion of dementia training and education for non-health workers;0.0;
316;Existence of dementia training for volunteers;0.0;
317;Existence of dementia training for police and fire services;0.0;
318;Existence of dementia training for first responders;0.0;
319;Existence of dementia training for school children;0.0;
320;Existence of dementia training for financial service staff;0.0;
321;Existence of dementia training for retail and hospitality staff;0.0;
322;Routine monitoring of people with dementia;0.0;
323;Data sources used to routinely monitor people with dementia (Clinical records);0.0;
324;Data sources used to routinely monitor people with dementia (Household surveys);0.0;
325;Data sources used to routinely monitor people with dementia (Administrative data);0.0;
326;Data sources used to routinely monitor people with dementia (Facility survey or records);0.0;
327;Data sources used to routinely monitor people with dementia (Other);0.0;
328;Electronic availability of data sources used to routinely monitor people with dementia;0.0;
329;Data used to routinely monitor people with dementia can be disaggregated;0.0;
330;Availability of routine hospital admissions records for people with dementia for monitoring purposes;0.0;
331;Availability of routine outpatient visit records for people with dementia for monitoring purposes;0.0;
332;Availability of routine outpatient intervention and treatment records for people with dementia for monitoring purposes;0.0;
333;Availability of routine pharmaceutical records for people with dementia for monitoring purposes;0.0;
334;Availability of routine antipsychotic prescription records for people with dementia for monitoring purposes;0.0;
335;Availability and status of dementia reporting in the past two years;0.0;
336;Existence of a current dementia research plan/programme;0.0;
337;Implementation level [national/subnational] of dementia research plan/programme;0.0;
338;Dementia integrated into other national research plan/programme;0.0;
339;Identification of other research plans in which dementia is integrated (Mental health);0.0;
340;Identification of other research plans in which dementia is integrated (Ageing);0.0;
341;Identification of other research plans in which dementia is integrated (Neuro or neurodegenerative disease);0.0;
342;Identification of other research plans in which dementia is integrated (NCD);0.0;
343;Implementation level [national/subnational] of research plan in which dementia is integrated;0.0;
344;Availability of funding for dementia-specific research plan/programme;0.0;
345;Total expenditure on dementia research (local currency, self-report);0.0;
346;Total expenditure on dementia basic research (local currency, self-report);0.0;
347;Total expenditure on dementia clinical/translational research (local currency, self-report);0.0;
348;Total expenditure on dementia implementation research (local currency, self-report);0.0;
349;Number of people with dementia involved in research routinely monitored;0.0;
350;Availability of investigational pharmaceutical trials for dementia;0.0;
351;Number of investigational pharmaceutical trials for dementia;0.0;
352;Inclusion of dementia in ministry portfolio;0.0;
353;Inclusion of dementia in a branch of government [health, ageing, social services, mental health, noncommunicable disease];0.0;
354;Existence of dementia representative in ministry;0.0;
355;Total number of published dementia research output;90.66666666666667;-10670.018786618726
356;Existence of dementia national plan;0.0;
357;Availability of funding for dementia national plan;0.0;
358;Targets for monitoring implementation of dementia national plan;0.0;
359;Dementia integrated into other national plan;0.0;
360;Identification of other plans in which dementia is integrated (Ageing);0.0;
361;Identification of other plans in which dementia is integrated (Disability);0.0;
362;Identification of other plans in which dementia is integrated (Mental health);0.0;
363;Identification of other plans in which dementia is integrated (NCD);0.0;
364;Identification of other plans in which dementia is integrated (Other);0.0;
365;Existence of dementia sub-national plan(s);0.0;
366;Percentage of sub-national regions covered by dementia plan;0.0;
367;Inclusion of human rights as a guiding principle of the dementia plan;0.0;
368;Inclusion of equity as a guiding principle of the dementia plan;0.0;
369;Inclusion of empowerment as a guiding principle of the dementia plan;0.0;
370;Inclusion of multisectoral collaboration as a guiding principles of the dementia plan;0.0;
371;Priorities;0.0;
372;Inclusion of universal health coverage as a guiding principle of the dementia plan;0.0;
373;Inclusion of dementia-friendly communities as a specific action of the dementia plan;0.0;
374;Inclusion of dementia risk reduction as a specific action of the dementia plan;0.0;
375;Inclusion of dementia diagnosis, care and support as a specific action of the dementia plan;0.0;
376;Inclusion of dementia workforce training as a specific action of the dementia plan;0.0;
377;Inclusion of support for dementia carers and families as a specific action of the dementia plan;0.0;
378;Inclusion of improved information system as a specific action of the dementia plan;0.0;
379;Inclusion of research and innovation as a specific action of the dementia plan;0.0;
380;Estimated population-based prevalence of depression;18.66666666666667;-9748.925842099832
381;Existence of dementia legislation;0.0;
382;Implementation level [national/subnational] of dementia legislation;0.0;
383;Existence of other laws that apply to the rights of people with dementia;0.0;
384;Existence of legislation for supported decision making for people with dementia;0.0;
385;Existence of legislation to file appeals protecting the rights of people with dementia;0.0;
386;Existence of legislation to promote community-based services for people with dementia;0.0;
387;Existence of legislation to promote monitoring of human rights conditions of people with dementia in facilities where they reside;0.0;
388;Existence of legislation to end coercieve practices for people with dementia;0.0;
389;Existence of legislation for advanced care directives for people with dementia;0.0;
390;Existence of legislation to end discrimination against people with dementia;0.0;
391;Existence of legislation to end discrimination against carers of people with dementia;0.0;
392;Existence of dementia standards/ guidelines/ protocols;0.0;
393;Implementation level of dementia standards/ guidelines/ protocols (National);0.0;
394;Implementation level of dementia standards/ guidelines/ protocols (Sub-national);0.0;
395;Existence of approved government dementia standards/ guidelines/ protocols;0.0;
396;Existence of standards/ guidelines/ protocols for prevention and risk reduction of dementia;0.0;
397;Existence of standards/ guidelines/ protocols for diagnosis of dementia;0.0;
398;Existence of standards/ guidelines/ protocols for management of dementia;0.0;
399;Existence of standards/ guidelines/ protocols for other post-diagnostic supports of people with dementia;0.0;
400;Existence of standards/ guidelines/ protocols for treatment and support of carers and families of people with dementia;0.0;
401;Existence of standards/ guidelines/ protocols for advance care directives, power of attorney or guardianship for people with dementia;0.0;
402;Existence of standards/ guidelines/ protocols for palliative and end-of-life care for people with dementia;0.0;
403;Existence of standards/ guidelines/ protocols of care in nursing & residential care facilities for people with dementia;0.0;
404;Existence of standards/ guidelines/ protocols of care in hospital for people with dementia;0.0;
405;Availability of mechanisms to coordinate dementia care across sectors;0.0;
406;Identification of different sectors in dementia care coordination  (Health);0.0;
407;Identification of different sectors in dementia care coordination (Social);0.0;
408;Identification of different sectors in dementia care coordination (Education);0.0;
409;Identification of different sectors in dementia care coordination (Employment);0.0;
410;Identification of different sectors in dementia care coordination (Justice);0.0;
411;Identification of different sectors in dementia care coordination (Housing);0.0;
412;Identification of different sectors in dementia care coordination (Civil society);0.0;
413;Identification of different sectors in dementia care coordination (Private sector);0.0;
414;Identification of different sectors in dementia care coordination (Other);0.0;
415;Implementation level [national/subnational] of dementia care coordination;0.0;
416;Presence of formal agreement/joint plan for dementia care coordination;0.0;
417;Availability of dementia care coordination standards/ guidelines/ protocols;0.0;
418;Number of neurologists (per 100,000);0.0;
419;Number of geriatricians or psychogeriatricians (per 100,000);0.0;
420;Inclusion of basic dementia competencies in training of physicians;0.0;
421;Inclusion of basic dementia competencies in training of specialists;0.0;
422;Inclusion of basic dementia competencies in training of nurses;0.0;
423;Inclusion of basic dementia competencies in training of pharmaceutical personnel;0.0;
424;Inclusion of basic dementia competencies in training of social workers;0.0;
425;Inclusion of basic dementia competencies in training of personal support workers;0.0;
426;Availability of dementia diagnostic rate;0.0;
427;Existence of community-based health or social care services for dementia;0.0;
428;Availability of diagnostic services in community for dementia;0.0;
429;Availability of behaviour and psychological management in community for dementia;0.0;
430;Availability of psychosocial and rehabilitation services in community for dementia;0.0;
431;Availability of activities of daily living support services in community for dementia;0.0;
432;Availability of palliative and end-of-life care services in community for dementia;0.0;
433;Availability of social and financial protection for dementia;0.0;
434;Accessibility of diagnostic services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
435;Accessibility of behaviour and psychological management in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
436;Accessibility of psychosocial and rehabilitation services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
437;Accessibility of activities of daily living support services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
438;Accessibility of palliative and end-of-life care services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
439;Accessibility of social and financial protection for dementia [Capital/capital and main cities/capital, main cities, rural areas];0.0;
440;Majority provider of diagnostic services in community for dementia [public, private];0.0;
441;Majority provider of behaviour and psychological management in community for dementia [public, private];0.0;
442;Majority provider of psychosocial and rehabilitation services in community for dementia [public, private];0.0;
443;Majority provider of activities of daily living support services in community for dementia [public, private];0.0;
444;Majority provider of palliative and end-of-life care services in community for dementia [public, private];0.0;
445;Majority provider of social and financial protection for dementia [public, private];0.0;
446;Estimated number of people receiving behaviour and psychological management services in community for dementia;0.0;
447;Estimated number of people receiving psychosocial and rehabilitation services in community for dementia;0.0;
448;Estimated number of people receiving activities of daily living support services in community for dementia;0.0;
449;Estimated number of people receiving palliative and end-of-life care services in community for dementia;0.0;
450;Estimated number of people with dementia receiving social and financial protection for dementia;0.0;
451;Dementia care facilities [hospitals];0.0;
452;Care facilities [long-term care];0.0;
453;Care facilities [hospice centres];0.0;
454;Adult day centres;0.0;
455;Outpatient health centres;0.0;
456;Outpatient social centres;0.0;
457;Dementia-specific hospital beds (per 10,000 population);86.66666666666667;-10651.535605417961
458;Geriatric-specific hospital beds (per 10,000 population);87.55555555555556;-10661.496450776405
459;Total dementia hospital admissions (per 100,000);89.77777777777777;-10707.295434239793
460;Estimated percentage of hospitals following national dementia standards;0.0;
461;Density of residential long-term care facilities (per 100,000 population);82.66666666666666;-10627.28336793085
462;Residential long-term care beds (per 10 000 population);86.22222222222223;-10667.994581953166
463;Dementia-specific residential long-term care beds (per 10,000 population);92.88888888888889;-10716.671842725307
464;Estimated number of people with dementia living in residential long-term care;0.0;
465;Estimated percentage of residential long-term care facilities following national dementia standards;0.0;
466;Density of hospice centres (per 100,000 population);87.55555555555556;-10649.531979954269
467;Hospice centre beds (per 10 000 population);92.0;-10695.487364539938
468;Dementia-specific hospice care beds (per 10,000 population);95.11111111111111;-10722.094994288305
469;Density of adult day centres (per 100,000 population);85.77777777777777;-10653.258858522111
470;Adult day centre places (per 10,000 population);91.55555555555556;-10702.552900912782
471;Dementia-specific adult day centre places (per 10,000 population);93.33333333333333;-10722.972675335564
472;Density of outpatient health centres (per 100,000 population);85.77777777777777;-10633.442210905112
473;Estimated number of people with dementia receiving services at outpatient health centre;0.0;
474;Density of outpatient social centres (per 100,000 population);91.55555555555556;-10683.694516982003
475;Estimated number of people with dementia receiving services at outpatient social centre;0.0;
476;Disability-adjusted life years (DALYs);0.0;
477;Disability-adjusted life years (DALYs) (per 100 000 population);0.0;
478;Years of healthy life lost due to disability (YLDs);0.0;
479;Years of healthy life lost due to disability (YLDs) (per 100 000 population);0.0;
480;Years of life lost from mortality (YLLs);0.0;
481;Years of life lost from mortality (YLLs) (per 100 000 population);0.0;
482;Current health expenditure (CHE) per capita in PPP int$;14.666666666666657;-50.83185596144583
483;Current health expenditure (CHE) per capita in US$;14.666666666666657;-50.864291674390685
484;Current health expenditure (CHE) as percentage of gross domestic product (GDP) (%);14.666666666666657;-51.83654325968506
485;External health expenditure (EXT) per capita in PPP int$;19.111111111111114;-147.93841198957315
486;External health expenditure (EXT) per capita in US$;19.111111111111114;-148.1943296011541
487;External health expenditure (EXT) as percentage of current health expenditure (CHE) (%);19.111111111111114;-148.14731031069456
488;Domestic general government health expenditure (GGHE-D) per capita in PPP int$;14.666666666666657;-50.86657254839959
489;Domestic general government health expenditure (GGHE-D) per capita in US$;14.666666666666657;-50.946594943412215
490;Domestic general government health expenditure (GGHE-D) as percentage of current health expenditure (CHE) (%);14.666666666666657;-50.98324239716832
491;Domestic general government health expenditure (GGHE-D) as percentage of gross domestic product (GDP) (%);14.666666666666657;-52.07048431928973
492;Domestic general government health expenditure (GGHE-D) as percentage of general government expenditure (GGE) (%);14.666666666666657;-51.5053515263291
493;Out-of-pocket expenditure (OOP) per capita in PPP int$;14.666666666666657;-50.85803163043695
494;Out-of-pocket expenditure (OOP) per capita in US$;14.666666666666657;-50.93109732242804
495;Out-of-pocket expenditure as percentage of current health expenditure (CHE) (%);14.666666666666657;-51.01344226551053
496;Domestic private health expenditure (PVT-D) per capita in PPP int$;14.666666666666657;-50.85784073363149
497;Domestic private health expenditure (PVT-D) per capita in US$;14.666666666666657;-50.90893260978613
498;Domestic private health expenditure (PVT-D) as percentage of current health expenditure (CHE) (%);14.666666666666657;-51.00879822290223
499;National universal health coverage strategy;0.0;
500;strategy refers to the use of ICT to support UHC;0.0;
501;National eHealth strategy;0.0;
502;National eHealth strategy refers to objectives of UHC;0.0;
503;National  health information system (HIS) policy or strategy;0.0;
504;Public funding for eHealth;0.0;
505;Private funding for eHealth;0.0;
506;Donor/ non-public development funding for eHealth;0.0;
507;Public-private partnerships for eHealth;0.0;
508;Strategy implementation funding available for eHealth;0.0;
509;Proportion of public funding;0.0;
510;Proportion of private funding;0.0;
511;Proportion of donor/non public development funding;0.0;
512;Proportion ofpublic private partnerships funding;0.0;
513;Government-supported health internet sites provide information in multiple languages;0.0;
514;Tertiary institutions provide students of health sciences with training on eHealth;0.0;
515;Institutions offer in-service training to health professionals on ICT for health;0.0;
516;mHealth programmes are sponsored by government;0.0;
517;Regulating mobile devices and software;0.0;
518;Promoting standards and interoperability;0.0;
519;Providing guidance on privacy and security;0.0;
520;Providing oversight and enforcement of data ownership;0.0;
521;Promoting the development and adoption of mHealth;0.0;
522;Regulatory oversight of mobile apps for quality, safety and reliability;0.0;
523;Providing incentives and guidance for innovation research and evaluation of health;0.0;
524;Government-sponsored mHealth programmes are being evaluated;0.0;
525;Capacity;0.0;
526;Infrastructure;0.0;
527;Funding;0.0;
528;Effectiveness;0.0;
529;Cost-effectiveness;0.0;
530;Demand;0.0;
531;Legal;0.0;
532;Country has telehealth policy or strategy;0.0;
533;Strategy includes objectives as to how telehealth contributes to UHC;0.0;
534;Evaluation of any government-sponsored telehealth programmes;0.0;
535;eLearning is used in pre-service education to teach health sciences students;0.0;
536;Reducing cost of delivering content;0.0;
537;Improving access to content and experts;0.0;
538;Enabling access to education where learning facilities are limited;0.0;
539;Pre-service eLearning programmes have been evaluated;0.0;
540;eLearning used for in-service training of health professionals;0.0;
541;Reducing cost of delivering content;0.0;
542;Improving access to content and experts;0.0;
543;Enabling access to education where learning facilities are limited;0.0;
544;eLearning courses accredited by continuing medical education or professional licensing bodies;0.0;
545;eLearning programmes for in-service training of health professionals have been evaluated;0.0;
546;Lack of capacity;0.0;
547;Lack of infrastructure;0.0;
548;Lack of funding;0.0;
549;Not possible to gain a health sciences degree entirely through eLearning;0.0;
550;Lack of evidence that eLearning is effective;0.0;
551;Lack of evidence over cost-effectiveness;0.0;
552;Lack of demand for eLearning programmes;0.0;
553;Lack of suitable courses available;0.0;
554;Insitutional educational policy does not include eLearning as an approach to teaching health sciences;0.0;
555;Competing educational priorities;0.0;
556;Country has national EHR;0.0;
557;Country has specific legislation governing the use of national EHR system;0.0;
558;Lack of capacity;0.0;
559;Lack of infrastructure;0.0;
560;Lack of funding;0.0;
561;lack of evidence showing effectiveness of EHR;0.0;
562;Lack of evidence showing cost-effectiveness or EHR;0.0;
563;Lack of demand by health professionals and patients;0.0;
564;Lack of legislation or regulations covering use of EHR;0.0;
565;National strategy does not promote the adoption of EHR;0.0;
566;Lack of national or international standards for interoperability of EHR;0.0;
567;Competing health system priorities;0.0;
568;To define medical jurisdiction, liability or reimbursement of eHealth services such as telehealth;0.0;
569;To address patient safety and quality of care based on data quality, data transmission standards, or clinical competency criteria;0.0;
570;To protect privacy of personally identifiable data of individuals irrespective of whether it is paper or digital format;0.0;
571;To protect the privacy of individuals' health-related  data held in electronic format as an EHR;0.0;
572;Which governs the sharing of digital data between health professionals in other health services in the same country through the use of an EHR;0.0;
573;Which governs the sharing of digital data between health professionals  in health services in other countries through the use of an EHR;0.0;
574;Which allows for the sharing of personal and health data between research entities;0.0;
575;Which allows individuals electronic access to their own health-related data when held in an EHR;0.0;
576;Which allows individuals to demand that their own data be corrected  when held in an EHR if it is known to be inaccurate;0.0;
577;Which allows individuals to demand the deletion of health-related data from their EHR;0.0;
578;Individuals have the legal right to specify which health-related data from their EHR can be shared with health professionals of their choice;0.0;
579;Country has national policy or strategy on the use of social media by government organizations;0.0;
580;Policy or strategy makes specific reference tothe use of social media in the health domain;0.0;
581;Country has  national policy or strategy regulating the use of big data in the health sector;0.0;
582;Country has national policy or strategy regulating the use of big data by private companies;0.0;
583;Effective standards and best practices for data capture not fully established;0.0;
584;Insufficient incentives for data sharing;0.0;
585;Capacity building required for new skills;0.0;
586;Privacy and security laws need to be in place;0.0;
587;Research into new analytical methods needs occur to meet the challenges of working with big data;0.0;
588;Lack of integration between various health services;0.0;
589;Testing and counselling facilities, reported number;48.0;-10003.091145885483
590;Testing and counselling facilities, estimated number per 100 000 adult population;51.55555555555556;-10040.331620311725
591;Reported number of children receiving antiretroviral therapy;55.55555555555556;-295.37062156919296
592;Reported number of children receiving antiretroviral therapy, month and year of report;36.88888888888889;-9870.435643113804
593;Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission;37.33333333333333;-2790.704949309925
594;Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission;58.666666666666664;-3745.299835371279
595;Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods;59.55555555555556;-361.2618551502014
596;Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines;56.0;-9949.415221317191
597;Estimated number of children needing antiretroviral therapy based on WHO methods;58.666666666666664;-281.9663851513783
598;Estimated antiretroviral therapy coverage among children;55.111111111111114;-303.58305236567793
599;Testing and counselling facilities, reporting period;0.0;
600;Number of new HIV infections;41.77777777777778;-9.687632895844857
601;Estimated antiretroviral therapy coverage among people living with HIV (%);40.44444444444445;-0.2600865621974142
602;Biomedical engineers density (per 10 000 population);63.55555555555556;-9823.994058335666
603;Number of licensed qualified surgeons actively working;30.666666666666657;-9964.988068626084
604;Number of licensed qualified obstetricians actively working;28.0;-9926.896130645137
605;Number of licensed qualified anaesthesiologists actively working;28.888888888888886;-9951.001301091279
606;Number of biomedical engineers;38.22222222222222;-9991.890992706883
607;Biomedical technicians density (per 10 000 population);90.22222222222223;-10641.834034109026
608;Number of biomedical technicians;86.66666666666667;-10579.561087857624
609;Countries that have passed legislation on Universal Health Coverage (UHC);0.0;
610;Medical doctors (per 10,000);13.777777777777771;-2609.8126288671924
611;Medical doctors (number);12.8888888888889;-2609.8180013552737
612;Generalist medical practitioners (number);36.44444444444444;-6826.04477622856
613;Specialist medical practitioners (number);36.44444444444444;-6817.009791408452
614;Medical doctors not further defined (number);16.0;-4287.902275186772
615;Nursing and midwifery personnel (per 10,000);13.777777777777771;-2509.9443582421663
616;Nursing and midwifery personnel  (number);12.444444444444443;-2509.949415864789
617;Nursing personnel (number);12.444444444444443;-2509.951124048381
618;Midwifery personnel (number);22.222222222222214;-4827.428697973354
619;Dentists (per 10,000);14.666666666666657;-3658.9906595386888
620;Dentists (number);13.777777777777771;-3659.0067891506524
621;Dental Assistants and Therapists (number);40.44444444444445;-8927.617987849078
622;Dental Prosthetic Technicians (number);42.666666666666664;-9177.269201432942
623;Pharmacists  (per 10,000);16.888888888888886;-4154.7068956223075
624;Pharmacists  (number);16.0;-4154.732297080775
625;Pharmaceutical Technicians and Assistants  (number);50.22222222222222;-8639.771720465431
626;Environmental and Occupational Health and Hygiene Professionals  (number);50.22222222222222;-8788.46361757206
627;Environmental and Occupational Health Inspectors and Associates  (number);67.11111111111111;-9734.64875886696
628;Medical and Pathology Laboratory scientists  (number);53.77777777777778;-9015.125744261444
629;Medical and Pathology Laboratory Technicians  (number);49.33333333333333;-8674.741721504783
630;Physiotherapists (number);32.888888888888886;-7727.511060661597
631;Physiotherapy Technicians and Assistants  (number);69.33333333333334;-9872.809257318637
632;Traditional and Complementary Medicine Professionals  (number);76.44444444444444;-10167.863239566655
633;Community Health Workers (number);59.11111111111111;-9243.95027307443
634;Handwashing with soap after using the toilet (%);96.0;-10689.23282429872
635;Handwashing with soap after cleaning child's stool (%);0.0;
636;Legislation;13.333333333333329;-5590.358339047174
637;Coordination;13.333333333333329;-5590.185349537059
638;Surveillance;13.333333333333329;-5590.188376008715
639;Response;13.333333333333329;-5590.090603516944
640;Preparedness;13.333333333333329;-5590.078741861847
641;Risk communication;13.333333333333329;-5590.28264357082
642;Human resources;13.333333333333329;-5590.300060166457
643;Laboratory;13.333333333333329;-5590.089500368265
644;Points of entry;13.333333333333329;-5589.976018968746
645;Zoonosis;13.333333333333329;-5590.281088188482
646;Food safety;13.333333333333329;-5590.177508974604
647;Chemical;13.333333333333329;-5590.177040273401
648;Radionuclear;13.333333333333329;-5590.1630632168435
649;Infant mortality rate (deaths per 1000 live births)-nan;59.11111111111111;0
650;Infant mortality rate (deaths per 1000 live births)-Female;59.11111111111111;0.4156174212317252
651;Infant mortality rate (deaths per 1000 live births)-Male;59.11111111111111;0.4156174212317252
652;Infant mortality rate (deaths per 1000 live births);59.11111111111111;-8816.04458628803
653;Mean BMI (kg/m²) (age-standardized estimate)-Both sexes;15.555555555555557;1.2742524912670383
654;Mean BMI (kg/m²) (age-standardized estimate)-Female;15.555555555555557;1.3153751022607976
655;Mean BMI (kg/m²) (age-standardized estimate)-Male;15.555555555555557;1.2439091838329608
656;Mean BMI (kg/m²) (age-standardized estimate);15.555555555555557;-409.54791386450796
657;Percentage of sites for which carbamate resistance was reported;76.44444444444444;-8689.650691648354
658;Carbamate resistance reported for at least one site;0.0;
659;Number of insecticide classes to which resistance was reported;62.666666666666664;-7131.087691813941
660;Percentage of sites for which organochlorine resistance was reported;70.22222222222223;-7977.612470033077
661;Organochlorine resistance reported for at least one site;0.0;
662;Percentage of sites for which organophosphate resistance was reported;72.88888888888889;-8786.715910491384
663;Organophosphate resistance reported for at least one site;0.0;
664;Percentage of sites for which pyrethroid resistance was reported;64.44444444444444;-7444.097189475986
665;Pyrethroid resistance reported for at least one site;0.0;
666;Children aged < 5 years sleeping under insecticide-treated nets (%)-nan;77.33333333333334;0
667;Children aged < 5 years sleeping under insecticide-treated nets (%)-Female;77.33333333333334;0.2786782809189683
668;Children aged < 5 years sleeping under insecticide-treated nets (%)-Male;77.33333333333334;0.2786782809189683
669;Children aged < 5 years sleeping under insecticide-treated nets (%);77.33333333333334;-9488.36238722096
670;Pregnant women sleeping under insecticide-treated nets (%);78.66666666666666;-9653.16910026677
671;Percentage of individuals using the Internet;16.444444444444443;-9743.837424178022
672;Mobile-cellular telephone subscriptions per 100 inhabitants;23.555555555555557;-9804.111531916733
673;ICT Development Index (IDI);31.111111111111114;-9006.298319428231
674;ICT Development Index (IDI) rank;31.111111111111114;-9006.335745835646
675;Percentage of the children under 15 years with blood lead levels above 5ug/dl;0.0;
676;Lead attributable DALYs per 100'000 children under 5 years;0.0;
677;Percentage of the children under 15 years with blood lead levels above 10ug/dl;0.0;
678;Percentage of the adults (15+ years) with blood lead levels above 5ug/dl;0.0;
679;Percentage of the adults (15+ years) with blood lead levels above 10ug/dl;0.0;
680;Lead attributable deaths;0.0;
681;Lead attributable DALYs ('000);0.0;
682;Lead attributable deaths per 100'000 capita;0.0;
683;Lead attributable DALYs per 100'000 capita;0.0;
684;Lead attributable DALYs ('000) in children under 5 years;0.0;
685;Legally-binding controls on lead paint;0.0;
686;nMx - age-specific death rate between ages x and x+n;18.66666666666667;-6182.791002362337
687;nqx - probability of dying between ages x and x+n;18.66666666666667;-6182.791002362337
688;lx - number of people left alive at age x;18.66666666666667;-6182.791002362337
689;ndx - number of people dying between ages x and x+n;18.66666666666667;-6183.396344817125
690;nLx - person-years lived between ages x and x+n;18.66666666666667;-6182.791002362337
691;Tx - person-years lived above age x;18.66666666666667;-6182.791002362337
692;ex - expectation of life at age x;18.66666666666667;-6182.791002362337
693;Adult indicator 1 rate;0.0;
694;Youth indicator 1 rate;0.0;
695;Adult indicator 1 definition;0.0;
696;Youth indicator 1 definition;0.0;
697;Adult indicator 2 rate;0.0;
698;Youth indicator 2 rate;0.0;
699;Adult indicator 2 definition;0.0;
700;Youth indicator 2 definition;0.0;
701;Estimate of current cigarette smoking prevalence (%)-Both sexes;27.111111111111114;0.8056783585904785
702;Estimate of current cigarette smoking prevalence (%)-Male;27.111111111111114;0.8822367487059282
703;Estimate of current cigarette smoking prevalence (%)-Female;27.111111111111114;0.6380258416535556
704;Estimate of current cigarette smoking prevalence (%);27.111111111111114;-5536.638507010782
705;Estimate of current tobacco use prevalence (%)-Both sexes;27.111111111111114;0.8469810469134305
706;Estimate of current tobacco use prevalence (%)-Male;27.111111111111114;0.8999645542570902
707;Estimate of current tobacco use prevalence (%)-Female;27.111111111111114;0.7496731427856043
708;Estimate of current tobacco use prevalence (%);27.111111111111114;-5536.623830017517
709;Monitoring tobacco use and prevention policies;13.333333333333329;-4713.250477432341
710;Adult survey age range - smokeless;0.0;
711;Youth survey age range - smokeless;0.0;
712;Adult smokeless tobacco use indicator definition;0.0;
713;Youth smokeless tobacco use indicator definition;0.0;
714;Adult smokeless tobacco use indicator rate;0.0;
715;Youth smokeless tobacco use indicator rate;0.0;
716;Name of survey of adults - smokeless;0.0;
717;Name of survey of youth - smokeless;0.0;
718;Representativeness of survey of adults - smokeless;0.0;
719;Representativeness of survey of youth - smokeless;0.0;
720;Name of survey of adults;0.0;
721;Name of survey of youth;0.0;
722;Adult survey age range;0.0;
723;Youth survey age range;0.0;
724;Representativeness of survey of adults;0.0;
725;Representativeness of youth survey;0.0;
726;Measles-containing-vaccine second-dose (MCV2) immunization coverage by the nationally recommended age (%);20.444444444444443;-2352.0165857760994
727;Adolescent birth rate (per 1000 women aged 15-19 years);14.222222222222229;-850.0955949652921
728;Median availability of selected generic medicines (%) - Public;84.0;-10493.460989100513
729;Median consumer price ratio of selected generic medicines - Public;91.11111111111111;-10616.942193241064
730;Children aged <5 years with fever who received treatment with any antimalarial (%);75.11111111111111;-10283.268850392753
731;Prevalence of condom use by adults during higher-risk sex (15-49) (%)-Male;82.66666666666666;0.06874501304089664
732;Prevalence of condom use by adults during higher-risk sex (15-49) (%)-Female;82.66666666666666;0.06977840560068449
733;Prevalence of condom use by adults during higher-risk sex (15-49) (%);82.66666666666666;-10400.77713691932
734;Deaths due to tuberculosis among HIV-negative people (per 100 000 population);14.222222222222229;1.6059928225292173
735;Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%)-Male;80.44444444444444;0.06690834686800873
736;Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%)-Female;80.44444444444444;0.07285559311774747
737;Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%);80.44444444444444;-10368.031800681334
738;Births attended by skilled health personnel (%);16.888888888888886;-3195.5810496307568
739;Births attended by skilled health personnel, among girls aged 15-19 (%);63.55555555555556;-10104.929280766924
740;Maternal mortality ratio (per 100 000 live births);18.66666666666667;-190.19596605548318
741;Prevalence of HIV among adults aged 15 to 49 (%);40.0;1.6295217019380743
742;Smear-positive tuberculosis case-detection rate (%);15.555555555555557;-8920.67892392866
743;Smear-positive tuberculosis treatment-success rate (%);15.555555555555557;-2364.054480668497
744;Maternal mortality ratio (per 100 000 live births) - Country reported estimates;99.55555555555556;-10750.845220291518
745;Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%);56.0;-9953.699335108082
746;Antiretroviral therapy coverage among people with advanced HIV infection (%), WHO 2006 guidelines;53.77777777777778;-9983.042728280632
747;Number of suspected meningitis deaths reported;91.55555555555556;-9974.800131052918
748;Number of suspected meningitis cases reported;91.55555555555556;-9838.081310465204
749;Number of meningitis epidemic districts;91.55555555555556;-9995.254692534636
750;Mental health policy;0.0;
751;Mental health outpatient facilities (per 100,000);38.22222222222222;-10001.212786204054
752;Mental health day treatment facilities (per 100,000);67.11111111111111;-10404.654724897247
753;Age-standardized suicide rates (per 100 000 population);18.66666666666667;-15.744516581713498
754;Beds for mental health in general hospitals (per 100,000);41.333333333333336;-10023.526409819386
755;Community residential facilities (per 100,000);71.11111111111111;-10436.456272793479
756;Beds in community residential facilities (per 100,000);74.22222222222223;-10472.018531772315
757;Beds in mental hospitals (per 100,000);41.77777777777778;-10048.20680016131
758;Mental hospitals (per 100,000);41.77777777777778;-10027.218646173174
759;Mental health units in general hospitals (per 100,000);38.66666666666667;-9973.685391654493
760;Mental hospital admissions (per 100,000);47.55555555555555;-10118.038065100078
761;Mental health plan;0.0;
762;Outpatient visits (per 100,000);60.44444444444444;-10281.710249598187
763;Mental health units in general hospitals admissions (per 100,000);60.44444444444444;-10267.578684377899
764;Stand-alone policy or plan for mental health;0.0;
765;Stand-alone mental health legislation;0.0;
766;Government expenditures on mental health as a percentage of total government expenditures on health (%);65.33333333333333;-10329.389299470633
767;Government expenditures on mental hospitals as a percentage of total government expenditures on mental health (%);65.33333333333333;-10371.2226519444
768;Psychiatrists working in mental health sector (per 100,000);35.111111111111114;-9956.693463244765
769;Nurses working in mental health sector (per 100,000);43.55555555555556;-10095.930310490707
770;Social workers working in mental health sector (per 100,000);55.55555555555556;-10198.968773846906
771;Psychologists working in mental health sector (per 100,000);46.666666666666664;-10088.91122270219
772;Number of deaths;13.777777777777771;-189.27545771518257
773;Deaths per 1 000 live births;13.777777777777771;-189.27495195292022
774;Distribution of causes of death among children aged < 5 years (%);13.777777777777771;-192.0360531360732
775;Deaths per 100 000 population;0.0;
776;Number of deaths;13.777777777777771;-189.27545771518257
777;Projection of number of deaths;0.0;
778;Projection of deaths per 100 000 population;0.0;
779;Number of maternal deaths;18.66666666666667;-190.6629355598366
780;Adolescent mortality rate (per 100 000 population);18.66666666666667;-9748.925842099832
781;Prevalence of underweight among adults, BMI < 18 (age-standardized estimate) (%)-Both sexes;15.555555555555557;1.6620551060007975
782;Prevalence of underweight among adults, BMI < 18 (age-standardized estimate) (%)-Female;15.555555555555557;1.6524540264185736
783;Prevalence of underweight among adults, BMI < 18 (age-standardized estimate) (%)-Male;15.555555555555557;1.6882048086805588
784;Prevalence of underweight among adults, BMI < 18 (age-standardized estimate) (%);15.555555555555557;-409.1033512311121
785;Prevalence of underweight among adults, BMI < 18 (crude estimate) (%)-Both sexes;15.555555555555557;1.6649638611517683
786;Prevalence of underweight among adults, BMI < 18 (crude estimate) (%)-Female;15.555555555555557;1.6551199384992619
787;Prevalence of underweight among adults, BMI < 18 (crude estimate) (%)-Male;15.555555555555557;1.6863455542787231
788;Prevalence of underweight among adults, BMI < 18 (crude estimate) (%);15.555555555555557;-409.05752578833426
789;"Prevalence of overweight among adults, BMI &GreaterEqual; 25 (age-standardized estimate) (%)";15.555555555555557;-408.70367106362943
790;"Prevalence of overweight among adults, BMI &GreaterEqual; 25 (crude estimate) (%)";15.555555555555557;-408.65743106237323
791;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (age-standardized estimate) (%)-Both sexes";15.555555555555557;1.7775990270645812
792;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (age-standardized estimate) (%)-Female";15.555555555555557;1.9011993747440932
793;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (age-standardized estimate) (%)-Male";15.555555555555557;1.6262392802216876
794;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (age-standardized estimate) (%)";15.555555555555557;-408.85380752092345
795;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (crude estimate) (%)-Both sexes";15.555555555555557;1.760126908113497
796;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (crude estimate) (%)-Female";15.555555555555557;1.8725315696164921
797;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (crude estimate) (%)-Male";15.555555555555557;1.602739708550049
798;"Prevalence of obesity among adults, BMI &GreaterEqual; 30 (crude estimate) (%)";15.555555555555557;-408.87827739219273
799;"Mean BMI (kg/m&#xb2;) (crude estimate)";15.111111111111114;-390.68225125317423
800;Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%)-Both sexes;15.555555555555557;1.5359728723424264
801;Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%)-Female;15.555555555555557;1.1127246138160256
802;Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%)-Male;15.555555555555557;1.3571058665482574
803;Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%);15.555555555555557;-408.68377371724745
804;Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%)-Both sexes;15.555555555555557;1.482478927272687
805;Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%)-Female;15.555555555555557;1.4866559854544317
806;Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%)-Male;15.555555555555557;1.4844285518530165
807;Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%);15.555555555555557;-408.46512011472373
808;Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%)-Both sexes;15.555555555555557;1.0144641505735006
809;Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%)-Female;15.555555555555557;0.981317872756494
810;Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%)-Male;15.555555555555557;1.04140826622125
811;Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%);15.555555555555557;-408.72013642801363
812;General availability of ACE inhibitors in the public health sector;0.0;
813;Existence of operational policy/strategy/action plan to reduce the harmful use of alcohol;0.0;
814;General availability of aspirin (100 mg) in the public health sector;0.0;
815;General availability of beta blockers in the public health sector;0.0;
816;General availability of colon cancer screening at the primary health care level;0.0;
817;General availability of breast cancer screening (by palpation or mammogram) at the primary health care level;0.0;
818;Existence of national screening program for breast cancer;0.0;
819;General availability of bronchodilators in the public health sector;0.0;
820;Existence of operational policy/strategy/action plan for cancer;0.0;
821;Existence of population-based cancer registry;0.0;
822;General availability of CC blockers in the public health sector;0.0;
823;General availability of cervical cytology at the primary health care level;0.0;
824;Most widely used screening method in national cervical cancer screening program;0.0;
825;Coverage of national cervical cancer screening program (%);0.0;
826;Type of national cervical cancer screening program;0.0;
827;Existence of national screening program for cervical cancer;0.0;
828;General availability of total cholesterol measurement at the primary health care level;0.0;
829;General availability of coronary bypass or stenting in the public health system;0.0;
830;Existence of operational policy/strategy/action plan for chronic respiratory diseases;0.0;
831;Existence of operational policy/strategy/action plan for cardiovascular diseases;0.0;
832;Existence of a diabetes registry;0.0;
833;General availability of diabetes testing (by blood glucose measurement, OGTT, or HbA1c) at the primary health care level;0.0;
834;Existence of operational policy/strategy/action plan for diabetes;0.0;
835;General availability of diabetes testing (by blood glucose measurement, OGTT) at the primary health care level;0.0;
836;General availability of dialysis in the public health system;0.0;
837;Implementation of diet and/or physical activity public awareness program;0.0;
838;Existence of operational policy/strategy/action plan to reduce unhealthy diet related to NCDs;0.0;
839;General availability of diabetes testing (by HbA1c) at the primary health care level;0.0;
840;Existence of national HPV vaccination programme;0.0;
841;General availability of insulin in the public health sector;0.0;
842;Existence of an operational, multisectoral national NCD policy, strategy or action plan that integrates several NCDs and their risk factors;0.0;
843;General availability of metformin in the public health sector;0.0;
844;Existence of any policies on marketing of foods to children;0.0;
845;Existence of a national multisectoral commission, agency or mechanism for NCDs;0.0;
846;Existence of evidence-based national guidelines/protocols/standards for the management of major NCDs through a primary care approach;0.0;
847;Existence of a set of national NCD indicators and has set time-bound national targets for these indicators;0.0;
848;Existence of an Operational Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs;0.0;
849;General availability of nicotine replacement therapy in the public health sector;0.0;
850;Existence of operational policy/strategy/action plan for oral health;0.0;
851;General availability of oral morphine in the public health sector;0.0;
852;Implementation of physical activity public awareness program;0.0;
853;General availability of palliative care in community or home-based care in the public health system;0.0;
854;General availability of palliative care in primary health care in the public health system;0.0;
855;Existence of operational policy/strategy/action plan to reduce physical inactivity;0.0;
856;General availability of retinal photocoagulation in the public health system;0.0;
857;Has a STEPS survey or a comprehensive health examination survey every 5 years;0.0;
858;General availability of renal replacement by transplantation in the public health system;0.0;
859;Provision for secondary prevention of rheumatic fever and rheumatic heart disease in more than 50% of public sector health facilities;0.0;
860;Has systems for follow-up/recall to deliver long-term penicillin prophylaxis to patients with rheumatic fever and rheumatic heart disease;0.0;
861;Existence of a register of patients who had rheumatic fever and rheumatic heart disease;0.0;
862;Availability of cardiovascular risk stratification in 50% or more primary health care facilities;0.0;
863;Existence of any policies to reduce population salt consumption;0.0;
864;Existence of national policies on saturated fatty acids / trans-fats;0.0;
865;Existence of tax on sugar-sweetened beverages;0.0;
866;General availability of statins in the public health sector;0.0;
867;General availability of steroid inhalers in the public health sector;0.0;
868;Provision for care of acute stroke and rehabilitation in more than 50% of public sector health facilities;0.0;
869;General availability of sulphonylurea(s) in the public health sector;0.0;
870;Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets;0.0;
871;Existence of a set of time-bound national targets based on WHO guidance;0.0;
872;General availability of thiazide diuretics in the public health sector;0.0;
873;General availability of thrombolytic therapy in the public health system;0.0;
874;Existence of operational policy/strategy/action plan to decrease tobacco use;0.0;
875;General availability of urine testing for albumin;0.0;
876;Total NCD Deaths (in thousands);18.66666666666667;-15.682835484453737
877;Mean fasting blood glucose (mmol/l) (age-standardized estimate);14.666666666666657;-854.3831328518478
878;Mean fasting blood glucose (mmol/l) (crude estimate)-Female;20.0;0.4679833864895051
879;Mean fasting blood glucose (mmol/l) (crude estimate)-Male;20.0;0.4812348352605751
880;Mean fasting blood glucose (mmol/l) (crude estimate);20.0;-2940.6403962402114
881;Raised fasting blood glucose (>= 7.0 mmol/L) (crude estimate)-Male;15.555555555555557;1.2127494299365331
882;Raised fasting blood glucose (>= 7.0 mmol/L) (crude estimate)-Female;15.555555555555557;1.2516386153713928
883;Raised fasting blood glucose (>= 7.0 mmol/L) (crude estimate)-Both sexes;15.555555555555557;1.2291883792429612
884;Raised fasting blood glucose (>= 7.0 mmol/L) (crude estimate);15.555555555555557;-894.0328088606617
885;Raised fasting blood glucose (>=7.0 mmol/L) (age-standardized estimate)-Male;15.555555555555557;1.14743256702327
886;Raised fasting blood glucose (>=7.0 mmol/L) (age-standardized estimate)-Female;15.555555555555557;1.2390512486168457
887;Raised fasting blood glucose (>=7.0 mmol/L) (age-standardized estimate)-Both sexes;15.555555555555557;1.2000524886856452
888;Raised fasting blood glucose (>=7.0 mmol/L) (age-standardized estimate);15.555555555555557;-894.0538033725311
889;Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%)-Both sexes;28.444444444444457;0.15377157048942713
890;Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%)-Female;28.444444444444457;0.15377157048942713
891;Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%)-Male;28.444444444444457;0.15377157048942713
892;Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%);28.444444444444457;-9934.105037769634
893;Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%)-Both sexes;28.444444444444457;0.15377157048942713
894;Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%)-Female;28.444444444444457;0.15377157048942713
895;Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%)-Male;28.444444444444457;0.15377157048942713
896;Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%);28.444444444444457;-9934.105037769634
897;Insufficiently active (crude estimate)-Male;40.888888888888886;1.6980952773988287
898;Insufficiently active (crude estimate)-Both sexes;40.888888888888886;1.697589515136472
899;Insufficiently active (crude estimate)-Female;40.888888888888886;1.6980952773988287
900;Insufficiently active (crude estimate);40.888888888888886;-3307.8578926587656
901;Premature deaths due to noncommunicable diseases (NCD) as a proportion of all NCD deaths;18.66666666666667;-15.683341246716093
902;Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease;18.66666666666667;-15.68384700897845
903;Basis for NHA estimate;61.77777777777778;-10223.67892390251
904;Neonatal mortality rate (deaths per 1000 live births)-nan;59.11111111111111;0
905;Neonatal mortality rate (deaths per 1000 live births)-Female;59.11111111111111;0.4133028673080821
906;Neonatal mortality rate (deaths per 1000 live births)-Male;59.11111111111111;0.4133028673080821
907;Neonatal mortality rate (deaths per 1000 live births);59.11111111111111;-8807.675272096356
908;National agency for tobacco control exists;0.0;
909;Budget year;28.0;-9227.165526180475
910;Reported currency;0.0;
911;Number of full-time equivalent staff in national agency;35.111111111111114;-7555.829047045178
912;Annual budget for tobacco control in currency reported;45.77777777777777;-7570.202020112939
913;Government objectives on tobacco control exist;0.0;
914;Number of new reported cases of Buruli ulcer;91.55555555555556;-8561.545150749558
915;Dracunculiasis certification status of countries at the beginning of the year;0.0;
916;Annual incidence of dracunculiasis cases;0.0;
917;Number of new reported cases of human African trypanosomiasis (T.b. gambiense);90.22222222222223;-7260.588792354675
918;Number of new reported cases of human African trypanosomiasis (T.b. rhodesiense);96.44444444444444;-9442.506969650492
919;Status of elimination of trachoma as a public health problem;0.0;
920;Population in areas that warrant treatment with antibiotics, facial cleanliness and environmental improvement for elimination of trachoma as a public health problem;73.77777777777777;-7753.89161059999
921;Number of people who received treatment with antibiotics for trachoma;72.0;-6311.504620374559
922;Status of bejel endemicity;0.0;
923;Status of endemicity of cutaneous leishmaniasis;0.0;
924;Number of cases of cutaneous leishmaniasis reported;65.33333333333333;-5594.420344776384
925;Number of imported cases of cutaneous leishmaniasis reported;57.33333333333333;-8524.556132088299
926;Status of endemicity of visceral leishmaniasis;0.0;
927;Number of cases of visceral leishmaniasis reported;66.22222222222223;-5821.016517619101
928;Number of imported cases of visceral leishmaniasis reported;53.77777777777778;-8376.022266824131
929;Number of female leprosy new cases;16.0;-5439.070452078777
930;New leprosy case detection rate per 1 000 000 population;15.555555555555557;-5111.68049884944
931;Leprosy - Number of cases registered for treatment;16.888888888888886;-5339.936470960211
932;Leprosy registered prevalence rate per 1 000 000 population;16.888888888888886;-5342.937803145263
933;Number of new G2D leprosy cases;17.33333333333333;-5479.24009905193
934;Leprosy - New leprosy cases with G2D rate per 1 000 000 population;17.33333333333333;-5478.954837210507
935;Leprosy - Number of new leprosy cases among children (less than 15 years of age);16.0;-5402.555223322429
936;Number of new leprosy cases with G2D among children (less than 15 years of age);20.888888888888886;-7315.838685869468
937;Estimated number of individuals in the country requiring preventive chemotherapy for onchocerciasis;86.22222222222223;-8799.77985530258
938;Status of endemicity of onchocerciasis;0.0;
939;Reported number of individuals treated for onchocerciasis;84.44444444444444;-7188.179669863238
940;Status of pinta endemicity;0.0;
941;Reported number of human rabies deaths;36.0;-7010.7013699844365
942;Number of people operated for trachomatous trichiasis;72.0;-7944.941578899319
943;Status of endemicity of Taenia solium;0.0;
944;Number of pigs in the country;18.222222222222214;-8988.999943744086
945;Practice of backyard pig production;0.0;
946;Status of yaws endemicity;0.0;
947;Number of cases of yaws reported;94.66666666666667;-10251.198365397746
948;Overweight numbers among children under 5 years of age (millions);0.0;
949;Overweight prevalence among children under 5 years of age (%);31.111111111111114;-14.973839785141354
950;Proportion of children aged 6-23 months who receive a minimum acceptable diet;71.11111111111111;-10034.108711419447
951;Children aged <5 years wasted for age (%)-Both sexes;31.111111111111114;0.49129860008125537
952;Children aged <5 years wasted for age (%)-Male;31.111111111111114;0.4441776984776711
953;Children aged <5 years wasted for age (%)-Female;31.111111111111114;0.4304545052238562
954;Children aged <5 years wasted for age (%);31.111111111111114;-7838.8798587460415
955;Early initiation of breastfeeding (%);42.22222222222223;-8334.006754668868
956;Exclusive breastfeeding under 6 months (%);48.0;-9418.882024703049
957;Prevalence of underweight children under 5 years of age   (% weight-for-age <-2 SD) (%);32.44444444444444;-6674.459805864054
958;Prevalence of wasted children under 5 years of age   (% weight-for-height <-2 SD);32.44444444444444;-6693.806996560774
959;Prevalence of severely wasted children under 5 years of age   (% weight-for-height <-3 SD)-Both sexes;33.33333333333334;0.4872845285201173
960;Prevalence of severely wasted children under 5 years of age   (% weight-for-height <-3 SD);33.33333333333334;-6877.581604450237
961;Severe wasted numbers among children under 5 years of age (millions);0.0;
962;Severe wasted prevalence among children under 5 years of age (%);0.0;
963;Stunting numbers among children under 5 years of age (millions);0.0;
964;Stunting prevalence among children under 5 years of age (%);31.111111111111114;-11.191346304960014
965;Underweight numbers among children under 5 years of age (millions);0.0;
966;Underweight prevalence among children under 5 years of age (%);0.0;
967;Wasted numbers among children under 5 years of age (millions);0.0;
968;Wasted prevalence among children under 5 years of age (%);0.0;
969;Treatment for tobacco dependence available in the community;0.0;
970;Treatment for tobacco dependence available in health clinics or other primary care facilities;0.0;
971;Treatment for tobacco dependence available in hospitals;0.0;
972;Treatment for tobacco dependence available in offices of health professionals;0.0;
973;Treatment for tobacco dependence available in other settings;0.0;
974;Bupropion - cost covered;0.0;
975;Bupropion - legally sold;0.0;
976;Bupropion - place available;0.0;
977;Offering help to quit tobacco use;13.333333333333329;-4713.267833299103
978;Treatment for tobacco dependence in the community cost covered;0.0;
979;Treatment for tobacco dependence in health clinics or other primary care facilities cost covered;0.0;
980;Treatment for tobacco dependence in hospitals cost covered;0.0;
981;Treatment for tobacco dependence in offices of health professionals cost covered;0.0;
982;Treatment for tobacco dependence in other settings cost covered;0.0;
983;Nicotine replacement therapy on the Essential Medicines List;0.0;
984;Nicotine replacement therapy - cost covered;0.0;
985;Nicotine replacement therapy - legally sold;0.0;
986;Nicotine replacement therapy - place available;0.0;
987;Access to a toll-free quit line;0.0;
988;Varenicline - cost covered;0.0;
989;Varenicline - legally sold;0.0;
990;Varenicline - place available;0.0;
991;Occupational risk factors attributable deaths;0.0;
992;Occupational carcinogens attributable DALYs ('000);0.0;
993;Occupational carcinogens attributable deaths per 100'000 capita;0.0;
994;Occupational carcinogens attributable DALYs per 100'000 capita;0.0;
995;Occupational noise attributable DALYs ('000);0.0;
996;Occupational noise attributable DALYs per 100'000 capita;0.0;
997;Occupational ergonomic stressors attributable deaths;0.0;
998;Occupational ergonomic stressors attributable DALYs ('000);0.0;
999;Occupational ergonomic stressors attributable deaths per 100'000 capita;0.0;
1000;Occupational ergonomic stressors attributable DALYs per 100'000 capita;0.0;
1001;Occupational injuries attributable deaths;0.0;
1002;Occupational risk factors attributable DALYs ('000);0.0;
1003;Occupational injuries attributable DALYs ('000);0.0;
1004;Occupational injuries attributable deaths per 100'000 capita;0.0;
1005;Occupational injuries attributable DALYs per 100'000 capita;0.0;
1006;Occupational risk factors attributable deaths per 100'000 capita;0.0;
1007;Occupational risk factors attributable DALYs per 100'000 capita;0.0;
1008;Occupational airborne particulates attributable deaths;0.0;
1009;Occupational airborne particulates attributable DALYs ('000);0.0;
1010;Occupational airborne particulates attributable deaths per 100'000 capita;0.0;
1011;Occupational airborne particulates attributable DALYs per 100'000 capita;0.0;
1012;Occupational carcinogens attributable deaths;0.0;
1013;Donor commitments (Million, constant 2009 US$);88.88888888888889;-9936.134175973602
1014;Commitments to recipient countries (Million, constant 2009 US$);47.111111111111114;-3198.8986860806417
1015;Donor disbursements (Million, constant 2009 US$);88.88888888888889;-9963.466405000465
1016;Disbursements to recipient countries (Million, constant 2009 US$);47.111111111111114;-3198.9002033674265
1017;Children aged < 5 years with diarrhoea receiving oral rehydration salts (%)-nan;50.22222222222222;0
1018;Children aged < 5 years with diarrhoea receiving oral rehydration salts (%)-Female;50.22222222222222;0.5146634786916855
1019;Children aged < 5 years with diarrhoea receiving oral rehydration salts (%)-Male;50.22222222222222;0.5156239655185186
1020;Children aged < 5 years with diarrhoea receiving oral rehydration salts (%);50.22222222222222;-8312.683442643078
1021;Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%)-nan;50.22222222222222;0
1022;Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%)-Female;50.22222222222222;0.5117671975099194
1023;Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%)-Male;50.22222222222222;0.5127282814405074
1024;Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%);50.22222222222222;-8326.573274476315
1025;Overweight prevalence in children aged <three years (%);0.0;
1026;Overweight prevalence in children aged <five years (%)-nan;54.22222222222222;0
1027;Overweight prevalence in children aged <five years (%)-Female;54.22222222222222;0.43010238119361865
1028;Overweight prevalence in children aged <five years (%)-Male;54.22222222222222;0.43010238119361865
1029;Overweight prevalence in children aged <five years (%);54.22222222222222;-8709.725364320902
1030;National smoking ban: NUMBER OF PLACES SMOKE-FREE;13.333333333333329;-4713.1786694555585
1031;Protecting people from tobacco smoke;13.333333333333329;-4713.270850038204
1032;Compliance of ban on smoking in HEALTH-CARE FACILITIES;52.88888888888889;-10182.94377516039
1033;National smoking ban in HEALTH-CARE FACILITIES;0.0;
1034;Subnational smoking bans - authority exists;0.0;
1035;National smoking ban: FINES FOR VIOLATIONS;0.0;
1036;National smoking ban: FINES ON THE ESTABLISHMENT;0.0;
1037;National smoking ban: FINES ON THE PATRON;0.0;
1038;National smoking ban: DEDICATED FUNDS FOR ENFORCEMENT;0.0;
1039;National smoking ban: CITIZEN COMPLAINTS AND INVESTIGATIONS;0.0;
1040;Comprehensive bans in place subnationally;0.0;
1041;Compliance of ban on smoking in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES;52.0;-10192.88691219596
1042;National smoking ban in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES;0.0;
1043;Compliance of ban on smoking in UNIVERSITIES;58.666666666666664;-10249.79611259415
1044;National smoking ban in UNIVERSITIES;0.0;
1045;Compliance of ban on smoking in GOVERNMENT FACILITIES;64.44444444444444;-10348.764356933061
1046;National smoking ban in GOVERNMENT FACILITIES;0.0;
1047;Compliance of ban on smoking in INDOOR OFFICES;75.55555555555556;-10460.114077193155
1048;National smoking ban in INDOOR OFFICES;0.0;
1049;Compliance of ban on smoking in RESTAURANTS;76.44444444444444;-10473.628563399057
1050;National smoking ban in RESTAURANTS;0.0;
1051;Compliance of ban on smoking in PUBS AND BARS;77.77777777777777;-10497.753173097366
1052;National smoking ban in PUBS AND BARS;0.0;
1053;Compliance of ban on smoking in PUBLIC TRANSPORT;64.0;-10323.357495946248
1054;National smoking ban in PUBLIC TRANSPORT;0.0;
1055;National smoking ban in ALL OTHER INDOOR PUBLIC PLACES;0.0;
1056;Compliance with regulations on smoke-free environments (national legislation);34.66666666666667;-8752.962572857054
1057;Pneumoccocal conjugate vaccines (PCV3) immunization coverage among 1-year-olds (%);34.66666666666667;-5043.002118412554
1058;Antenatal care attendees who were positive for syphilis (%);34.66666666666667;-5362.326813335777
1059;Men who have sex with men (MSM) with active syphilis (%);52.88888888888889;-8881.100691853044
1060;Sex workers with active syphilis (%);48.88888888888889;-8524.503567410762
1061;Women accessing antenatal care (ANC) services who were tested for syphilis (%);35.55555555555556;-6120.90017244971
1062;Antenatal care attendees positive for syphilis who received treatment (%);0.0;
1063;Postnatal care visit within two days of birth (in the x years preceding the survey) (%);0.0;
1064;Postnatal care visit within two days of birth (in the three years preceding the survey) (%)-Male;80.0;0.08247143903020326
1065;Postnatal care visit within two days of birth (in the three years preceding the survey) (%)-Female;80.0;0.08145991450548973
1066;Postnatal care visit within two days of birth (in the three years preceding the survey) (%)-nan;80.0;0
1067;Postnatal care visit within two days of birth (in the three years preceding the survey) (%);80.0;-10360.25501032995
1068;Postnatal care visit within two days of birth (in the five years preceding the survey) (%)-Male;80.0;0.08247143903020326
1069;Postnatal care visit within two days of birth (in the five years preceding the survey) (%)-Female;80.0;0.08247143903020326
1070;Postnatal care visit within two days of birth (in the five years preceding the survey) (%)-nan;80.0;0
1071;Postnatal care visit within two days of birth (in the five years preceding the survey) (%);80.0;-10360.25501032995
1072;Postnatal care visit within two days of birth - born outside a health facility (in the x years preceding the survey) (%);0.0;
1073;Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%)-Male;84.0;0.06485145777804924
1074;Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%)-Female;84.0;0.06434569551569247
1075;Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%)-nan;84.0;0
1076;Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%);84.0;-10442.515589240635
1077;Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%)-Male;83.55555555555556;0.06535166434091622
1078;Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%)-Female;83.55555555555556;0.06434569551569247
1079;Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%)-nan;83.55555555555556;0
1080;Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%);83.55555555555556;-10437.30112964438
1081;Polio immunization coverage among one-year-olds (%)-nan;51.55555555555556;0
1082;Polio immunization coverage among one-year-olds (%)-Female;51.55555555555556;0.8456640814454208
1083;Polio immunization coverage among one-year-olds (%)-Male;51.55555555555556;0.8461300627432764
1084;Polio immunization coverage among one-year-olds (%);51.55555555555556;-8321.808917069317
1085;Average - taxes as a % of cigarette price - ad valorem excise;49.33333333333333;-9645.199536515054
1086;Most sold brand of cigarettes - taxes as a % of price - ad valorem excise;13.333333333333329;-4964.015027342415
1087;Tax administration: If duty free imports are limited, duty free allowance (number of cigarette sticks);0.0;
1088;Tax administration: Bans or limits on duty free imports by travellers;0.0;
1089;Tax administration: Tax stamps applied on tobacco products;0.0;
1090;Affordability - percentage of GDP per capita required to purchase 2000 cigarettes of the most sold brand;14.666666666666657;-5723.192502619791
1091;Affordability: Price dispersion: share of cheapest brand price in premium brand price (the higher the % the smaller the gap);29.777777777777786;-9944.646001179579
1092;Affordability: Specific tax component automatically adjusted for inflation (or other);0.0;
1093;Cheapest brand of cigarettes - currency reported;0.0;
1094;Most sold brand of cigarettes - currency reported;0.0;
1095;Premium brand of cigarettes - currency reported;0.0;
1096;Tobacco excises increased over the survey period;0.0;
1097;Tax structure: Minimum specific tax applied in ad valorem or mixed excise regime;0.0;
1098;Tax structure: Excise tax proportion of price;19.555555555555557;-9819.094184183763
1099;Tax structure: Retail price used as base of ad valorem component in ad valorem or mixed excise regime (or retail price exclusive of VAT);0.0;
1100;Tax structure: Greater reliance on specific tax in mixed excise regime;0.0;
1101;Tax structure: Type of excise tax applied;0.0;
1102;Tax structure: Uniform excise tax;0.0;
1103;Raising taxes on tobacco;14.222222222222229;-5449.384844572091
1104;Average - taxes as a % of cigarette price - import duties;49.33333333333333;-9645.288423838967
1105;Most sold brand of cigarettes - taxes as a % of price - import duties;13.333333333333329;-4964.333405400984
1106;Average - taxes as a % of cigarette price - other taxes;49.33333333333333;-9645.288237491885
1107;Most sold brand of cigarettes - taxes as a % of price - other taxes;13.333333333333329;-4964.304414500619
1108;Most sold brand of cigarettes - price in currency reported;13.333333333333329;-4956.455563940115
1109;Premium brand of cigarettes - price in currency reported;25.77777777777777;-9902.333741112378
1110;Premium brand of cigarettes - price in international dollars;28.0;-9911.157015258857
1111;Premium brand of cigarettes - price in US$ at official exchange rates;25.77777777777777;-9902.333642397818
1112;Average - taxes as a % of cigarette price - specific excise;49.33333333333333;-9645.181655891967
1113;Most sold brand of cigarettes - taxes as a % of price - specific excise;13.333333333333329;-4964.046238857531
1114;Average - taxes as a % of cigarette price - total tax;49.33333333333333;-9645.143636882261
1115;Most sold brand of cigarettes - taxes as a % of price - total tax;13.333333333333329;-4960.260177219985
1116;Average - taxes as a % of cigarette price - value added tax;49.33333333333333;-9645.20334700483
1117;Most sold brand of cigarettes - taxes as a % of price - value added tax;13.333333333333329;-4964.0825840408825
1118;Existence of any national radon activity;0.0;
1119;Existence of national radon survey(s);0.0;
1120;National radon concentration levels;98.66666666666667;-10753.997143460134
1121;Existence of national radon database;0.0;
1122;Data in national radon database;0.0;
1123;Existence of national radon action plan;0.0;
1124;Existence of national radon regulations;0.0;
1125;Radon in building regulations for new buildings;0.0;
1126;Radon in building regulations for existing buildings i.e. renovation/remodeling/major alteration;0.0;
1127;Radon in national drinking-water regulations;0.0;
1128;Existence of national reference level for dwellings and buildings with high public occupancy;0.0;
1129;Existence of national reference level for buildings with high public occupancy;0.0;
1130;Existence of official protocols for radon measurements;0.0;
1131;Radon concentration measurements for new buildings;0.0;
1132;Radon concentration measurements for existing buildings;0.0;
1133;Authorization/accreditation required for official radon measurement providers;0.0;
1134;Mandatory preventive measures (new buildings);0.0;
1135;Mandatory mitigation measures if legal value is exceeded (existing buildings);0.0;
1136;Financial support provided for mitigation (existing dwellings);0.0;
1137;Authorization/accreditation required for prevention/mitigation service providers;0.0;
1138;Official standards/guidelines for prevention/mitigation;0.0;
1139;Existence of training/education on prevention/mitigation;0.0;
1140;Existence of national radon risk communication strategy;0.0;
1141;Inclusion of radon measurements in property transactions;0.0;
1142;Inclusion of radon in national cancer control strategy;0.0;
1143;Congenital syphilis rate per 100 000 live births;0.0;
1144;Annual tax revenues - currency;0.0;
1145;Annual tax revenues - total excise (specific and ad valorem);34.222222222222214;-9992.115426112501
1146;Annual tax revenues - total revenues;72.44444444444444;-10373.646519387346
1147;Annual tax revenues - import duties and all other taxes (excluding corporate taxes on tobacco companies);64.44444444444444;-10302.463129764743
1148;Annual tax revenues - tobacco products included;0.0;
1149;Annual tax revenues - value added tax (vat) and other sales taxes;65.33333333333333;-10267.37557142351
1150;Annual tax revenues - year;0.0;
1151;Intimate partner violence prevalence among ever partnered women (%);0.0;
1152;Non-partner sexual violence prevalence (%);0.0;
1153;Rotavirus vaccines completed dose (RotaC) immunization coverage among 1-year-olds (%);52.0;-6274.234319505525
1154;Income level;0.0;
1155;Number of registered vehicles;0.0;
1156;Estimated number of road traffic deaths;18.66666666666667;-15.738298211820734
1157;Estimated road traffic death rate (per 100 000 population);18.66666666666667;-15.682835484453737
1158;Existence of a national drink-driving law;0.0;
1159;Definition of drink-driving by BAC;0.0;
1160;Blood Alcohol Concentration (BAC) limit for drivers;0.0;
1161;Attribution of road traffic deaths to alcohol (%);0.0;
1162;Existence of a national seat-belt law;0.0;
1163;Applicability of seat-belt law to all occupants;0.0;
1164;Seat-belt wearing rate (%);0.0;
1165;Existence of a national child-restraint law;0.0;
1166;Existence of national speed limits;0.0;
1167;Maximum speed limits;0.0;
1168;Applicability of national motorcycle helmet law to all occupants;0.0;
1169;Law requires helmet to be fastened;0.0;
1170;Existence of a road safety lead agency;0.0;
1171;Existence of a national road safety strategy;0.0;
1172;Availability of funding for national road safety strategy;0.0;
1173;Existence of a formal pre-hospital care system;0.0;
1174;Existence of a universal access telephone number for pre-hospital care;0.0;
1175;Vehicle standards;0.0;
1176;Distribution of road traffic deaths by type of road user (%);34.66666666666667;-10009.303408894008
1177;Gross national income per capita (Atlas method);21.333333333333343;-9795.95313406193
1178;Point prevalence (%), alcohol use disorders, 15+ years-Female;15.111111111111114;0.15805490227948038
1179;Point prevalence (%), alcohol use disorders, 15+ years-Male;15.111111111111114;0.18194464452390768
1180;Point prevalence (%), alcohol use disorders, 15+ years;15.111111111111114;-9766.497567149647
1181;National survey on substance use among children and adolescents;0.0;
1182;Government unit/official responsible for prevention for substance use;0.0;
1183;Data on substance use disorders disseminated in national annual reports;0.0;
1184;Ministry/office that takes primary responsibility for prevention for substance use;0.0;
1185;Substance use policy at the national level;0.0;
1186;Five years change in international cooperation for prevention for substance use;0.0;
1187;Substance use policy at the national level, level of integration;0.0;
1188;Government unit/official responsible for treatment of substance use disorders;0.0;
1189;Policy documents on the pharmacological treatment of substance use disorders;0.0;
1190;Ministry/office that takes primary responsibility for treatment of substance use disorders;0.0;
1191;Guidelines on the pharmacological treatment of substance use disorders;0.0;
1192;Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for treatment of substance use disorders;0.0;
1193;Legislative provision for treatment and rehabilitation of substance use disorders;0.0;
1194;Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for treatment of substance use disorders;0.0;
1195;Legislative provision for compulsory treatment;0.0;
1196;Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for prevention for alcohol and drugs;0.0;
1197;Drug courts;0.0;
1198;Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for prevention for alcohol and drugs;0.0;
1199;Programmes diverting clients from the justice system towards treatment;0.0;
1200;Five years change in international cooperation for treatment of substance use disorders;0.0;
1201;Point prevalence (%), drug use disorders, 15+ years-Female;15.111111111111114;0.13182035876461784
1202;Point prevalence (%), drug use disorders, 15+ years-Male;15.111111111111114;0.15500133906928992
1203;Point prevalence (%), drug use disorders, 15+ years;15.111111111111114;-9766.515958955586
1204;Confidentiality of health records on substance use disorders  protected by law;0.0;
1205;Confidentiality of people in treatment for substance use disorders;0.0;
1206;Government unit for substance use disorder treatment;0.0;
1207;Voluntary treatment for people with alcohol use disorders in the criminal justice system;0.0;
1208;Budget line for substance use disorder treatment;0.0;
1209;Voluntary treatment for people with drug use disorders in the criminal justice system;0.0;
1210;Financing method for substance use disorder treatment;0.0;
1211;Compulsory treatment for people with alcohol use disorders in the criminal justice system;0.0;
1212;Compulsory treatment for people with drug use disorders in the criminal justice system;0.0;
1213;Five-year change in government resources for prevention for substance use;0.0;
1214;Governement benefits for persons with substance use disorders;0.0;
1215;Five-year change in government resources for treatment of substance use disorders;0.0;
1216;Government benefits for alcohol use disorders, subsidy or disability pension;0.0;
1217;Financing methods for treatment for alcohol use disorders;0.0;
1218;Government benefits for drug use disorders, subsidy or disability pension;0.0;
1219;Financing methods for treatment for drug use disorders;0.0;
1220;Sector for inpatient detoxification of alcohol use disorders;0.0;
1221;Hypothecated taxes to be spent on prevention and treatment for substance use disorders;0.0;
1222;Age-standardized death rates, alcohol and drug use disorders, per 100 000;16.0;-9749.261600624151
1223;Sector for inpatient treatment of alcohol dependence;0.0;
1224;Government benefits for people with alcohol use disorders;0.0;
1225;Sector for outpatient treatment of alcohol dependence;0.0;
1226;Government benefits for people with drug use disorders;0.0;
1227;Sector for the treatment of alcohol-induced psychoses and other alcohol-induced psychiatric conditions;0.0;
1228;Main sector for treatment for alcohol use disorders;0.0;
1229;Sector for residential long-term rehabilitation of alcohol use disorders;0.0;
1230;Main sector for treatment for drug use disorders;0.0;
1231;Sector for inpatient detoxification of drug use disorders;0.0;
1232;Treatment programmes for children and adolescents with alcohol use disorders;0.0;
1233;Sector for inpatient treatment of drug dependence;0.0;
1234;Treatment programmes for children and adolescents with drug use disorders;0.0;
1235;Sector for outpatient treatment of drug dependence;0.0;
1236;Specialized treatment facilities for substance use disorders;0.0;
1237;Sector for substitution maintenance therapy of opioid dependence;0.0;
1238;Specialized treatment facilities for alcohol use disorders;0.0;
1239;Sector for residential long-term rehabilitation of drug use disorders;0.0;
1240;Specialized treatment facilities for drug use disorders;0.0;
1241;Treatment system for substance use disorders;0.0;
1242;Self-help groups;0.0;
1243;Treatment setting for substance use disorders, most common;0.0;
1244;Main substance at treatment entry;0.0;
1245;Specialized treatment services for drug use disoders and HIV/AIDS;0.0;
1246;Reported treatment coverage for substance dependence;0.0;
1247;Specialized treatment services for substance use disorders and TB;0.0;
1248;Guidelines on pharmacological treatment for substance use disorders;0.0;
1249;Open access services for substance use disorders;0.0;
1250;Pharmacotherapy with methadone;0.0;
1251;Treatment slots for alcohol and drug use disorders, outpatient, per 10 000;85.33333333333333;-10590.661577162706
1252;Pharmacotherapy with buprenorphine;0.0;
1253;Beds for the treatment of substance use disorders, per 100 000;63.55555555555556;-10299.036944901294
1254;Pharmacotherapy with buprenorphine/naloxone;0.0;
1255;Length of stay for inpatient detoxification, days;75.11111111111111;-10444.852117249942
1256;Access restrictions to maintenance treatment;0.0;
1257;Length of stay for inpatient short-term treatment, days;68.88888888888889;-10338.880957448495
1258;Timeframe for maintenance treatment of opioid dependence;0.0;
1259;Length of stay for inpatient long-term residential treatment, days;74.22222222222223;-10443.91772797318
1260;Registration of medications for alcohol dependence and withdrawal;0.0;
1261;Opioid agonist pharmacotherapy for the treatment of opioid dependence (detoxification or maintenance);0.0;
1262;Registration of medications for opioid dependence;0.0;
1263;Age-standardized DALYs, alcohol and drug use disorders, per 100 000;15.555555555555557;-9749.226912468259
1264;Timeframe of opioid agonist treatment;0.0;
1265;Registration of medications for opioid withdrawal;0.0;
1266;Methadone used for the treatment of opioid dependence;0.0;
1267;Registration of naloxone for injection for opioid overdose;0.0;
1268;Methadone used for detoxification or maintenance;0.0;
1269;Availability of naloxone;0.0;
1270;Methadone formulation used for the treatment of opiod dependence;0.0;
1271;Screening and brief intervention for substance use in primary health care;0.0;
1272;Buprenorphine used for the treatment of opioid dependence;0.0;
1273;Screening and brief intervention for substance use in antenatal services;0.0;
1274;Buprenorphine used for detoxification or maintenance;0.0;
1275;Recommendations for screening and brief interventions for substance use in primary health care;0.0;
1276;Buprenorphine/naloxone used for the treatment of opioid dependence;0.0;
1277;Recommendations for screening and brief interventions for substance use in antenatal services;0.0;
1278;Buprenorphine/naloxone used for detoxification or maintenance;0.0;
1279;Groups and agencies involved in prevention programs;0.0;
1280;Methadone provision in clinical and community-based settings;0.0;
1281;Prevention programmes for alcohol;0.0;
1282;Buprenorphine provision in clinical and community-based settings;0.0;
1283;Prevention programmes for specific populations for alcohol;0.0;
1284;Buprenorphine/naloxone provision in clinical and community-based settings;0.0;
1285;Prevention programmes for drugs;0.0;
1286;Supervision requirements for methadone administration;0.0;
1287;Prevention programmes for specific populations for drugs;0.0;
1288;Supervision requirements for buprenorphine administration;0.0;
1289;HIV, Hepatitis counselling and treatment availability in specialized facilities and services;0.0;
1290;Supervision requirements for buprenorphine/naloxone administration;0.0;
1291;Programmes readily available;0.0;
1292;Prescription requirements for methadone;0.0;
1293;Standards of treatment and care for public specialized treatment facilities;0.0;
1294;Prescription requirements for buprenorphine;0.0;
1295;Special treatment programmes for gambling disorder;0.0;
1296;Prescription requirements for buprenorphine/naloxone;0.0;
1297;Treatment programmes for women with alcohol use disorders;0.0;
1298;Commencement of treatment with opioid agonists;0.0;
1299;Treatment programmes for women with drug use disorders;0.0;
1300;Pharmacotherapy used for the management of alcohol withdrawal;0.0;
1301;Special housing services for alcohol use disorders;0.0;
1302;Pharmacotherapy used for the management of benzodiazepine withdrawal;0.0;
1303;Special housing services for drug use disorders;0.0;
1304;Psychoactive substance causing entry into treatment;0.0;
1305;Pharmacotherapy used for the management of cannabis withdrawal;0.0;
1306;Employment services for alcohol use disorders;0.0;
1307;Essential list of medicines;0.0;
1308;Employment services for drug use disorders;0.0;
1309;Essential list of medicines, pharmacotherapy for substance use disorders;0.0;
1310;Open access interventions for alcohol;0.0;
1311;Government unit for substance use disorder prevention;0.0;
1312;Open access interventions for drugs;0.0;
1313;Budget line for substance use disorder prevention;0.0;
1314;Health professionals providing treatment for alcohol and drug use disorders;0.0;
1315;Funding method for substance use disorder prevention;0.0;
1316;Standards of care for professionals providing treatment for alcohol and drug use disorders;0.0;
1317;Prevention activities for substance use disorders, main focus;0.0;
1318;Educational attainment in prevention;0.0;
1319;Programmes for the prevention of substance use disorders for special populations;0.0;
1320;Postgraduate training programme in prevention;0.0;
1321;Screening and brief interventions for substance use and substance use disorders;0.0;
1322;Continuing professional development in prevention;0.0;
1323;Harm reduction programmes for IDUs;0.0;
1324;Educational attainment in treatment;0.0;
1325;Epidemiological data collection system for substance use disorders;0.0;
1326;Health professionals mostly involved in treatment of substance use disorders;0.0;
1327;Postgraduate training programme in treatment;0.0;
1328;Clinical supervision of health care staff;0.0;
1329;Continuing professional development in treatment;0.0;
1330;Standards of care for health professionals;0.0;
1331;Epidemiological data collection for substance use;0.0;
1332;Standards of care for health professionals, maintenance;0.0;
1333;Service delivery data collection for substance use;0.0;
1334;Standards of care for health professionals, human rights;0.0;
1335;Regular reports on epidemiological and service delivery data for substance use;0.0;
1336;NGOs for alcohol use disorders;0.0;
1337;System of monitoring alcohol involvement in forensic pathology;0.0;
1338;NGOs for drug use disorders;0.0;
1339;System of monitoring drugs involvement in forensic pathology;0.0;
1340;Self-help groups for substance use disorders;0.0;
1341;Epidemiological data collection system for substance use among children and adolescents;0.0;
1342;Groups and agencies for the prevention of substance use disorders;0.0;
1343;Epidemiological data collection system for substance use among children and adolescents;0.0;
1344;Opioid agonist pharmacotherapy for the treatment of opioid dependence (maintenance);0.0;
1345;Treatment programmes for children and adolescents with alcohol use disorders;0.0;
1346;Service delivery data collection system for substance use disorders;0.0;
1347;Treatment programmes for children and adolescents with drug use disorders;0.0;
1348;Alcohol, consumption of pure alcohol by type of beverage (%);99.55555555555556;-10753.997143460134
1349;Alcohol, consumption of pure alcohol by type of beverage (%);99.55555555555556;-10753.997143460134
1350;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-29.07284636905385
1351;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-29.07284636905385
1352;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average;15.555555555555557;-8805.530634519815
1353;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average;15.555555555555557;-8805.530634519815
1354;Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010;0.0;
1355;Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010;0.0;
1356;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Both sexes;15.555555555555557;0.5454172835147904
1357;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Male;15.555555555555557;0.333733674591008
1358;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Female;15.555555555555557;0.2847157227591688
1359;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-8805.472045217883
1360;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Both sexes;15.555555555555557;0.5454172835147904
1361;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Male;15.555555555555557;0.333733674591008
1362;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)-Female;15.555555555555557;0.2847157227591688
1363;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-8805.472045217883
1364;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Female;15.555555555555557;0.5124067817260265
1365;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Both sexes;15.555555555555557;0.5257895305420868
1366;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Male;15.555555555555557;0.5337425842654642
1367;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol;15.555555555555557;-8176.7539897042425
1368;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Female;15.555555555555557;0.5124067817260265
1369;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Male;15.555555555555557;0.5337425842654642
1370;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol-Both sexes;15.555555555555557;0.5257895305420868
1371;Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol;15.555555555555557;-8176.752978179718
1372;Alcohol, tourist consumption (in litres of pure alcohol);16.0;-9734.679986208237
1373;Alcohol, tourist consumption (in litres of pure alcohol);16.0;-9734.679986208237
1374;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-7903.786135804697
1375;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol);15.555555555555557;-7903.786135804697
1376;Alcohol, abstainers lifetime (%)-Male;58.22222222222222;0.03853882198073855
1377;Alcohol, abstainers lifetime (%)-Both sexes;58.22222222222222;0.03644153203506173
1378;Alcohol, abstainers lifetime (%)-Female;58.22222222222222;0.048490361834801377
1379;Alcohol, abstainers lifetime (%);58.22222222222222;-10230.941109017904
1380;Alcohol, abstainers lifetime (%)-Both sexes;58.22222222222222;0.03644153203506173
1381;Alcohol, abstainers lifetime (%)-Male;58.22222222222222;0.03853882198073855
1382;Alcohol, abstainers lifetime (%)-Female;58.22222222222222;0.048490361834801377
1383;Alcohol, abstainers lifetime (%);58.22222222222222;-10230.941109017904
1384;Abstainers (15-19 years), lifetime (%)-Male;79.11111111111111;0.06044589242604248
1385;Abstainers (15-19 years), lifetime (%)-Female;79.11111111111111;0.059434367901328944
1386;Abstainers (15-19 years), lifetime (%)-Both sexes;79.11111111111111;0.06259419999100535
1387;Abstainers (15-19 years), lifetime (%);79.11111111111111;-10444.757313245795
1388;Alcohol, abstainers past 12 months (%)-Male;15.111111111111114;0.20685542646919508
1389;Alcohol, abstainers past 12 months (%)-Both sexes;15.111111111111114;0.19987996153547494
1390;Alcohol, abstainers past 12 months (%)-Female;15.111111111111114;0.22144079625391733
1391;Alcohol, abstainers past 12 months (%);15.111111111111114;-9338.382944996878
1392;Alcohol, abstainers past 12 months (%)-Male;15.111111111111114;0.20685542646919508
1393;Alcohol, abstainers past 12 months (%)-Both sexes;15.111111111111114;0.19987996153547494
1394;Alcohol, abstainers past 12 months (%)-Female;15.111111111111114;0.22144079625391733
1395;Alcohol, abstainers past 12 months (%);15.111111111111114;-9338.382944996878
1396;Abstainers (15-19 years), past 12 months (%)-Both sexes;93.77777777777777;0.01709332621389814
1397;Abstainers (15-19 years), past 12 months (%)-Male;93.77777777777777;0.013119483280827016
1398;Abstainers (15-19 years), past 12 months (%)-Female;93.77777777777777;0.013119483280827016
1399;Abstainers (15-19 years), past 12 months (%);93.77777777777777;-10665.533155492203
1400;Alcohol, consumers past 12 months (%)-Male;39.55555555555556;0.061469082089271154
1401;Alcohol, consumers past 12 months (%)-Both sexes;39.55555555555556;0.059105067500746955
1402;Alcohol, consumers past 12 months (%)-Female;39.55555555555556;0.08451331528467287
1403;Alcohol, consumers past 12 months (%);39.55555555555556;-9987.384444561156
1404;Alcohol, consumers past 12 months (%)-Male;39.55555555555556;0.061469082089271154
1405;Alcohol, consumers past 12 months (%)-Female;39.55555555555556;0.08451331528467287
1406;Alcohol, consumers past 12 months (%)-Both sexes;39.55555555555556;0.059105067500746955
1407;Alcohol, consumers past 12 months (%);39.55555555555556;-9987.384444561156
1408;Alcohol, former drinkers (%)-Both sexes;47.55555555555555;0.05054220139715948
1409;Alcohol, former drinkers (%)-Female;47.55555555555555;0.02858321923879359
1410;Alcohol, former drinkers (%)-Male;47.55555555555555;0.04523549188098963
1411;Alcohol, former drinkers (%);47.55555555555555;-10125.189917218413
1412;Alcohol, former drinkers (%)-Male;47.55555555555555;0.04523549188098963
1413;Alcohol, former drinkers (%)-Female;47.55555555555555;0.02858321923879359
1414;Alcohol, former drinkers (%)-Both sexes;47.55555555555555;0.05054220139715948
1415;Alcohol, former drinkers (%);47.55555555555555;-10125.189917218413
1416;Alcohol, heavy episodic drinking (population) past 30 days (%)-Male;46.666666666666664;0.06317683446052635
1417;Alcohol, heavy episodic drinking (population) past 30 days (%)-Female;46.666666666666664;0.047509884248887246
1418;Alcohol, heavy episodic drinking (population) past 30 days (%)-Both sexes;46.666666666666664;0.05526310908374432
1419;Alcohol, heavy episodic drinking (population) past 30 days (%);46.666666666666664;-10102.436505567197
1420;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Both sexes;16.0;0.21950546117591285
1421;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Female;16.0;0.22695042334242155
1422;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Male;16.0;0.2325186788188618
1423;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%);16.0;-9096.275571578177
1424;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Male;16.0;0.2325186788188618
1425;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Both sexes;16.0;0.21950546117591285
1426;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)-Female;16.0;0.22695042334242155
1427;Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%);16.0;-9096.275065815915
1428;Alcohol, patterns of drinking score;0.0;
1429;Alcohol, patterns of drinking score;0.0;
1430;Age-standardized DALYs, alcohol use disorders, per 100,000-Male;16.888888888888886;0.1844767203705131
1431;Age-standardized DALYs, alcohol use disorders, per 100,000-Both sexes;16.888888888888886;0.18226277451562645
1432;Age-standardized DALYs, alcohol use disorders, per 100,000-Female;16.888888888888886;0.15491858310262296
1433;Age-standardized DALYs, alcohol use disorders, per 100,000;16.888888888888886;-9771.54692105699
1434;Age-standardized DALYs, breast cancer, per 100,000-Female;15.111111111111114;0.17941583321212384
1435;Age-standardized DALYs, breast cancer, per 100,000-Both sexes;15.111111111111114;0.17662919694085844
1436;Age-standardized DALYs, breast cancer, per 100,000-Male;15.111111111111114;0.0008699325296444016
1437;Age-standardized DALYs, breast cancer, per 100,000;15.111111111111114;-9766.496679593774
1438;Age-standardized DALYs, colon and rectum cancers, per 100,000-Both sexes;15.555555555555557;0.1667113808105043
1439;Age-standardized DALYs, colon and rectum cancers, per 100,000-Male;15.555555555555557;0.16895058075843794
1440;Age-standardized DALYs, colon and rectum cancers, per 100,000-Female;15.555555555555557;0.1647135858541242
1441;Age-standardized DALYs, colon and rectum cancers, per 100,000;15.555555555555557;-9766.500095960959
1442;Age-standardized DALYs, diabetes mellitus, per 100,000-Male;15.111111111111114;0.1832710345055184
1443;Age-standardized DALYs, diabetes mellitus, per 100,000-Female;15.111111111111114;0.1803604295828154
1444;Age-standardized DALYs, diabetes mellitus, per 100,000-Both sexes;15.111111111111114;0.1849792180980483
1445;Age-standardized DALYs, diabetes mellitus, per 100,000;15.111111111111114;-9766.492127733414
1446;Age-standardized DALYs, drownings, per 100,000-Male;16.0;0.1772018873572372
1447;Age-standardized DALYs, drownings, per 100,000-Both sexes;16.0;0.17973069866902103
1448;Age-standardized DALYs, drownings, per 100,000-Female;16.0;0.16374629394313756
1449;Age-standardized DALYs, drownings, per 100,000;16.0;-9766.494656544724
1450;Age-standardized DALYs, falls, per 100,000-Male;15.111111111111114;0.17599946602706407
1451;Age-standardized DALYs, falls, per 100,000-Female;15.111111111111114;0.16897583485148493
1452;Age-standardized DALYs, falls, per 100,000-Both sexes;15.111111111111114;0.17340372656125824
1453;Age-standardized DALYs, falls, per 100,000;15.111111111111114;-9766.500601723223
1454;Age-standardized DALYs, fires, per 100,000-Female;16.888888888888886;0.16317988894873636
1455;Age-standardized DALYs, fires, per 100,000-Both sexes;16.888888888888886;0.1743208792445241
1456;Age-standardized DALYs, fires, per 100,000-Male;16.888888888888886;0.1734739192501018
1457;Age-standardized DALYs, fires, per 100,000;16.888888888888886;-9771.549831661912
1458;Age-standardized DALYs, ischaemic heart disease, per 100,000-Male;15.111111111111114;0.18700226714747537
1459;Age-standardized DALYs, ischaemic heart disease, per 100,000-Female;15.111111111111114;0.18700226714747537
1460;Age-standardized DALYs, ischaemic heart disease, per 100,000-Both sexes;15.111111111111114;0.1864965048851186
1461;Age-standardized DALYs, ischaemic heart disease, per 100,000;15.111111111111114;-9766.493139257938
1462;Age-standardized DALYs, liver cancer, per 100,000-Male;15.555555555555557;0.18440626800626259
1463;Age-standardized DALYs, liver cancer, per 100,000-Both sexes;15.555555555555557;0.18491203026861935
1464;Age-standardized DALYs, liver cancer, per 100,000-Female;15.555555555555557;0.18440626800626259
1465;Age-standardized DALYs, liver cancer, per 100,000;15.555555555555557;-9775.695824363207
1466;Age-standardized DALYs, liver cirrhosis, per 100,000-Both sexes;15.555555555555557;0.17663246147568
1467;Age-standardized DALYs, liver cirrhosis, per 100,000-Male;15.555555555555557;0.18175701225326968
1468;Age-standardized DALYs, liver cirrhosis, per 100,000-Female;15.555555555555557;0.1722045697659067
1469;Age-standardized DALYs, liver cirrhosis, per 100,000;15.555555555555557;-9771.547932581516
1470;Age-standardized DALYs, mouth and oropharynx cancer, per 100,000-Both sexes;15.111111111111114;0.16104633603822238
1471;Age-standardized DALYs, mouth and oropharynx cancer, per 100,000-Female;15.111111111111114;0.14101131862066918
1472;Age-standardized DALYs, mouth and oropharynx cancer, per 100,000-Male;15.111111111111114;0.17015626662343264
1473;Age-standardized DALYs, mouth and oropharynx cancer, per 100,000;15.111111111111114;-9766.503760265447
1474;Age-standardized DALYs, oesophagus cancer, per 100,000-Female;20.444444444444443;0.11386370827218162
1475;Age-standardized DALYs, oesophagus cancer, per 100,000-Male;20.444444444444443;0.15455878083228436
1476;Age-standardized DALYs, oesophagus cancer, per 100,000-Both sexes;20.444444444444443;0.14604044446497522
1477;Age-standardized DALYs, oesophagus cancer, per 100,000;20.444444444444443;-9814.250646970075
1478;Age-standardized DALYs, poisoning, per 100,000-Female;23.555555555555557;0.14271714242354827
1479;Age-standardized DALYs, poisoning, per 100,000-Male;23.555555555555557;0.16283523515613618
1480;Age-standardized DALYs, poisoning, per 100,000-Both sexes;23.555555555555557;0.16155935336061988
1481;Age-standardized DALYs, poisoning, per 100,000;23.555555555555557;-9827.055977786145
1482;Age-standardized DALYs, prematurity and low birth rate, per 100,000-Male;15.555555555555557;0.18397095810815633
1483;Age-standardized DALYs, prematurity and low birth rate, per 100,000-Female;15.555555555555557;0.18681463487683736
1484;Age-standardized DALYs, prematurity and low birth rate, per 100,000-Both sexes;15.555555555555557;0.1864965048851186
1485;Age-standardized DALYs, prematurity and low birth rate, per 100,000;15.555555555555557;-9766.494150782462
1486;Age-standardized DALYs, road traffic accidents, per 100,000-Both sexes;15.111111111111114;0.18599074262276183
1487;Age-standardized DALYs, road traffic accidents, per 100,000-Male;15.111111111111114;0.18700226714747537
1488;Age-standardized DALYs, road traffic accidents, per 100,000-Female;15.111111111111114;0.18428255903023194
1489;Age-standardized DALYs, road traffic accidents, per 100,000;15.111111111111114;-9766.492633495676
1490;Age-standardized DALYs, self-inflicted injury, per 100,000-Male;15.555555555555557;0.183461931310978
1491;Age-standardized DALYs, self-inflicted injury, per 100,000-Both sexes;15.555555555555557;0.1786555105251071
1492;Age-standardized DALYs, self-inflicted injury, per 100,000-Female;15.555555555555557;0.17309580343300057
1493;Age-standardized DALYs, self-inflicted injury, per 100,000;15.555555555555557;-9766.49566806925
1494;Age-standardized DALYs, other unintentional injuries, per 100,000-Female;15.111111111111114;0.1849792180980483
1495;Age-standardized DALYs, other unintentional injuries, per 100,000-Male;15.111111111111114;0.18750802940983213
1496;Age-standardized DALYs, other unintentional injuries, per 100,000-Both sexes;15.111111111111114;0.18447345583569152
1497;Age-standardized DALYs, other unintentional injuries, per 100,000;15.111111111111114;-9766.4936450202
1498;Age-standardized DALYs, violence, per 100,000-Male;15.111111111111114;0.18750802940983213
1499;Age-standardized DALYs, violence, per 100,000-Female;15.111111111111114;0.18005659672443297
1500;Age-standardized DALYs, violence, per 100,000-Both sexes;15.111111111111114;0.1864965048851186
1501;Age-standardized DALYs, violence, per 100,000;15.111111111111114;-9766.492127733414
1502;Age-standardized death rates, alcohol use disorders, per 100,000-Male;17.777777777777786;0.13911229109963763
1503;Age-standardized death rates, alcohol use disorders, per 100,000-Female;17.777777777777786;0.10048543152891964
1504;Age-standardized death rates, alcohol use disorders, per 100,000-Both sexes;17.777777777777786;0.12422868950024357
1505;Age-standardized death rates, alcohol use disorders, per 100,000-nan;17.777777777777786;0
1506;Age-standardized death rates, alcohol use disorders, per 100,000;17.777777777777786;-8838.204385218289
1507;Age-standardized death rates, breast cancer, per 100,000-nan;15.111111111111114;0
1508;Age-standardized death rates, breast cancer, per 100,000-Female;15.111111111111114;0.17612343467850167
1509;Age-standardized death rates, breast cancer, per 100,000-Male;15.111111111111114;0.050512463537081054
1510;Age-standardized death rates, breast cancer, per 100,000-Both sexes;15.111111111111114;0.16721061076153942
1511;Age-standardized death rates, breast cancer, per 100,000;15.111111111111114;-8828.494714488965
1512;Age-standardized death rates, colon and rectum cancers, per 100,000-Both sexes;15.111111111111114;0.17059183619694585
1513;Age-standardized death rates, colon and rectum cancers, per 100,000-Male;15.111111111111114;0.16822775846203042
1514;Age-standardized death rates, colon and rectum cancers, per 100,000-Female;15.111111111111114;0.16709226528587928
1515;Age-standardized death rates, colon and rectum cancers, per 100,000-nan;15.111111111111114;0
1516;Age-standardized death rates, colon and rectum cancers, per 100,000;15.111111111111114;-8828.49035352541
1517;Age-standardized death rates, diabetes mellitus, per 100,000-Female;15.111111111111114;0.18245040678626445
1518;Age-standardized death rates, diabetes mellitus, per 100,000-Both sexes;15.111111111111114;0.1835858999624156
1519;Age-standardized death rates, diabetes mellitus, per 100,000-Male;15.111111111111114;0.18295616904862122
1520;Age-standardized death rates, diabetes mellitus, per 100,000;15.111111111111114;-9766.494150782462
1521;Age-standardized death rates, drownings, per 100,000-Female;15.111111111111114;0.14597107881221172
1522;Age-standardized death rates, drownings, per 100,000-Both sexes;15.111111111111114;0.15990390053343173
1523;Age-standardized death rates, drownings, per 100,000-Male;15.111111111111114;0.16815520713223098
1524;Age-standardized death rates, drownings, per 100,000-nan;15.111111111111114;0
1525;Age-standardized death rates, drownings, per 100,000;15.111111111111114;-8828.496514854805
1526;Age-standardized death rates, falls, per 100,000-Female;16.0;0.1481000686277314
1527;Age-standardized death rates, falls, per 100,000-Both sexes;16.0;0.15109632348618174
1528;Age-standardized death rates, falls, per 100,000-Male;16.0;0.1590580187211308
1529;Age-standardized death rates, falls, per 100,000-nan;16.0;0
1530;Age-standardized death rates, falls, per 100,000;16.0;-8828.49959110244
1531;Age-standardized death rates, fires, per 100,000-Female;17.33333333333333;0.15298808686600607
1532;Age-standardized death rates, fires, per 100,000-Male;17.33333333333333;0.1538950584173877
1533;Age-standardized death rates, fires, per 100,000-Both sexes;17.33333333333333;0.1462581162959422
1534;Age-standardized death rates, fires, per 100,000-nan;17.33333333333333;0
1535;Age-standardized death rates, fires, per 100,000;17.33333333333333;-8838.119559979867
1536;Age-standardized death rates, ischaemic heart disease, per 100,000-Female;15.111111111111114;0.18750802940983213
1537;Age-standardized death rates, ischaemic heart disease, per 100,000-Both sexes;15.111111111111114;0.18599074262276183
1538;Age-standardized death rates, ischaemic heart disease, per 100,000-Male;15.111111111111114;0.1880137916721889
1539;Age-standardized death rates, ischaemic heart disease, per 100,000;15.111111111111114;-9766.493139257938
1540;Age-standardized death rates, liver cancer, per 100,000-Male;15.111111111111114;0.18099016049660976
1541;Age-standardized death rates, liver cancer, per 100,000-Both sexes;15.111111111111114;0.16332526693300897
1542;Age-standardized death rates, liver cancer, per 100,000-Female;15.111111111111114;0.16827917578366858
1543;Age-standardized death rates, liver cancer, per 100,000-nan;15.111111111111114;0
1544;Age-standardized death rates, liver cancer, per 100,000;15.111111111111114;-8828.49035352541
1545;Age-standardized death rates, liver cirrhosis, per 100,000-Male;15.555555555555557;0.17610144512027626
1546;Age-standardized death rates, liver cirrhosis, per 100,000-Female;15.555555555555557;0.10660974803414192
1547;Age-standardized death rates, liver cirrhosis, per 100,000-Both sexes;15.555555555555557;0.16481488648279852
1548;Age-standardized death rates, liver cirrhosis, per 100,000-nan;15.555555555555557;0
1549;Age-standardized death rates, liver cirrhosis, per 100,000;15.555555555555557;-8838.11000753738
1550;Age-standardized death rates, mouth and oropharynx cancer, per 100,000-nan;15.111111111111114;0
1551;Age-standardized death rates, mouth and oropharynx cancer, per 100,000-Both sexes;15.111111111111114;0.15990390053343173
1552;Age-standardized death rates, mouth and oropharynx cancer, per 100,000-Female;15.111111111111114;0.08713635147268173
1553;Age-standardized death rates, mouth and oropharynx cancer, per 100,000-Male;15.111111111111114;0.16829559575159658
1554;Age-standardized death rates, mouth and oropharynx cancer, per 100,000;15.111111111111114;-8837.600425072062
1555;Age-standardized death rates, oesophagus cancer, per 100,000-Female;15.555555555555557;0.08452911331732649
1556;Age-standardized death rates, oesophagus cancer, per 100,000-Both sexes;15.555555555555557;0.15007335795527954
1557;Age-standardized death rates, oesophagus cancer, per 100,000-Male;15.555555555555557;0.1692907003083821
1558;Age-standardized death rates, oesophagus cancer, per 100,000-nan;15.555555555555557;0
1559;Age-standardized death rates, oesophagus cancer, per 100,000;15.555555555555557;-8837.60403233605
1560;Age-standardized death rates, poisoning, per 100,000-nan;18.222222222222214;0
1561;Age-standardized death rates, poisoning, per 100,000-Female;18.222222222222214;0.08776909255577259
1562;Age-standardized death rates, poisoning, per 100,000-Both sexes;18.222222222222214;0.15641503560405257
1563;Age-standardized death rates, poisoning, per 100,000-Male;18.222222222222214;0.16275084183693433
1564;Age-standardized death rates, poisoning, per 100,000;18.222222222222214;-8842.929439640382
1565;Age-standardized death rates, prematurity and low birth rate, per 100,000-Both sexes;17.33333333333333;0.17853154187366949
1566;Age-standardized death rates, prematurity and low birth rate, per 100,000-Male;17.33333333333333;0.17903730413602625
1567;Age-standardized death rates, prematurity and low birth rate, per 100,000-Female;17.33333333333333;0.13990326668034037
1568;Age-standardized death rates, prematurity and low birth rate, per 100,000;17.33333333333333;-9771.547932581514
1569;Age-standardized death rates, road traffic accidents, per 100,000-nan;15.111111111111114;0
1570;Age-standardized death rates, road traffic accidents, per 100,000-Both sexes;15.111111111111114;0.1788431427957451
1571;Age-standardized death rates, road traffic accidents, per 100,000-Female;15.111111111111114;0.1293896098602514
1572;Age-standardized death rates, road traffic accidents, per 100,000-Male;15.111111111111114;0.1849792180980483
1573;Age-standardized death rates, road traffic accidents, per 100,000;15.111111111111114;-8828.488139579556
1574;Age-standardized death rates, self-inflicted injury, per 100,000-nan;16.0;0
1575;Age-standardized death rates, self-inflicted injury, per 100,000-Both sexes;16.0;0.17188643977418794
1576;Age-standardized death rates, self-inflicted injury, per 100,000-Male;16.0;0.1775322636465182
1577;Age-standardized death rates, self-inflicted injury, per 100,000-Female;16.0;0.10739247095866755
1578;Age-standardized death rates, self-inflicted injury, per 100,000;16.0;-8828.492185677655
1579;Age-standardized death rates, other unintentional injuries, per 100,000-Male;15.111111111111114;0.18086619184517216
1580;Age-standardized death rates, other unintentional injuries, per 100,000-Female;15.111111111111114;0.17125670886039357
1581;Age-standardized death rates, other unintentional injuries, per 100,000-Both sexes;15.111111111111114;0.1725830988420043
1582;Age-standardized death rates, other unintentional injuries, per 100,000;15.111111111111114;-9766.494656544724
1583;Age-standardized death rates, violence, per 100,000-nan;15.111111111111114;0
1584;Age-standardized death rates, violence, per 100,000-Female;15.111111111111114;0.11162262314465732
1585;Age-standardized death rates, violence, per 100,000-Male;15.111111111111114;0.1817537477184481
1586;Age-standardized death rates, violence, per 100,000-Both sexes;15.111111111111114;0.17643830013539885
1587;Age-standardized death rates, violence, per 100,000;15.111111111111114;-8828.489027135429
1588;Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000-Female;75.11111111111111;0.18978044106067493
1589;Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000-Male;75.11111111111111;0.2042629801136231
1590;Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000-Both sexes;75.11111111111111;0.19876019313165916
1591;Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000;75.11111111111111;-9582.413532247687
1592;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Male;52.44444444444444;0.27920851568456584
1593;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Female;52.44444444444444;0.2903308339483943
1594;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Both sexes;52.44444444444444;0.2444608172428615
1595;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population;52.44444444444444;-8936.142618735399
1596;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Male;52.44444444444444;0.27920851568456584
1597;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Female;52.44444444444444;0.2903308339483943
1598;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population-Both sexes;52.44444444444444;0.2444608172428615
1599;Liver cirrhosis, age-standardized death rates (15+), per 100,000 population;52.44444444444444;-8936.142618735399
1600;Age-standardized death rates (15+ years), poisoning, per 100,000-Both sexes;70.22222222222223;0.2300184783088599
1601;Age-standardized death rates (15+ years), poisoning, per 100,000-Female;70.22222222222223;0.2130306138039062
1602;Age-standardized death rates (15+ years), poisoning, per 100,000-Male;70.22222222222223;0.23729004678731425
1603;Age-standardized death rates (15+ years), poisoning, per 100,000;70.22222222222223;-9297.134148380797
1604;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population-Female;87.55555555555556;0.01919917329386145
1605;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population-Male;87.55555555555556;0.025276111208711427
1606;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population;87.55555555555556;-10593.80072148011
1607;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population-Female;87.55555555555556;0.01919917329386145
1608;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population-Male;87.55555555555556;0.025276111208711427
1609;Road traffic crash deaths, age-standardized death rates (15+), per 100,000 population;87.55555555555556;-10593.80072148011
1610;Age-standardized death rates (15+ years), violence, per 100,000-Both sexes;70.22222222222223;0.24775124999933507
1611;Age-standardized death rates (15+ years), violence, per 100,000-Male;70.22222222222223;0.25097672037893526
1612;Age-standardized death rates (15+ years), violence, per 100,000-Female;70.22222222222223;0.2392772601907076
1613;Age-standardized death rates (15+ years), violence, per 100,000;70.22222222222223;-9295.624042754811
1614;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Male;48.88888888888889;0.04039486950269833
1615;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Female;48.88888888888889;0.040540759993176856
1616;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Both sexes;48.88888888888889;0.054207459601289365
1617;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI;48.88888888888889;-10132.55059627025
1618;Random breath testing (RBT) use;0.0;
1619;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Male;48.88888888888889;0.04039486950269833
1620;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Female;48.88888888888889;0.040540759993176856
1621;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI-Both sexes;48.88888888888889;0.054207459601289365
1622;Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI;48.88888888888889;-10132.55059627025
1623;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Female;42.22222222222223;0.06032298664436686
1624;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Male;42.22222222222223;0.05434470257969615
1625;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Both sexes;42.22222222222223;0.0394410748768772
1626;Alcohol use disorders (15+), 12 month prevalence (%) with 95%;42.22222222222223;-10011.108386969841
1627;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Female;42.22222222222223;0.06032298664436686
1628;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Male;42.22222222222223;0.05434470257969615
1629;Alcohol use disorders (15+), 12 month prevalence (%) with 95%-Both sexes;42.22222222222223;0.0394410748768772
1630;Alcohol use disorders (15+), 12 month prevalence (%) with 95%;42.22222222222223;-10011.108386969841
1631;Alcoholic psychosis, incidence, per 100,000;84.88888888888889;-9889.387120426087
1632;Alcoholic psychosis, incidence, per 100,000;84.88888888888889;-9889.387120426087
1633;Cautions and arrests for drink-driving, per 100,000 population;83.11111111111111;-10368.841519757418
1634;Cautions and arrests for drink-driving, per 100,000 population;83.11111111111111;-10368.841519757418
1635;Hospital discharges, alcohol-related injuries and poisoning, per 100,000;77.33333333333334;-9700.379614507192
1636;Hospital discharges, alcoholic liver disease, per 100,000;88.44444444444444;-10494.15841435933
1637;Perceived trend in alcohol-related harm and consequences;0.0;
1638;Treatment admissions (inpatient), alcohol dependence, per 100,000;92.44444444444444;-10759.301872830627
1639;Treatment admissions (inpatient), alcoholic psychosis, per 100,000;88.0;-10562.660571002163
1640;Alcohol-related road traffic crashes, per 100,000 population;69.77777777777777;-10303.481063847814
1641;Alcohol-related road traffic crashes, per 100,000 population;69.77777777777777;-10303.481063847814
1642;Alcohol-related road traffic crashes (% of all traffic crashes);77.77777777777777;-10261.619774444673
1643;Alcohol-related road traffic crashes (% of all traffic crashes);77.77777777777777;-10261.619774444673
1644;Alcohol-related injury mortality, per 1,000-Male;65.77777777777777;0.0
1645;Alcohol-related injury mortality, per 1,000-Female;65.77777777777777;0.0
1646;Alcohol-related injury mortality, per 1,000;65.77777777777777;-10759.301872830627
1647;Alcohol-related disease mortality, per 100,000 (15+ years)-Both sexes;89.77777777777777;0.025426208345380896
1648;Alcohol-related disease mortality, per 100,000 (15+ years)-Female;89.77777777777777;0.03402222075038264
1649;Alcohol-related disease mortality, per 100,000 (15+ years)-Male;89.77777777777777;0.03553950753745294
1650;Alcohol-related disease mortality, per 100,000 (15+ years);89.77777777777777;-10514.753175520867
1651;Alcoholic excise tax revenue as a per cent of government revenue;82.66666666666666;-9584.176705400763
1652;Alcoholic excise tax revenue as a per cent of government revenue;82.66666666666666;-9584.176705400763
1653;Annual revenues from alcohol excise tax in millions US$;61.77777777777778;-7595.5361936748905
1654;Annual revenues from alcohol excise tax in millions US$;61.77777777777778;-7595.5361936748905
1655;Alcohol expenditure as a per cent of total household expenditure;75.55555555555556;-9659.663121899588
1656;Alcohol expenditure as a per cent of total household expenditure;75.55555555555556;-9659.663121899588
1657;Social costs of alcohol use in millions US$;95.11111111111111;-10735.208008686554
1658;Social costs of alcohol use in millions US$;95.11111111111111;-10735.208008686554
1659;Adopted written national policy on alcohol;0.0;
1660;Adopted written national policy on alcohol;0.0;
1661;Alcoholic beverage legally defined;0.0;
1662;Alcohol use is banned;0.0;
1663;Alcohol use is banned;0.0;
1664;National legislation to prevent illegal alcohol;0.0;
1665;National legislation to prevent illegal alcohol;0.0;
1666;Advertising restrictions on national television;0.0;
1667;Advertising restrictions on national television;0.0;
1668;Advertising restrictions on cable television;0.0;
1669;Advertising restrictions on cable television;0.0;
1670;Advertising restrictions on national radio;0.0;
1671;Advertising restrictions on national radio;0.0;
1672;Advertising restrictions on local radio;0.0;
1673;Advertising restrictions on local radio;0.0;
1674;Advertising restrictions in print media;0.0;
1675;Advertising restrictions in print media;0.0;
1676;Advertising restrictions at cinemas;0.0;
1677;Advertising restrictions at cinemas;0.0;
1678;Advertising restrictions on billboards;0.0;
1679;Advertising restrictions on billboards;0.0;
1680;Advertising restrictions at point-of-sale;0.0;
1681;Advertising restrictions at point-of-sale;0.0;
1682;Advertising restrictions on the internet;0.0;
1683;Advertising restrictions on the internet;0.0;
1684;Restrictions on product placement on national television;0.0;
1685;Restrictions on product placement on national television;0.0;
1686;Restrictions on product placement on cable television;0.0;
1687;Restrictions on product placement on cable television;0.0;
1688;Age limits on-premise service;0.0;
1689;Age limits on-premise service;0.0;
1690;Minimum legal drinking age;69.77777777777777;-10351.491725440492
1691;Legal blood alcohol concentration (BAC) limits;0.0;
1692;Random breath testing (RBT) use;0.0;
1693;Prices for alcoholic beverages (average, US$);0.0;
1694;Prices for alcoholic beverages (average, US$);0.0;
1695;Off-premise sales restrictions on days;0.0;
1696;Off-premise sales restrictions on days;0.0;
1697;Off-premise sales restrictions on hours;0.0;
1698;Off-premise sales restrictions on hours;0.0;
1699;Off-premise sales restrictions on places;0.0;
1700;Off-premise sales restrictions on places;0.0;
1701;Off-premise sales restrictions on outlet density;0.0;
1702;Off-premise sales restrictions on outlet density;0.0;
1703;Off-premise sales restrictions at specific events;0.0;
1704;Off-premise sales restrictions at specific events;0.0;
1705;Off-premise sales restrictions at petrol stations;0.0;
1706;Off-premise sales restrictions at petrol stations;0.0;
1707;On-premise sales restrictions on days;0.0;
1708;On-premise sales restrictions on days;0.0;
1709;On-premise sales restrictions on hours;0.0;
1710;On-premise sales restrictions on hours;0.0;
1711;On-premise sales restrictions on places;0.0;
1712;On-premise sales restrictions on places;0.0;
1713;On-premise sales restrictions on outlet density;0.0;
1714;On-premise sales restrictions on outlet density;0.0;
1715;On-premise sales restrictions at specific events;0.0;
1716;On-premise sales restrictions at specific events;0.0;
1717;On-premise sales restrictions to intoxicated persons;0.0;
1718;On-premise sales restrictions to intoxicated persons;0.0;
1719;Restrictions on sponsorship of sporting events;0.0;
1720;Restrictions on sponsorship of sporting events;0.0;
1721;Restrictions on sponsorship of youth events;0.0;
1722;Restrictions on sponsorship of youth events;0.0;
1723;Restrictions on sales promotion from producers (parties, events);0.0;
1724;Restrictions on sales promotion from producers (parties, events);0.0;
1725;Restrictions on sales promotion from retailers (sales below cost);0.0;
1726;Restrictions on sales promotion from retailers (sales below cost);0.0;
1727;Restrictions on sales promotion from owners of pubs and bars (alcohol for free);0.0;
1728;Restrictions on sales promotion from owners of pubs and bars (alcohol for free);0.0;
1729;Government monopoly on production;0.0;
1730;Government monopoly on production;0.0;
1731;Government monopoly on retail sales;0.0;
1732;Government monopoly on retail sales;0.0;
1733;Licence required for production;0.0;
1734;Licence required for production;0.0;
1735;Licence required for retail sales;0.0;
1736;Licence required for retail sales;0.0;
1737;Excise tax as a per cent of the retail price of alcoholic beverages;99.55555555555556;-10749.164858434839
1738;Excise tax as a per cent of the retail price of alcoholic beverages;99.55555555555556;-10749.164858434839
1739;Excise duty (average) per hectolitre in Euros;83.11111111111111;-9970.479092174228
1740;Excise duty (average) per hectolitre in Euros;83.11111111111111;-9970.479092174228
1741;Excise tax as a per cent of the total retail price for 1 litre of pure alcohol;0.0;
1742;Excise tax as a per cent of the total retail price for 1 litre of pure alcohol;0.0;
1743;Duty paid or excise stamp on alcohol container;0.0;
1744;Duty paid or excise stamp on alcohol container;0.0;
1745;Excise tax on alcoholic beverages;0.0;
1746;Excise tax on alcoholic beverages;0.0;
1747;Value-added tax (VAT) on alcohol (%);0.0;
1748;Value-added tax (VAT) on alcohol (%);0.0;
1749;Restrictions on alcohol use in public places;0.0;
1750;Restrictions on alcohol use in public places;0.0;
1751;Health warning labels on alcohol advertising;0.0;
1752;Health warning labels on alcohol advertising;0.0;
1753;Health warning labels on alcohol containers;0.0;
1754;Health warning labels on alcohol containers;0.0;
1755;Awareness activities;0.0;
1756;Awareness activities;0.0;
1757;Information, education, prevention;0.0;
1758;National drinking guidelines;0.0;
1759;Standard drink measures, in grams per unit;92.44444444444444;-10700.155318006111
1760;Standard drink measures, in grams per unit;92.44444444444444;-10700.155318006111
1761;Monitoring;0.0;
1762;Interventions, projects, training;0.0;
1763;Treatment, services;0.0;
1764;Surveys, research;0.0;
1765;Counselling;0.0;
1766;Production in 1000s hectolitres;27.555555555555557;-5929.453641214601
1767;Imports in 1000s hectolitres;35.111111111111114;-6054.348310538894
1768;Sales of beer in 1000s hectolitres;23.111111111111114;-3371.9238921426618
1769;Exports of beer (barley) in 1000s hectolitres;57.77777777777778;-7089.767973226636
1770;Perceived trend in production;0.0;
1771;Perceived trend in imports;0.0;
1772;Perceived trend in sales;0.0;
1773;Perceived trend in exports;0.0;
1774;Sales of wine in 1000s hectolitres;66.22222222222223;-8418.574454950114
1775;Sales of spirits in 1000s hectolitres;86.66666666666667;-10105.073382214632
1776;Exports of wine (grape) in 1000s hectolitres;70.22222222222223;-9221.300384311591
1777;Exports of spirits in 1000s hectolitres;67.11111111111111;-8848.230688382142
1778;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) (SDG Indicator 3.5.2);16.444444444444443;-38.91364461217535
1779;Total (recorded+unrecorded) alcohol per capita (15+) consumption;74.22222222222223;-10430.381802975573
1780;Age-standardized DALYs, cerebrovascular disease, per 100,000-Female;15.111111111111114;0.1864965048851186
1781;Age-standardized DALYs, cerebrovascular disease, per 100,000-Both sexes;15.111111111111114;0.186305608079659
1782;Age-standardized DALYs, cerebrovascular disease, per 100,000-Male;15.111111111111114;0.18750802940983213
1783;Age-standardized DALYs, cerebrovascular disease, per 100,000;15.111111111111114;-9766.492633495676
1784;Age-standardized death rates, cerebrovascular disease, per 100,000-Male;15.111111111111114;0.18700226714747537
1785;Age-standardized death rates, cerebrovascular disease, per 100,000-Both sexes;15.111111111111114;0.18700226714747537
1786;Age-standardized death rates, cerebrovascular disease, per 100,000-Female;15.111111111111114;0.18548498036040506
1787;Age-standardized death rates, cerebrovascular disease, per 100,000;15.111111111111114;-9766.492633495676
1788;Central coordinating entity for alcohol policy implementation;0.0;
1789;Central coordinating entity for alcohol policy implementation;0.0;
1790;Framework of national alcohol policy;0.0;
1791;Framework of national alcohol policy;0.0;
1792;Level of adoption of national alcohol policy;0.0;
1793;Level of adoption of national alcohol policy;0.0;
1794;Sectors represented in national alcohol policy;0.0;
1795;Sectors represented in national alcohol policy;0.0;
1796;Cautions and arrests for public drunkenness, per 100,000 population;91.55555555555556;-10642.642556746301
1797;Cautions and arrests for public drunkenness, per 100,000 population;91.55555555555556;-10642.642556746301
1798;Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities);76.88888888888889;-9748.660440395504
1799;Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities);76.88888888888889;-9748.660440395504
1800;Adopted written national policy on alcohol, year adopted;0.0;
1801;Adopted written national policy on alcohol, year revised;0.0;
1802;Age limits off-premise sales;0.0;
1803;Age limits off-premise sales;0.0;
1804;Consumer information on alcohol and health at points of sale;0.0;
1805;Educational programmes involving target groups in school curriculum;0.0;
1806;Brief interventions as health promotion/disease prevention;0.0;
1807;Server training on a regular basis;0.0;
1808;Data collection on alcohol-related health indicators;0.0;
1809;System for monitoring alcohol-related harm;0.0;
1810;National treatment policy for alcohol use disorders;0.0;
1811;Persons with alcohol use disorders receiving treatment (%);84.44444444444444;-10592.51532234101
1812;Designation of alcohol tax revenues to health services;0.0;
1813;National surveys on drink-driving;0.0;
1814;Public-funded alcohol research/monitoring programmes;0.0;
1815;Public funds designated for alcohol research/monitoring programmes, in Euros;97.33333333333333;-10742.579038692082
1816;Community-based interventions/projects involving stakeholders;0.0;
1817;Interventions/projects actively involving young people and civil society;0.0;
1818;Training in screening and brief interventions for alcohol problems;0.0;
1819;Counselling to children in families with alcohol problems;0.0;
1820;Counselling to pregnant women with alcohol problems;0.0;
1821;Prevention/counselling at workplaces for those with alcohol problems;0.0;
1822;Advertising restrictions on social media;0.0;
1823;Advertising restrictions on social media;0.0;
1824;Restrictions on product placement in films/movies;0.0;
1825;Restrictions on product placement in films/movies;0.0;
1826;Importance of measures for enhancing compliance with age limits;0.0;
1827;Importance of measures for enhancing compliance with age limits;0.0;
1828;Government support for community action;0.0;
1829;Government support for community action;0.0;
1830;Community-based interventions involving stakeholders;0.0;
1831;Community-based interventions involving stakeholders;0.0;
1832;National guidelines for implementing effective community-based interventions;0.0;
1833;National guidelines for implementing effective community-based interventions;0.0;
1834;National alcohol policy specifically involves young people activities;0.0;
1835;National alcohol policy specifically involves young people activities;0.0;
1836;Penalties for drink driving;0.0;
1837;Penalties for drink driving;0.0;
1838;Sobriety checkpoints;0.0;
1839;Sobriety checkpoints;0.0;
1840;Detection of marketing infringements;0.0;
1841;Detection of marketing infringements;0.0;
1842;Penalties for marketing infringements;0.0;
1843;Price measures;0.0;
1844;Price measures;0.0;
1845;Level of taxation adjusted for inflation;0.0;
1846;Level of taxation adjusted for inflation;0.0;
1847;New types of alcoholic beverages emerging;0.0;
1848;New types of alcoholic beverages emerging;0.0;
1849;Consumer information about calories, additives, etc on containers;0.0;
1850;Consumer information about calories, additives, etc on containers;0.0;
1851;Number of standard alcoholic drinks displayed on containers;0.0;
1852;Number of standard alcoholic drinks displayed on containers;0.0;
1853;Alcohol content displayed on containers;0.0;
1854;Alcohol content displayed on containers;0.0;
1855;Action Plan for implementation of alcohol policy;0.0;
1856;Action Plan for implementation of alcohol policy;0.0;
1857;Alcohol, regional per capita (15+) consumption (in litres of pure alcohol);0.0;
1858;Alcohol, regional per capita (15+) consumption (in litres of pure alcohol);0.0;
1859;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Both sexes;16.0;0.388775827102704
1860;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Female;16.0;0.19702605726374056
1861;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Male;16.0;0.23237974241032067
1862;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI;16.0;-8805.319604388536
1863;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Both sexes;16.0;0.388775827102704
1864;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Female;16.0;0.19702605726374056
1865;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI-Male;16.0;0.23237974241032067
1866;Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI;16.0;-8805.319604388536
1867;Alcohol-attributable Years of Life Lost (YLL) score;0.0;
1868;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)-Male;87.11111111111111;0.023720263390878404
1869;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)-Female;87.11111111111111;0.011201152752697396
1870;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%);87.11111111111111;-10600.162987223352
1871;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)-Male;87.11111111111111;0.023720263390878404
1872;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)-Female;87.11111111111111;0.011201152752697396
1873;Alcohol-attributable fractions (15+), liver cirrhosis deaths (%);87.11111111111111;-10600.162987223352
1874;Alcohol-attributable fractions (15+), road traffic crash deaths (%);0.0;
1875;Alcohol-attributable fractions (15+), road traffic crash deaths (%);0.0;
1876;Alcohol-attributable fractions, all-cause deaths (%)-Female;65.77777777777777;0.037506164523730234
1877;Alcohol-attributable fractions, all-cause deaths (%)-Both sexes;65.77777777777777;0.017728347515670873
1878;Alcohol-attributable fractions, all-cause deaths (%)-Male;65.77777777777777;0.010901227047153572
1879;Alcohol-attributable fractions, all-cause deaths (%);65.77777777777777;-10341.886118004626
1880;Alcohol-attributable fractions, all-cause deaths (%)-Both sexes;65.77777777777777;0.017728347515670873
1881;Alcohol-attributable fractions, all-cause deaths (%)-Female;65.77777777777777;0.037506164523730234
1882;Alcohol-attributable fractions, all-cause deaths (%)-Male;65.77777777777777;0.010901227047153572
1883;Alcohol-attributable fractions, all-cause deaths (%);65.77777777777777;-10341.886118004626
1884;Alcohol, regional prevalence of alcohol dependence (%);0.0;
1885;Alcohol, regional prevalence of alcohol dependence (%);0.0;
1886;Alcohol, regional prevalence of alcohol use disorders (%);0.0;
1887;Alcohol, regional prevalence of alcohol use disorders (%);0.0;
1888;Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025;16.888888888888886;-8839.449592314364
1889;Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025;16.888888888888886;-8839.449592314364
1890;Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average with 95%CI;15.555555555555557;-7882.358711987593
1891;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-7946.7237214575725
1892;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-7946.7237214575725
1893;15-years old first drink at 13 years or younger, (%)-Male;82.66666666666666;0.0677648362509422
1894;15-years old first drink at 13 years or younger, (%)-Both sexes;82.66666666666666;0.06632966187795031
1895;15-years old first drink at 13 years or younger, (%)-Female;82.66666666666666;0.0705327691232438
1896;15-years old first drink at 13 years or younger, (%);82.66666666666666;-10374.801169630377
1897;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Female;15.555555555555557;0.2847157227591688
1898;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Both sexes;15.555555555555557;0.3235841505052286
1899;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Male;15.555555555555557;0.333733674591008
1900;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-9747.64406100051
1901;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Female;15.555555555555557;0.2847157227591688
1902;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Both sexes;15.555555555555557;0.3235841505052286
1903;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Male;15.555555555555557;0.333733674591008
1904;Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-9747.643049475984
1905;Alcohol, average daily intake in grams among drinkers with 95%CI-Both sexes;15.555555555555557;0.24354556486638312
1906;Alcohol, average daily intake in grams among drinkers with 95%CI-Female;15.555555555555557;0.24306879911271606
1907;Alcohol, average daily intake in grams among drinkers with 95%CI-Male;15.555555555555557;0.25960141442069995
1908;Alcohol, average daily intake in grams among drinkers with 95%CI;15.555555555555557;-8969.609489486113
1909;Alcohol, average daily intake in grams among drinkers with 95%CI-Both sexes;15.555555555555557;0.24354556486638312
1910;Alcohol, average daily intake in grams among drinkers with 95%CI-Female;15.555555555555557;0.24306879911271606
1911;Alcohol, average daily intake in grams among drinkers with 95%CI-Male;15.555555555555557;0.25960141442069995
1912;Alcohol, average daily intake in grams among drinkers with 95%CI;15.555555555555557;-8969.60898372385
1913;Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016;17.33333333333333;-9748.899888516995
1914;Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016;17.33333333333333;-9748.899888516995
1915;Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI-Male;45.333333333333336;0.05367705815922541
1916;Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI-Female;45.333333333333336;0.039011131603587934
1917;Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI-Both sexes;45.333333333333336;0.0633420027031324
1918;Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI;45.333333333333336;-10121.1409069862
1919;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Both sexes;51.111111111111114;0.04628043206290933
1920;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Female;51.111111111111114;0.03126124390385199
1921;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Male;51.111111111111114;0.045554855166821895
1922;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI;51.111111111111114;-10187.922038852681
1923;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Female;51.111111111111114;0.03126124390385199
1924;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Both sexes;51.111111111111114;0.04628043206290933
1925;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI-Male;51.111111111111114;0.045554855166821895
1926;Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI;51.111111111111114;-10187.922038852681
1927;15-19 years old heavy episodic drinkers (population), % with 95%CI-Female;15.555555555555557;0.36025499333154
1928;15-19 years old heavy episodic drinkers (population), % with 95%CI-Both sexes;15.555555555555557;0.42267741234672807
1929;15-19 years old heavy episodic drinkers (population), % with 95%CI-Male;15.555555555555557;0.43773653283788416
1930;15-19 years old heavy episodic drinkers (population), % with 95%CI;15.555555555555557;-8805.331916465773
1931;15-19 years old heavy episodic drinkers (population), % with 95%CI-Female;15.555555555555557;0.36025499333154
1932;15-19 years old heavy episodic drinkers (population), % with 95%CI-Both sexes;15.555555555555557;0.42267741234672807
1933;15-19 years old heavy episodic drinkers (population), % with 95%CI-Male;15.555555555555557;0.43773653283788416
1934;15-19 years old heavy episodic drinkers (population), % with 95%CI;15.555555555555557;-8805.331916465773
1935;15-19 years old heavy episodic drinkers (drinkers only), %-Female;15.555555555555557;0.3353438369003898
1936;15-19 years old heavy episodic drinkers (drinkers only), %-Male;15.555555555555557;0.35366392980189554
1937;15-19 years old heavy episodic drinkers (drinkers only), %-Both sexes;15.555555555555557;0.1736904271962172
1938;15-19 years old heavy episodic drinkers (drinkers only), %;15.555555555555557;-8805.312358074152
1939;15-19 years old abstainers, lifetime (%)-Female;15.555555555555557;0.3546339392149216
1940;15-19 years old abstainers, lifetime (%)-Male;15.555555555555557;0.34521342682369394
1941;15-19 years old abstainers, lifetime (%);15.555555555555557;-9747.64001490241
1942;15-19 years old abstainers, lifetime (%)-Female;15.555555555555557;0.3546339392149216
1943;15-19 years old abstainers, lifetime (%)-Male;15.555555555555557;0.34521342682369394
1944;15-19 years old abstainers, lifetime (%);15.555555555555557;-9747.64001490241
1945;15-19 years old former drinkers (%)-Female;15.555555555555557;0.19843891965782623
1946;15-19 years old former drinkers (%)-Male;15.555555555555557;0.17975498526099187
1947;15-19 years old former drinkers (%);15.555555555555557;-9747.7036847375
1948;15-19 years old former drinkers (%)-Female;15.555555555555557;0.19843891965782623
1949;15-19 years old former drinkers (%)-Male;15.555555555555557;0.17975498526099187
1950;15-19 years old former drinkers (%);15.555555555555557;-9747.706529153907
1951;15-19 years old, current drinkers (%)-Both sexes;15.555555555555557;0.17602834170254145
1952;15-19 years old, current drinkers (%)-Female;15.555555555555557;0.34819272716304006
1953;15-19 years old, current drinkers (%)-Male;15.555555555555557;0.3524867625647694
1954;15-19 years old, current drinkers (%);15.555555555555557;-8805.308824270627
1955;15-19 years old, current drinkers (%)-Female;15.555555555555557;0.34819272716304006
1956;15-19 years old, current drinkers (%)-Both sexes;15.555555555555557;0.17602834170254145
1957;15-19 years old, current drinkers (%)-Male;15.555555555555557;0.3524867625647694
1958;15-19 years old, current drinkers (%);15.555555555555557;-8805.308318508363
1959;15-19 years old total alcohol consumption in litres of pure alcohol-Male;16.0;0.3325251432520737
1960;15-19 years old total alcohol consumption in litres of pure alcohol-Female;16.0;0.28805274274864257
1961;15-19 years old total alcohol consumption in litres of pure alcohol-Both sexes;16.0;0.3123782258666994
1962;15-19 years old total alcohol consumption in litres of pure alcohol;16.0;-9752.695416481598
1963;15-19 years old total alcohol consumption in litres of pure alcohol-Male;16.0;0.3325251432520737
1964;15-19 years old total alcohol consumption in litres of pure alcohol-Both sexes;16.0;0.3123782258666994
1965;15-19 years old total alcohol consumption in litres of pure alcohol-Female;16.0;0.28805274274864257
1966;15-19 years old total alcohol consumption in litres of pure alcohol;16.0;-9752.695416481598
1967;National guidelines for the prevention and reduction of alcohol-related harm in schools;0.0;
1968;National guidelines for alcohol problem prevention and counselling at workplaces;0.0;
1969;National guidelines for alcohol problem prevention and counselling at workplaces;0.0;
1970;Workplace representatives nationally involved to prevent and address alcohol-related harm;0.0;
1971;Workplace representatives nationally involved to prevent and address alcohol-related harm;0.0;
1972;Server training;0.0;
1973;Server training;0.0;
1974;Legal obligation for schools to include alcohol use prevention;0.0;
1975;Legal obligation for schools to include alcohol use prevention;0.0;
1976;Legal obligation for schools to interact with parents regarding education and well-being;0.0;
1977;Legal obligation for schools to interact with parents regarding education and well-being;0.0;
1978;Legislation on alcohol testing at workplaces;0.0;
1979;Legislation on alcohol testing at workplaces;0.0;
1980;Standard drink defined;0.0;
1981;Standard drink defined;0.0;
1982;National systems for monitoring alcohol consumption and harms;0.0;
1983;National systems for monitoring alcohol consumption and harms;0.0;
1984;Regular reports from national monitoring systems;0.0;
1985;Regular reports from national monitoring systems;0.0;
1986;Comprehensive and regular reporting of alcohol situation;0.0;
1987;Comprehensive and regular reporting of alcohol situation;0.0;
1988;Clinical guidelines for brief interventions;0.0;
1989;Clinical guidelines for brief interventions;0.0;
1990;National surveys on adult alcohol consumption;0.0;
1991;National surveys on adult alcohol consumption;0.0;
1992;National surveys on youth alcohol consumption;0.0;
1993;National surveys on youth alcohol consumption;0.0;
1994;National surveys on heavy espisodic drinking;0.0;
1995;National surveys on heavy espisodic drinking;0.0;
1996;Data collection on Foetal Alcohol Syndome;0.0;
1997;Data collection on Foetal Alcohol Syndome;0.0;
1998;Data collected on harm from alcohol at workplace;0.0;
1999;Data collected on harm from alcohol at workplace;0.0;
2000;Level of enforcement of BAC limits;0.0;
2001;15-years old any alcoholic beverage consumed in past 12 months, (%)-Female;68.44444444444444;0.08030933203872026
2002;15-years old any alcoholic beverage consumed in past 12 months, (%)-Male;68.44444444444444;0.07879738750265242
2003;15-years old any alcoholic beverage consumed in past 12 months, (%)-Both sexes;68.44444444444444;0.12341073835052674
2004;15-years old any alcoholic beverage consumed in past 12 months, (%);68.44444444444444;-10225.446175174575
2005;15-years old any alcoholic beverage consumed in past 12 months, (%)-Both sexes;68.44444444444444;0.12341073835052674
2006;15-years old any alcoholic beverage consumed in past 12 months, (%)-Male;68.44444444444444;0.07879738750265242
2007;15-years old any alcoholic beverage consumed in past 12 months, (%)-Female;68.44444444444444;0.08030933203872026
2008;15-years old any alcoholic beverage consumed in past 12 months, (%);68.44444444444444;-10225.446175174575
2009;15-years old first drink at 13 years or younger, (%)-Female;82.66666666666666;0.0705327691232438
2010;15-years old first drink at 13 years or younger, (%)-Both sexes;82.66666666666666;0.06632966187795031
2011;15-years old first drink at 13 years or younger, (%)-Male;82.66666666666666;0.0677648362509422
2012;15-years old first drink at 13 years or younger, (%);82.66666666666666;-10374.801169630377
2013;15-years old any alcoholic beverage consumed in past 30 days, (%)-Both sexes;74.66666666666666;0.12651301416095873
2014;15-years old any alcoholic beverage consumed in past 30 days, (%)-Female;74.66666666666666;0.06697048182211329
2015;15-years old any alcoholic beverage consumed in past 30 days, (%)-Male;74.66666666666666;0.06298544592956556
2016;15-years old any alcoholic beverage consumed in past 30 days, (%);74.66666666666666;-10328.89370733591
2017;15-years old any alcoholic beverage consumed in past 30 days, (%)-Both sexes;74.66666666666666;0.12651301416095873
2018;15-years old any alcoholic beverage consumed in past 30 days, (%)-Female;74.66666666666666;0.06697048182211329
2019;15-years old any alcoholic beverage consumed in past 30 days, (%)-Male;74.66666666666666;0.06298544592956556
2020;15-years old any alcoholic beverage consumed in past 30 days, (%);74.66666666666666;-10328.89370733591
2021;15-years old, any alcoholic beverage consumed at least once a week, (%)-Male;82.66666666666666;0.06170278558781783
2022;15-years old, any alcoholic beverage consumed at least once a week, (%)-Female;82.66666666666666;0.06784803971534892
2023;15-years old, any alcoholic beverage consumed at least once a week, (%);82.66666666666666;-10374.800663868114
2024;15-years old, any alcoholic beverage consumed at least once a week, (%)-Male;82.66666666666666;0.06170278558781783
2025;15-years old, any alcoholic beverage consumed at least once a week, (%)-Female;82.66666666666666;0.06784803971534892
2026;15-years old, any alcoholic beverage consumed at least once a week, (%);82.66666666666666;-10374.800663868114
2027;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Female;75.55555555555556;0.06790405242140274
2028;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Male;75.55555555555556;0.06739829015904597
2029;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Both sexes;75.55555555555556;0.0668925278966892
2030;13-15-years old any alcoholic beverage consumed in past 30 days, (%);75.55555555555556;-10399.52868462723
2031;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Male;75.55555555555556;0.06739829015904597
2032;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Female;75.55555555555556;0.06790405242140274
2033;13-15-years old any alcoholic beverage consumed in past 30 days, (%)-Both sexes;75.55555555555556;0.0668925278966892
2034;13-15-years old any alcoholic beverage consumed in past 30 days, (%);75.55555555555556;-10399.52868462723
2035;13-15-years old first drink before age 14, (%)-Both sexes;75.11111111111111;0.10263825795708437
2036;13-15-years old first drink before age 14, (%)-Female;75.11111111111111;0.08075814413215676
2037;13-15-years old first drink before age 14, (%)-Male;75.11111111111111;0.09364634282807582
2038;13-15-years old first drink before age 14, (%);75.11111111111111;-10384.858452343668
2039;13-15-years old first drink before age 14, (%)-Female;75.11111111111111;0.08075814413215676
2040;13-15-years old first drink before age 14, (%)-Both sexes;75.11111111111111;0.10263825795708437
2041;13-15-years old first drink before age 14, (%)-Male;75.11111111111111;0.09364634282807582
2042;13-15-years old first drink before age 14, (%);75.11111111111111;-10384.857946581405
2043;Alcohol-related road traffic crashes with fatalities, per 100,000  population;82.22222222222223;-9967.702988319315
2044;Alcohol-related road traffic crashes with fatalities, per 100,000  population;82.22222222222223;-9967.702988319315
2045;Alcohol-related crimes (% of all crimes);90.22222222222223;-10570.343347631777
2046;Alcohol-related crimes (% of all crimes);90.22222222222223;-10570.343347631777
2047;National drinking guidelines;0.0;
2048;Graduated licensing;0.0;
2049;National legislation to prevent illegal alcohol sales;0.0;
2050;Penalties for drink driving, repeated offense;0.0;
2051;Licensing required for exports of alcoholic beverages;0.0;
2052;Licensing required for imports of alcoholic beverages;0.0;
2053;Licensing required for wholesale/distribution of alcoholic beverages;0.0;
2054;Licenses issued for production, change since 2010;0.0;
2055;Licenses issued for retail sale, change since 2010;0.0;
2056;Licenses issued for wholesale/distribution, change since 2010;0.0;
2057;Monopoly on exports of alcoholic beverages;0.0;
2058;Monopoly on imports of alcoholic beverages;0.0;
2059;Monopoly on wholesale /distribution of alcoholic beverages;0.0;
2060;Health warning labels on pregnancy;0.0;
2061;Health warning labels on under-age drinking;0.0;
2062;Health warning labels on drink-driving;0.0;
2063;Legal requirement for size of health warning labels;0.0;
2064;Cancer, age-standardized death rates (15+), per 100,000 population;0.0;
2065;Alcohol-attributable fractions (15+), cancer deaths;0.0;
2066;National system of epidemiological data collection for alcohol use;0.0;
2067;National system of data collection based on health service delivery;0.0;
2068;Report with epidemiological data on lcohol use and AUDs;0.0;
2069;Report with data from health services on alcohol use and AUDs;0.0;
2070;National organization for monitoring alcohol;0.0;
2071;Taxation of ethanol production;0.0;
2072;Ethanol tax deducted from excise tax;0.0;
2073;Tax incentives for production low/no alcohol content beer;0.0;
2074;Tax incentives for production of other alcoholic beverages;0.0;
2075;Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2020 and 2025;16.0;-9785.541781841399
2076;Heavy episodic drinking (youth 15 -19 years) past 30 days (%)-Female;16.0;0.1476240960618882
2077;Heavy episodic drinking (youth 15 -19 years) past 30 days (%)-Male;16.0;0.17343260223673562
2078;Heavy episodic drinking (youth 15 -19 years) past 30 days (%)-Both sexes;16.0;0.16751851624788028
2079;Heavy episodic drinking (youth 15 -19 years) past 30 days (%);16.0;-9767.096933161865
2080;Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%)-Female;16.0;0.17641013531346061
2081;Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%)-Both sexes;16.0;0.1736904271962172
2082;Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%)-Male;16.0;0.18045623341231476
2083;Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%);16.0;-9767.089976458843
2084;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-7946.7237214575725
2085;Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI;15.555555555555557;-7946.7237214575725
2086;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Both sexes;16.0;0.40480624945611154
2087;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Female;16.0;0.3171896528841889
2088;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Male;16.0;0.43792220150085504
2089;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI;16.0;-7924.354099753661
2090;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Both sexes;16.0;0.40480624945611154
2091;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Female;16.0;0.3171896528841889
2092;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI-Male;16.0;0.43792220150085504
2093;Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI;16.0;-7924.355457236152
2094;Alcohol, tourist consumption (in litres of pure alcohol);16.0;-9734.679986208237
2095;Alcohol, tourist consumption (in litres of pure alcohol);16.0;-9734.679986208237
2096;Alcohol, regional alcohol per capita (15+) consumption (in litres of pure alcohol);0.0;
2097;Regional prevalence, AAFs (15+), liver cirrhosis deaths (%);0.0;
2098;Regional prevalence, AAFs (15+), road traffic crash deaths (%);0.0;
2099;Regional prevalence, AAFs (15+), cancer;0.0;
2100;Regional prevalence, AAFs ,all-cause deaths (%);0.0;
2101;Average price 500 mls Beer in US$;25.77777777777777;-9885.298212758164
2102;Average price 750 mls Wine in US$;41.333333333333336;-10063.96085022168
2103;Average price 500 mls Spirits in US$;70.22222222222223;-10467.291519683922
2104;Births attended by skilled health personnel (in the two or three years preceding the survey) (%);49.33333333333333;-8278.011944406111
2105;Births attended by skilled health personnel (in the five years preceding the survey) (%);66.22222222222223;-9199.373212014165
2106;Number of deaths attributed to non-communicable diseases, by type of disease and sex;18.66666666666667;-15.682835484453737
2107;Ambient and household air pollution attributable death rate (per 100 000 population)-Both sexes;18.66666666666667;0.9809985020819636
2108;Ambient and household air pollution attributable death rate (per 100 000 population)-Female;18.66666666666667;0.9809985020819636
2109;Ambient and household air pollution attributable death rate (per 100 000 population)-Male;18.66666666666667;0.9809985020819636
2110;Ambient and household air pollution attributable death rate (per 100 000 population);18.66666666666667;-9757.285138704374
2111;Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized)-Female;18.66666666666667;0.9806054500941213
2112;Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized)-Both sexes;18.66666666666667;0.9809985020819636
2113;Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized)-Male;18.66666666666667;0.9809985020819636
2114;Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized);18.66666666666667;-9757.285138704374
2115;Completeness of cause-of-death data (%);47.55555555555555;-10282.8732783247
2116;Estimated direct deaths from major conflicts (per 100 000 population);18.66666666666667;-9757.327157160384
2117;Average death rate due to natural disasters (per 100 000 population)-Male;18.66666666666667;0.15581920408829575
2118;Average death rate due to natural disasters (per 100 000 population)-Female;18.66666666666667;0.1546696449582905
2119;Average death rate due to natural disasters (per 100 000 population)-Both sexes;18.66666666666667;0.15581920408829575
2120;Average death rate due to natural disasters (per 100 000 population);18.66666666666667;-9757.316144080949
2121;Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years (%);20.444444444444443;-9816.556043426863
2122;New HIV infections (per 1000 uninfected population);41.333333333333336;-9.806243662416922
2123;Average of 13 International Health Regulations core capacity scores;13.777777777777771;-5596.811051909513
2124;Reported number of people requiring interventions against NTDs;13.777777777777771;-2386.352712266973
2125;Total net official development assistance to medical research and basic health sectors per capita (constant 2014 US$), by recipient;39.11111111111111;-9858.64153496792
2126;Total net official development assistance to medical research and basic health sectors per capita (US$), by recipient country;37.33333333333333;-6771.766191011071
2127;Concentrations of fine particulate matter (PM2.5);13.777777777777771;-4688.325207383976
2128;Mortality rate attributed to unintentional poisoning (per 100 000 population);18.66666666666667;-15.682835484453737
2129;Skilled health professionals density (per 10 000 population);20.888888888888886;-9506.920840407036
2130;Crude suicide rates (per 100 000 population);18.66666666666667;-15.777690627787145
2131;Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2)-Male;18.66666666666667;0.18682458066441443
2132;Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2)-Female;18.66666666666667;0.18682458066441443
2133;Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2)-Both sexes;18.66666666666667;0.18682458066441443
2134;Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2);18.66666666666667;-9757.285138704374
2135;Children aged 36-59 months who are developmentally on track in at least three of the following domains: literacy-numeracy, physical development, social-emotional development and learning (%);73.33333333333333;-10358.274717173455
2136;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%)-Both sexes;59.55555555555556;0.2231624862976811
2137;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%)-Female;59.55555555555556;0.17388878876742098
2138;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%)-Male;59.55555555555556;0.1733830265050642
2139;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%);59.55555555555556;-9602.952501221334
2140;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%)-Both sexes;76.88888888888889;0.13231116000086018
2141;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%)-Female;76.88888888888889;0.09595158133954884
2142;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%)-Male;76.88888888888889;0.09765976493207873
2143;Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%);76.88888888888889;-10106.661950664628
2144;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%)-Both sexes;53.77777777777778;0.3421089566859812
2145;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%)-Male;53.77777777777778;0.282492254604938
2146;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%)-Female;53.77777777777778;0.282492254604938
2147;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%);53.77777777777778;-8831.593573295686
2148;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%)-Both sexes;62.666666666666664;0.13846864405447468
2149;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%)-Female;62.666666666666664;0.09572340622154529
2150;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%)-Male;62.666666666666664;0.09572340622154529
2151;Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%);62.666666666666664;-9977.990957281852
2152;Participation rate in organized learning (one year before the official primary entry age) (%)-Both sexes;29.777777777777786;1.3302247871903123
2153;Participation rate in organized learning (one year before the official primary entry age) (%)-Female;29.777777777777786;1.198913001913545
2154;Participation rate in organized learning (one year before the official primary entry age) (%)-Male;29.777777777777786;1.2473656062261442
2155;Participation rate in organized learning (one year before the official primary entry age) (%);29.777777777777786;-4573.751619865002
2156;Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%)-Male;64.88888888888889;0.21296874809139021
2157;Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%)-Both sexes;64.88888888888889;0.27476041350477054
2158;Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%)-Female;64.88888888888889;0.21347451035374698
2159;Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%);64.88888888888889;-9448.462449767552
2160;Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%)-Both sexes;78.22222222222223;0.12042385953295609
2161;Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%)-Female;78.22222222222223;0.07780939824226962
2162;Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%)-Male;78.22222222222223;0.07730363597991285
2163;Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%);78.22222222222223;-10172.843646091442
2164;Proportion of countries that have conducted at least one population and housing census in the last 10 years (%);0.0;
2165;Proportion of girls and women aged 15-49 years who have undergone female genital mutilation/cutting (FMG/C) (%);87.11111111111111;-10494.11404329089
2166;Percentage of children under 15 years exposed to second-hand smoke;0.0;
2167;Second-hand smoke attributable DALYs ('000) in children under 5 years;0.0;
2168;Second-hand smoke  attributable DALYs per 100'000 children under 5 years;0.0;
2169;Percentage of women (15+ years) exposed to second-hand smoke;0.0;
2170;Percentage of men (15+ years) exposed to second-hand smoke;0.0;
2171;Second-hand smoke attributable deaths;0.0;
2172;Second-hand smoke attributable DALYs ('000);0.0;
2173;Second-hand smoke attributable deaths per 100'000 capita;0.0;
2174;Second-hand smoke attributable DALYs per 100'000 capita;0.0;
2175;Second-hand smoke attributable deaths ('000) in children under 5 years;0.0;
2176;Second-hand smoke  attributable deaths per 100'000 children under 5 years;0.0;
2177;Proportion of population below the international poverty line of US$1.90 per day (%);30.222222222222214;-5399.966140645888
2178;Proportion of women aged 20-24 years who were married or in a union by age 15 (%);44.888888888888886;-9921.277917513022
2179;Proportion of women aged 20-24 years who were married or in a union by age 18 (%);44.888888888888886;-9921.253526343453
2180;Stunting prevalence in children aged < 5 years (%)-nan;54.22222222222222;0
2181;Stunting prevalence in children aged < 5 years (%)-Female;54.22222222222222;0.43137034624289816
2182;Stunting prevalence in children aged < 5 years (%)-Male;54.22222222222222;0.43137034624289816
2183;Stunting prevalence in children aged < 5 years (%);54.22222222222222;-8699.574831094049
2184;Existence of national regulation;0.0;
2185;Existence of subnational regulation;0.0;
2186;Year of national implementation of regulation;0.0;
2187;Access restrictions;0.0;
2188;Restriction and inspection of facilities;0.0;
2189;Information requirements;0.0;
2190;Safety requirements;0.0;
2191;Training requirements;0.0;
2192;Tuberculosis treatment coverage;13.777777777777771;-2.150105394333316
2193;New cases tested for RR-/MDR-TB (%);14.666666666666657;-1888.0329149396503
2194;Previously treated cases tested for RR-/MDR-TB (%);16.0;-1917.9642526458094
2195;Laboratories providing tuberculosis diagnostic services using culture (per 5 million population);15.111111111111114;-3554.1543929109166
2196;Laboratories providing drug susceptibility testing (DST) (per 5 million population);16.0;-3658.4278705394386
2197;Laboratories providing tuberculosis diagnostic services using sputum smear microscopy (per 100 000 population);18.66666666666667;-3509.2617879372556
2198;Treatment success rate for patients treated for MDR-TB (%);22.222222222222214;-3038.959713693357
2199;Cases started on MDR-TB treatment;13.777777777777771;-2029.8789079036849
2200;Treatment success rate for new pulmonary smear-negative and extrapulmonary tuberculosis cases;21.333333333333343;-5566.6258682917905
2201;Treatment success rate: new TB cases;13.777777777777771;-95.28532694752084
2202;Tuberculosis - new and relapse cases;13.777777777777771;0.3972971183819518
2203;Total number of notified TB cases;13.777777777777771;-1980.6394416502933
2204;Treatment success rate: previously treated TB cases;16.0;-384.2099412395227
2205;Treatment success rate: HIV-positive TB cases;24.444444444444443;-3503.904964055998
2206;Treatment success rate: XDR-TB cases;48.88888888888889;-7947.564020713792
2207;Confirmed cases of MDR-TB started treatment for MDR-TB (%);28.0;-7373.960490740562
2208;Number of incident tuberculosis cases;13.777777777777771;1.913407425727196
2209;Number of incident tuberculosis cases in children aged 0 - 14;13.777777777777771;-9775.912719853948
2210;Estimated MDR-TB cases among notified pulmonary TB cases;16.0;-9739.729997818
2211;Number of deaths due to tuberculosis, excluding HIV;14.222222222222229;1.8278443558612212
2212;Number of prevalent tuberculosis cases;13.777777777777771;-863.4536190750046
2213;Tuberculosis effective treatment coverage (%);14.666666666666657;-369.9760347729181
2214;HIV-positive TB patients on ART (antiretroviral therapy) (%);28.0;-1797.0373253124296
2215;HIV-positive TB patients on CPT (co-trimoxazole preventive therapy) (%);32.0;-4988.990687193627
2216;TB patients with known HIV status (%);17.777777777777786;-829.654883744707
2217;Tested TB patients HIV-positive (%);22.222222222222214;-960.3026186106756
2218;Confirmed cases of MDR-TB;15.555555555555557;-5356.99275326343
2219;New or unknown treatment history cases: Pulmonary, clinically diagnosed;13.777777777777771;-4147.211254654733
2220;New cases: extrapulmonary;13.777777777777771;-2.2525370932714814
2221;New or unknown treatment history cases: Pulmonary, bacteriologically confirmed;13.777777777777771;-3132.4886410816366
2222;New cases: other;15.555555555555557;-5309.055462708217
2223;New cases: pulmonary smear-negative;13.777777777777771;-1704.4771792598185
2224;New cases: Pulmonary, smear-negative/unknown/not done and other new cases;13.777777777777771;-1689.1728455638386
2225;New cases: Pulmonary, smear-positive;13.777777777777771;-1660.6461254750188
2226;New cases: pulmonary smear unknown/not done;13.777777777777771;-2882.6026710478213
2227;Treatment history unknown;14.222222222222229;-4839.117359034431
2228;Previously treated  cases, excluding relapse;13.777777777777771;-118.29926035772593
2229;Retreatment cases: other;13.777777777777771;-3507.1184609367288
2230;Relapse cases (pre-2013 definition);14.222222222222229;-1831.871828038385
2231;Relapse cases: Pulmonary, clinically diagnosed;16.888888888888886;-4815.7349548356515
2232;Relapse cases: extrapulmonary;16.888888888888886;-4841.321152212435
2233;Relapse cases: Pulmonary, bacteriologically confirmed;16.0;-4250.709375789749
2234;Retreatment cases: treatment after default (pulmonary smear and/or culture positive);14.222222222222229;-3183.012228457206
2235;Retreatment cases: treatment after failure (pulmonary smear and/or culture positive);14.222222222222229;-3109.0434209632263
2236;Confirmed cases of RR-/MDR-TB;13.777777777777771;-1238.1124086536402
2237;Second-line drug susceptibility testing (DST) available;0.0;
2238;Tuberculosis - new and relapse cases;13.777777777777771;0.3972971183819518
2239;Total fertility rate (per woman);59.11111111111111;-8807.675272096356
2240;Deaths attributable to the environment;13.777777777777771;-9730.299526273535
2241;Total environment  attributable DALYs per 100'000 children under 5 years;0.0;
2242;Deaths attributable to the environment in children under 5 years (%);0.0;
2243;DALYs attributable to the environment in children under 5 years (%);0.0;
2244;Age-standardized deaths attributable to the environment (per 100 000 population);13.777777777777771;-9730.299526273535
2245;Disability-adjusted life years (DALYs) attributable to the environment;13.777777777777771;-9730.299526273535
2246;Age-standardized DALYs attributable to the environment (per 100 000 population);13.777777777777771;-9730.299526273535
2247;Deaths attributable to the environment (%);13.777777777777771;-9730.384704782728
2248;Disability-adjusted life years (DALYs) attributable to the environment (%);13.777777777777771;-9730.387624321264
2249;Total environment attributable deaths ('000) in children under 5 years;0.0;
2250;Total environment  attributable deaths per 100'000 children under 5 years;0.0;
2251;Total environment attributable DALYs ('000) in children under 5 years;0.0;
2252;Under-five mortality rate (deaths per 1000 live births)-nan;59.11111111111111;0
2253;Under-five mortality rate (deaths per 1000 live births)-Female;59.11111111111111;0.4156174212317252
2254;Under-five mortality rate (deaths per 1000 live births)-Male;59.11111111111111;0.4156174212317252
2255;Under-five mortality rate (deaths per 1000 live births);59.11111111111111;-8816.04458628803
2256;Primary data availability for UHC Service Coverage Index (SDG 3.8.1) (%);13.777777777777771;-9789.075537428274
2257;Compliance with international health regulations;14.222222222222229;-6257.889169541768
2258;UHC Service Coverage Index (SDG 3.8.1);13.777777777777771;-5515.69468978241
2259;UHC Service Coverage sub-index on service capacity and access;13.777777777777771;-5515.76244394855
2260;UHC Service Coverage sub-index on infectious diseases;13.777777777777771;-5515.69468978241
2261;UHC Service Coverage sub-index on noncommunicable diseases;13.777777777777771;-5515.69468978241
2262;UHC Service Coverage sub-index on reproductive, maternal, newborn and child health;13.777777777777771;-5515.69468978241
2263;Children aged <5 years with diarrhoea receiving ORS (%);45.77777777777777;-8192.5443451264
2264;Women age 15-49 years who received a health check within 2 days after delivery of their most recent live birth in the last 2 years (%);62.22222222222222;-9761.613328121648
2265;Proportion of newborns who have postnatal contact with a health provider within 2 days of delivery (%);64.88888888888889;-9922.312800842596
2266;UV radiation;15.111111111111114;-9766.493139257938
2267;UV radiation attributable deaths;15.555555555555557;-9772.482388397075
2268;UV radiation attributable DALYs ('000);0.0;
2269;UV radiation attributable deaths per 100'000 capita;0.0;
2270;UV radiation attributable DALYs per 100'000 capita;0.0;
2271;Lifetime prevalence of child emotional abuse (%);0.0;
2272;Lifetime prevalence of child physical neglect (%);0.0;
2273;Lifetime prevalence of child physical abuse (%);0.0;
2274;Lifetime prevalence of child sexual abuse (%);0.0;
2275;Extent of implementation of  mental health services for victims of all types of violence;0.0;
2276;Child maltreatment: Extent of implementation of home-visiting programmes;0.0;
2277;Extent of implementation of child protection services;0.0;
2278;Elder abuse: Extent of implementation  of caregiver-support programmes;0.0;
2279;Intimate partner violence: Extent of implementation  of dating violence prevention programmes;0.0;
2280;Extent of implementation of medico-legal services for victims of sexual violence;0.0;
2281;Youth violence: Extent of implementation of life-skills and social development programmes;0.0;
2282;Estimates of number of homicides;18.66666666666667;-15.682835484453737
2283;Estimates of rates of homicides per 100 000 population;18.66666666666667;-15.682835484453737
2284;Children aged 6-59 months who received vitamin A supplementation (%)-nan;61.333333333333336;0
2285;Children aged 6-59 months who received vitamin A supplementation (%)-Female;61.333333333333336;0.40513517259368026
2286;Children aged 6-59 months who received vitamin A supplementation (%)-Male;61.333333333333336;0.40513517259368026
2287;Children aged 6-59 months who received vitamin A supplementation (%);61.333333333333336;-8578.556188335095
2288;Warning about the dangers of tobacco;13.333333333333329;-4713.281091580574
2289;Law mandates that health warnings appear on tobacco packages;0.0;
2290;Law mandates that health warnings appear on other smoked tobacco packages;0.0;
2291;Law mandates that health warnings appear on smokeless tobacco packages;0.0;
2292;Do the health warnings on cigarette packaging include a photograph or graphic?;0.0;
2293;Do the health warnings on other smoked tobacco packaging include a photograph or graphic?;0.0;
2294;Do the health warnings on smokeless tobacco packaging include a photograph or graphic?;0.0;
2295;Do health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale?;0.0;
2296;Do health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale?;0.0;
2297;Do health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale?;0.0;
2298;Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale;0.0;
2299;Health warnings on other smoked tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale;0.0;
2300;Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale;0.0;
2301;Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry;0.0;
2302;Health warnings on other smoked tobacco packaging do not remove or diminish the liability of the tobacco industry;0.0;
2303;Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry;0.0;
2304;Do health warnings on cigarette packaging describe the harmful effects of tobacco use on health?;0.0;
2305;Do health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health?;0.0;
2306;Do health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health?;0.0;
2307;Does the law mandate specific health warnings on cigarette packaging?;0.0;
2308;Does the law mandate specific health warnings on other smoked tobacco packaging?;0.0;
2309;Does the law mandate specific health warnings on smokeless tobacco packaging?;0.0;
2310;How many health warnings are approved by the law for cigarette packaging?;30.666666666666657;-6037.232392091921
2311;How many health warnings are approved by the law for other smoked tobacco packaging?;28.0;-6717.472307016718
2312;How many health warnings are approved by the law for smokeless tobacco packaging?;46.22222222222222;-7492.3634194455735
2313;Health warnings on cigarette packaging law requires or establishes fines for violations;0.0;
2314;Health warnings on other smoked tobacco packaging law requires or establishes fines for violations;0.0;
2315;Health warnings on smokeless tobacco packaging law requires or establishes fines for violations;0.0;
2316;Ban on deceitful terms on cigarette packaging;0.0;
2317;Ban on deceitful terms on other smoked tobacco packaging;0.0;
2318;Ban on deceitful terms on smokeless tobacco packaging;0.0;
2319;Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors;0.0;
2320;Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors;0.0;
2321;Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors;0.0;
2322;Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging;27.555555555555557;-6473.853635892262
2323;Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging;31.111111111111114;-7071.8854017942085
2324;Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging;42.22222222222223;-7645.631801687963
2325;Cigarette packaging and labelling must not use descriptors depicting flavours;0.0;
2326;Other smoked tobacco packaging and labelling must not use descriptors depicting flavours;0.0;
2327;Smokeless tobacco packaging and labelling must not use descriptors depicting flavours;0.0;
2328;Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark;0.0;
2329;Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark;0.0;
2330;Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark;0.0;
2331;Cigarette packaging and labelling must display qualitative information on relevant constituents and emissions;0.0;
2332;Other smoked tobacco packaging and labelling must display qualitative information on relevant constituents and emissions;0.0;
2333;Smokeless tobacco packaging and labelling must display qualitative information on relevant constituents and emissions;0.0;
2334;Cigarette packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas;99.55555555555556;-10749.600820933652
2335;Other smoked tobacco packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas;99.55555555555556;-10749.600820933652
2336;Smokeless tobacco packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas;99.55555555555556;-10749.600820933652
2337;Cigarette packaging and labelling must not display expiry dates;0.0;
2338;Other smoked tobacco packaging and labelling must not display expiry dates;0.0;
2339;Smokeless tobacco packaging and labelling must not display expiry dates;0.0;
2340;The quit line number must appear on cigarette packaging or labelling;0.0;
2341;The quit line number must appear on other smoked tobacco packaging or labelling;0.0;
2342;The quit line number must appear on smokeless tobacco packaging or labelling;0.0;
2343;Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited).;0.0;
2344;Plain packaging of other smoked tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited).;0.0;
2345;Congenital Rubella Syndrome - number of reported cases;15.111111111111114;-2447.822939120503
2346;Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited).;0.0;
2347;The sale of all smokeless tobacco products is completely banned;0.0;
2348;Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging;29.777777777777786;-6619.461029746489
2349;Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging;32.888888888888886;-7191.426802717119
2350;Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging;44.44444444444444;-7847.400179972722
2351;Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging;29.777777777777786;-6619.430944058482
2352;Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging;32.888888888888886;-7191.396324119984
2353;Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging;44.44444444444444;-7847.394764973172
2354;Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package;0.0;
2355;Health warnings on other smoked tobacco packaging must be placed at the top of the principal display areas of the package;0.0;
2356;Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package;0.0;
2357;Does the law mandate font style, font size and colour of health warnings on cigarette packaging?;0.0;
2358;Does the law mandate font style, font size and colour of health warnings on other smoked tobacco packaging?;0.0;
2359;Does the law mandate font style, font size and colour of health warnings on smokeless tobacco packaging?;0.0;
2360;Are the health warnings on cigarette packaging rotating?;0.0;
2361;Are the health warnings on other smoked tobacco packaging rotating?;0.0;
2362;Are the health warnings on smokeless tobacco packaging rotating?;0.0;
2363;Are the health warnings on cigarette packaging written in the principal language(s) of the country?;0.0;
2364;Are the health warnings on other smoked tobacco packaging written in the principal language(s) of the country?;0.0;
2365;Are the health warnings on smokeless tobacco packaging written in the principal language(s) of the country?;0.0;
2366;Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps;0.0;
2367;Health warnings on other smoked tobacco packaging must not be obscured in any way including by required markings such as tax stamps;0.0;
2368;Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps;0.0;
2369;Wasting prevalence in children aged < 5 years (%)-nan;54.22222222222222;0
2370;Wasting prevalence in children aged < 5 years (%)-Female;54.22222222222222;0.43010238119361865
2371;Wasting prevalence in children aged < 5 years (%)-Male;54.22222222222222;0.4295966189312619
2372;Wasting prevalence in children aged < 5 years (%);54.22222222222222;-8709.725364320902
2373;Life expectancy at birth (years)-Female;18.66666666666667;0.7331021103478741
2374;Life expectancy at birth (years)-Male;18.66666666666667;0.7331021103478741
2375;Life expectancy at birth (years)-Both sexes;18.66666666666667;0.7331021103478741
2376;Life expectancy at birth (years);18.66666666666667;-7079.589830220905
2377;Healthy life expectancy (HALE) at birth (years)-Male;18.66666666666667;0.7331021103478741
2378;Healthy life expectancy (HALE) at birth (years)-Both sexes;18.66666666666667;0.7331021103478741
2379;Healthy life expectancy (HALE) at birth (years)-Female;18.66666666666667;0.7331021103478741
2380;Healthy life expectancy (HALE) at birth (years);18.66666666666667;-7079.589830220905
2381;Adult mortality rate (probability of dying between 15 and 60 years per 1000 population);18.66666666666667;-346.6483493271914
2382;Infants exclusively breastfed for the first six months of life (%);40.0;-7472.528060214129
2383;Healthy life expectancy (HALE) at age 60 (years)-Female;18.66666666666667;0.7331021103478741
2384;Healthy life expectancy (HALE) at age 60 (years)-Both sexes;18.66666666666667;0.7331021103478741
2385;Healthy life expectancy (HALE) at age 60 (years)-Male;18.66666666666667;0.7331021103478741
2386;Healthy life expectancy (HALE) at age 60 (years);18.66666666666667;-7079.589830220905
2387;Stillbirth rate (per 1000 total births);13.333333333333329;-15.682835484453737
2388;Life expectancy at age 60 (years)-Male;18.66666666666667;0.7331021103478741
2389;Life expectancy at age 60 (years)-Female;18.66666666666667;0.7331021103478741
2390;Life expectancy at age 60 (years)-Both sexes;18.66666666666667;0.7331021103478741
2391;Life expectancy at age 60 (years);18.66666666666667;-7079.589830220905
2392;Preterm birth rate (per 100 live births);18.66666666666667;-9756.131721430665
2393;Civil registration coverage of cause-of-death (%);47.111111111111114;-9538.588140604972
2394;Ill-defined causes in cause-of-death registration (%);49.33333333333333;-10277.24016378406
2395;Distribution of years of life lost by major cause group;23.555555555555557;-8822.502396911483
2396;Age-standardized NCD mortality rate  (per 100 000 population);18.66666666666667;-15.682835484453737
2397;Deaths due to HIV/AIDS (per 100 000 population);57.33333333333333;-9436.519336879612
2398;Deaths due to malaria (per 100 000 population);0.0;
2399;Age-standardized mortality rate by cause (per 100 000 population) - Cancer;0.0;
2400;Age-standardized mortality rate by cause (per 100 000 population) - Cardiovascular;0.0;
2401;Distribution of years of life lost by broader causes (%) - Injuries;0.0;
2402;Diphtheria - number of reported cases;13.333333333333329;-543.1100590766468
2403;Japanese encephalitis - number of reported cases;24.8888888888889;-5865.218124194224
2404;Pertussis - number of reported cases;13.333333333333329;-431.1059736933806
2405;Number of new leprosy cases;13.777777777777771;-2162.68598246636
2406;Total tetanus - number of reported cases;13.333333333333329;-280.8113617227035
2407;Poliomyelitis - number of reported cases;13.777777777777771;-142.09179905256283
2408;Yellow fever - number of reported cases;14.222222222222229;-1009.8675151931277
2409;Number of reported cases of tuberculosis;0.0;
2410;Mumps - number of reported cases;19.111111111111114;-2486.6523242291814
2411;Neonatal tetanus - number of reported cases;13.333333333333329;-104.15662920735015
2412;Rubella - number of reported cases;13.333333333333329;-387.2926623916471
2413;Measles - number of reported cases;13.333333333333329;-12.558240793949121
2414;Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%);13.333333333333329;0.6749290468026232
2415;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%)-Female;45.333333333333336;0.4597691097362384
2416;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%)-nan;45.333333333333336;0
2417;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%)-Both sexes;45.333333333333336;0.5039956402753192
2418;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%)-Male;45.333333333333336;0.46900166380480357
2419;Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%);45.333333333333336;-8041.624863843224
2420;Children aged <5 years with diarrhoea receiving ORT (%);54.22222222222222;-9288.312410591067
2421;Children aged <5 years with ARI symptoms who took antibiotic treatment (%);61.333333333333336;-9805.605566179576
2422;Antenatal care coverage - at least one visit (%);29.33333333333333;-9845.668580432057
2423;Antenatal care coverage - at least one visit, among girls aged 15-19 (%);62.666666666666664;-10089.239027857571
2424;Births by caesarean section (%);23.555555555555557;-9822.671758020428
2425;Hepatitis B (HepB3) immunization coverage among 1-year-olds (%);15.555555555555557;-289.9556782417069
2426;Children aged 6-59 months who received vitamin A supplementation (%)-nan;61.333333333333336;0
2427;Children aged 6-59 months who received vitamin A supplementation (%)-Female;61.333333333333336;0.40513517259368026
2428;Children aged 6-59 months who received vitamin A supplementation (%)-Male;61.333333333333336;0.40513517259368026
2429;Children aged 6-59 months who received vitamin A supplementation (%);61.333333333333336;-8578.556188335095
2430;Neonates protected at birth against neonatal tetanus (PAB) (%);52.88888888888889;-509.3465782903503
2431;Hib (Hib3) immunization coverage among 1-year-olds (%);14.666666666666657;-884.4429622309796
2432;Antenatal care coverage - at least four visits (%);29.33333333333333;-7014.728935654781
2433;BCG immunization coverage among 1-year-olds (%);27.111111111111114;-59.9411740764529
2434;Polio (Pol3) immunization coverage among 1-year-olds (%);13.333333333333329;0.0966675479279826
2435;Population using solid fuels (%);50.22222222222222;-10038.405821232822
2436;Radiotherapy units (per 1 000 000 population);0.0;
2437;Median availability of selected generic medicines (%) - Private;83.11111111111111;-10487.243022046325
2438;Hospital beds (per 10 000 population);20.888888888888886;-4368.979036347021
2439;Median consumer price ratio of selected generic medicines - Private;85.77777777777777;-10531.69419555215
2440;Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%);13.333333333333329;0.09243921383161924
2441;Anti-tobacco mass media campaigns;13.333333333333329;-6199.36266468545
2442;SDG 3.9.2 WASH deaths;18.66666666666667;-9757.285138704374
2443;Number of diarrhoea deaths from inadequate water, sanitation and hygiene-Male;18.66666666666667;0.18682458066441443
2444;Number of diarrhoea deaths from inadequate water, sanitation and hygiene-Both sexes;18.66666666666667;0.3383332499231133
2445;Number of diarrhoea deaths from inadequate water, sanitation and hygiene-Female;18.66666666666667;0.18682458066441443
2446;Number of diarrhoea deaths from inadequate water, sanitation and hygiene;18.66666666666667;-9757.285138704374
2447;Number of diarrhoea deaths from inadequate hygiene-Both sexes;18.66666666666667;0.3308651162545666
2448;Number of diarrhoea deaths from inadequate hygiene-Male;18.66666666666667;0.18682458066441443
2449;Number of diarrhoea deaths from inadequate hygiene-Female;18.66666666666667;0.18682458066441443
2450;Number of diarrhoea deaths from inadequate hygiene;18.66666666666667;-9757.285138704374
2451;Number of diarrhoea deaths from inadequate sanitation-Both sexes;41.333333333333336;0.312334678154627
2452;Number of diarrhoea deaths from inadequate sanitation-Male;41.333333333333336;0.17258210408973973
2453;Number of diarrhoea deaths from inadequate sanitation-Female;41.333333333333336;0.17258210408973973
2454;Number of diarrhoea deaths from inadequate sanitation;41.333333333333336;-9873.295581053822
2455;Number of diarrhoea deaths from inadequate water-Both sexes;41.333333333333336;0.3190055912965324
2456;Number of diarrhoea deaths from inadequate water-Female;41.333333333333336;0.17258210408973973
2457;Number of diarrhoea deaths from inadequate water-Male;41.333333333333336;0.17258210408973973
2458;Number of diarrhoea deaths from inadequate water;41.333333333333336;-9873.295581053822
2459;Water, sanitation and hygiene attributable deaths ('000) in children under 5 years;0.0;
2460;Attributable fraction of diarrhoea to inadequate water, sanitation and hygiene;18.66666666666667;-9757.33436820805
2461;Attributable fraction of diarrhoea to inadequate hygiene;18.66666666666667;-9757.402888934566
2462;Attributable fraction of diarrhoea to inadequate sanitation;41.333333333333336;-9873.337696533252
2463;Attributable fraction of diarrhoea to inadequate water;41.333333333333336;-9873.345184252628
2464;Water, sanitation and hygiene attributable deaths per 100'000 capita;0.0;
2465;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene-Both sexes;18.66666666666667;0.3537387767998119
2466;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene-Female;18.66666666666667;0.18682458066441443
2467;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene-Male;18.66666666666667;0.18682458066441443
2468;Number of diarrhoea DALYs from inadequate water, sanitation and hygiene;18.66666666666667;-9757.285138704374
2469;Number of diarrhoea DALYs from inadequate hygiene-Female;18.66666666666667;0.18682458066441443
2470;Number of diarrhoea DALYs from inadequate hygiene-Male;18.66666666666667;0.18682458066441443
2471;Number of diarrhoea DALYs from inadequate hygiene-Both sexes;18.66666666666667;0.3537387767998119
2472;Number of diarrhoea DALYs from inadequate hygiene;18.66666666666667;-9757.285138704374
2473;Number of diarrhoea DALYs from inadequate sanitation-Male;41.333333333333336;0.17258210408973973
2474;Number of diarrhoea DALYs from inadequate sanitation-Both sexes;41.333333333333336;0.32889385279272876
2475;Number of diarrhoea DALYs from inadequate sanitation-Female;41.333333333333336;0.17258210408973973
2476;Number of diarrhoea DALYs from inadequate sanitation;41.333333333333336;-9873.295581053822
2477;Number of diarrhoea DALYs from inadequate water-Both sexes;41.333333333333336;0.32889385279272876
2478;Number of diarrhoea DALYs from inadequate water-Female;41.333333333333336;0.17258210408973973
2479;Number of diarrhoea DALYs from inadequate water-Male;41.333333333333336;0.17258210408973973
2480;Number of diarrhoea DALYs from inadequate water;41.333333333333336;-9873.295581053822
2481;Water, sanitation and hygiene  attributable deaths per 100'000 children under 5 years;0.0;
2482;Water, sanitation and hygiene attributable DALYs ('000);0.0;
2483;Water, sanitation and hygiene attributable DALYs ('000) in children under 5 years;0.0;
2484;Water, sanitation and hygiene attributable DALYs per 100'000 capita;0.0;
2485;Water, sanitation and hygiene  attributable DALYs per 100'000 children under 5 years;0.0;
2486;Population with basic handwashing facilities at home (%);53.77777777777778;-3655.6072331786477
2487;Population using safely managed sanitation services (%);41.77777777777778;-1289.3965817879568
2488;Population using safely managed drinking-water services (%);41.77777777777778;-1552.1827054054381
2489;General availability of Angiotensin II receptor blockers (ARBs) in the public health sector;0.0;
2490;Legislation and Financing;14.222222222222229;-8080.760874014337
2491;Early initiation of breastfeeding (in the two years preceding the survey) (%)-nan;48.88888888888889;0
2492;Early initiation of breastfeeding (in the two years preceding the survey) (%)-Female;48.88888888888889;0.3362011680270012
2493;Early initiation of breastfeeding (in the two years preceding the survey) (%)-Male;48.88888888888889;0.3362011680270012
2494;Early initiation of breastfeeding (in the two years preceding the survey) (%);48.88888888888889;-8256.199678651545
2495;Cheapest brand of cigarettes - price in PPP$;26.66666666666667;-9903.47525095018
2496;Sources of assistive products (%);90.22222222222223;-10748.371323297852
2497;Number of indigenous P. falciparum malaria cases;58.666666666666664;-5351.576192302131
2498;Cytisine - legally sold;13.333333333333329;-9743.918840708055
2499;Households further impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities) (%);85.77777777777777;-10216.361979974177
2500;Radiation Emergencies;14.222222222222229;-8080.82012447412
2501;Population with primary reliance on fuels and technologies)for cooking, by fuel type (in millions);42.22222222222223;-318.67961809669066
2502;Prevalence of current cigarette smoking among adolescents (%)-Female;20.0;0.1443428505846529
2503;Prevalence of current cigarette smoking among adolescents (%)-Male;20.0;0.1539523335694315
2504;Prevalence of current cigarette smoking among adolescents (%)-Both sexes;20.0;0.1499432128024325
2505;Prevalence of current cigarette smoking among adolescents (%);20.0;-9821.013977093287
2506;Number of imported malaria cases;74.22222222222223;-7981.96881202674
2507;Reported use of earmarked tobacco taxes;0.0;
2508;Zoonotic Events and the Human-animal Interface;14.222222222222229;-8080.839830400624
2509;Human Resources (SPAR);14.222222222222229;-8080.830575603498
2510;Population with primary reliance on polluting fuels and technologies for cooking (in millions);15.555555555555557;-30.94849088779845
2511;Surveillance (SPAR);14.222222222222229;-8080.8073892903785
2512;Population with access to an insecticide-treated bed net (ITN) for malaria protection (%), modelled;82.22222222222223;-9702.918869526022
2513;Prevalence of current smokeless tobacco use among adults (%)-Male;43.111111111111114;0.09778477048163081
2514;Prevalence of current smokeless tobacco use among adults (%)-Female;43.111111111111114;0.09249461370040857
2515;Prevalence of current smokeless tobacco use among adults (%)-Both sexes;43.111111111111114;0.08754263433646114
2516;Prevalence of current smokeless tobacco use among adults (%);43.111111111111114;-10104.132882329337
2517;Name of latest youth prevalence survey (nonsmoked);0.0;
2518;Reference level for dwellings (Bq/m3);99.55555555555556;-10759.301872830627
2519;Care-seeking by type of patient and source of care (%);0.0;
2520;Compliance with ban on promotional discounts (score);56.888888888888886;-10265.290463886598
2521;Representation of latest adult prevalence survey (nonsmoked);0.0;
2522;Year of latest youth prevalence survey (nonsmoked);0.0;
2523;Compliance with ban on appearance of tobacco products in TV and/or films (score);82.22222222222223;-10528.605327557785
2524;Total population pushed  further below the $3.20 a day poverty line by household health expenditures (millions);0.0;
2525;Compliance with smoke-free health-care facilities law (score);49.33333333333333;-10154.868572816416
2526;Existence of national reference level for workplaces;0.0;
2527;Estimated number of malaria deaths;52.44444444444444;-413.4294460981802
2528;Population pushed further below the $3.20 a day poverty line by household health expenditures (%);36.44444444444444;-7272.7398742092455
2529;Most sold brand of cigarettes - price in PPP$;16.0;-5017.110516985311
2530;Compliance with smoke-free government facilities law (score);57.33333333333333;-10251.362333317033
2531;Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark;0.0;
2532;Estimated malaria incidence (per 1000 population at risk);52.44444444444444;-429.6228714022937
2533;Risk Communication (SPAR);14.222222222222229;-8080.8240554616095
2534;Ban on tobacco vending machines;0.0;
2535;Subnational bans on tobacco advertising, promotion and sponsorship authority exists;0.0;
2536;Workforce availability for assistive technology;0.0;
2537;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months-Female;52.44444444444444;0.5526838084834185
2538;Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months;52.44444444444444;-10154.047519225622
2539;Proportion of health facilities with a core set of relevant essential medicines available and affordable on a sustainable basis;88.88888888888889;-10473.925357203967
2540;General availability of bone marrow transplantation in the public health system;0.0;
2541;Reference level for buildings with high public occupancy (Bq/m3);99.55555555555556;-10759.301872830627
2542;Points of Entry (SPAR);14.222222222222229;-8080.787052080186
2543;Mean hemoglobin level of children aged 6-59 months;13.333333333333329;-18.393287660550577
2544;Age range of latest adult prevalence survey (nonsmoked);0.0;
2545;Reporting countries;0.0;
2546;Cheapest brand of cigarettes - price in currency reported;24.0;-9889.579370709287
2547;Prevalence of previous diagnosis of hypertension among adults aged 30-79 with hypertension, age-standardized;13.333333333333329;-16.172424992748617
2548;Prevalence of daily smokeless tobacco use among adolescents (%)-Male;99.55555555555556;0.0005029112635823729
2549;Prevalence of daily smokeless tobacco use among adolescents (%)-Female;99.55555555555556;0.0005029112635823729
2550;Prevalence of daily smokeless tobacco use among adolescents (%);99.55555555555556;-10753.997143460134
2551;Availability of education/training for assistive technology;0.0;
2552;Overall compliance with bans on promotion and sponsorship (score);40.0;-10075.890819909784
2553;Mean hemoglobin level of pregnant women (aged 15-49 years);13.333333333333329;-18.652282264228525
2554;Existence of financial mechanisms for assistive technology;0.0;
2555;Existence of any subnational radon activity;0.0;
2556;Contraceptive prevalence - use of modern methods (%);50.666666666666664;-8349.487787677685
2557;Mean HDL cholesterol, age-standardized-Male;15.111111111111114;0.3392036067789528
2558;Mean HDL cholesterol, age-standardized-Female;15.111111111111114;0.39608331388396767
2559;Mean HDL cholesterol, age-standardized-Both sexes;15.111111111111114;0.35272031992350694
2560;Mean HDL cholesterol, age-standardized;15.111111111111114;-97.85226547625817
2561;Overall compliance with bans on direct advertising (score);37.33333333333333;-10044.197162732415
2562;Representativeness of most recent survey of adults;0.0;
2563;IHR Coordination and National IHR Focal Point Functions;14.222222222222229;-8080.789935779981
2564;Number of malaria suspects examined by microscopy;55.55555555555556;-4556.257792857261
2565;Estimated number of malaria cases;52.44444444444444;-403.0351132437557
2566;Compliance with smoke-free indoor offices law (score);67.55555555555556;-10355.72817531528
2567;Chemical Events;14.222222222222229;-8080.826475217774
2568;Prevalence of current e-cigarette use among adults (%)-Male;82.66666666666666;0.01806411623307458
2569;Prevalence of current e-cigarette use among adults (%)-Female;82.66666666666666;0.018569878495431347
2570;Prevalence of current e-cigarette use among adults (%)-Both sexes;82.66666666666666;0.018165263576979562
2571;Prevalence of current e-cigarette use among adults (%);82.66666666666666;-10629.223075281989
2572;Population pushed further  below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%);36.0;-7246.431865389687
2573;Laboratory (SPAR);14.222222222222229;-8080.772406612619
2574;Number of suspected malaria cases;55.55555555555556;-4243.401860047001
2575;Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in their lifetime;32.888888888888886;-9923.700756344517
2576;Prevalence of hypertension among adults aged 30-79 years, age-standardized-Female;13.333333333333329;1.9727610542882803
2577;Prevalence of hypertension among adults aged 30-79 years, age-standardized-Both sexes;13.333333333333329;1.962771376533635
2578;Prevalence of hypertension among adults aged 30-79 years, age-standardized;13.333333333333329;-16.57664960099231
2579;National Health Emergency Framework;14.222222222222229;-8080.765172609884
2580;Prevalence of hypertension among adults aged 30-79 years, crude-Both sexes;13.777777777777771;1.9981700425291689
2581;Prevalence of hypertension among adults aged 30-79 years, crude;13.777777777777771;-16.55033570335682
2582;Cytisine - place available;13.333333333333329;-9743.918840708055
2583;BCG immunization coverage among one-year-olds (%)-nan;52.44444444444444;0
2584;BCG immunization coverage among one-year-olds (%)-Female;52.44444444444444;0.5138717396575969
2585;BCG immunization coverage among one-year-olds (%)-Male;52.44444444444444;0.5131750805897806
2586;BCG immunization coverage among one-year-olds (%);52.44444444444444;-8342.742513176621
2587;Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months;30.666666666666657;-9896.983086503593
2588;Status of indigenous malaria cases;0.0;
2589;Publication year of the policy or plan (latest revision);0.0;
2590;Estimated number of tests performed where results were received by a person (testing volume), estimated number per 1000 population;56.44444444444445;-10105.822500767359
2591;Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, age-standardized-Both sexes;13.333333333333329;1.9948375467271247
2592;Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, age-standardized-Male;13.333333333333329;1.8038874564644405
2593;Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, age-standardized;13.333333333333329;-16.527456125047166
2594;Number of indigenous P. vivax malaria cases;69.77777777777777;-7226.545097792503
2595;Proportion of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA), median (%);62.22222222222222;-9650.567772047203
2596;Proportion of vaccination cards seen (%);45.77777777777777;-9953.015565890646
2597;Proportion of isolates with decreased susceptibility or resistance (DS/R) to cefixime reported to WHO-GASP;70.66666666666667;-9632.52013948665
2598;Number of indigenous malaria cases;55.55555555555556;-4036.5421196869925
2599;Inclusion of radon education for building professionals;0.0;
2600;Existence of initiatives/collaborations on assistive technology;0.0;
2601;Number of confirmed malaria cases;56.0;-4065.6531575041254
2602;Compliance with ban on indentifying non-tobacco products with tobacco brand names (score);71.55555555555556;-10406.747022358288
2603;Prevalence of anaemia in non-pregnant women (aged 15-49) (%)-nan;13.333333333333329;0
2604;Prevalence of anaemia in non-pregnant women (aged 15-49) (%);13.333333333333329;-16.42536090316566
2605;Satisfaction with assistive products for different environments and activities (%);90.22222222222223;-10748.371323297852
2606;Compliance with ban on advertising at point of sale (score);63.111111111111114;-10330.725257255393
2607;Number of malaria suspects examined by rapid diagnostic test (RDT);60.44444444444444;-5519.7017656087455
2608;Underweight prevalence in children aged < 5 years (%)-nan;54.22222222222222;0
2609;Underweight prevalence in children aged < 5 years (%)-Female;54.22222222222222;0.43010238119361865
2610;Underweight prevalence in children aged < 5 years (%)-Male;54.22222222222222;0.43010238119361865
2611;Underweight prevalence in children aged < 5 years (%);54.22222222222222;-8709.725364320902
2612;Care-seeking by type of patient and source of care (%) (see CARE_SOURCE);0.0;
2613;Status of endemicity of buruli ulcder;0.0;
2614;Compliance with smoke-free restaurants law (score);69.33333333333334;-10378.348949606388
2615;Estimate of current tobacco smoking prevalence (%)-Both sexes;27.111111111111114;0.8427205453439375
2616;Estimate of current tobacco smoking prevalence (%)-Male;27.111111111111114;0.8952641650477751
2617;Estimate of current tobacco smoking prevalence (%)-Female;27.111111111111114;0.6968666601084572
2618;Estimate of current tobacco smoking prevalence (%);27.111111111111114;-5536.62965122736
2619;Mean total cholesterol,  crude-Male;15.111111111111114;0.8374274188417345
2620;Mean total cholesterol,  crude-Female;15.111111111111114;0.812056504526137
2621;Mean total cholesterol,  crude-Both sexes;15.111111111111114;0.8400738047294625
2622;Mean total cholesterol,  crude;15.111111111111114;-97.23800293063914
2623;Households impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities) (%);85.77777777777777;-10216.364915833194
2624;Authorization/accreditation required for official radon measurement providers;0.0;
2625;Prevalence of daily smokeless tobacco use among adults (%)-Male;64.88888888888889;0.06311537264275069
2626;Prevalence of daily smokeless tobacco use among adults (%)-Female;64.88888888888889;0.06380619993397563
2627;Prevalence of daily smokeless tobacco use among adults (%)-Both sexes;64.88888888888889;0.06665721845765704
2628;Prevalence of daily smokeless tobacco use among adults (%);64.88888888888889;-10331.672471494196
2629;Ban on Corporate Social Responsibility activities (CSR);0.0;
2630;One-year-old children who have not received any doses of the DTP vaccine (%)-nan;51.55555555555556;0
2631;One-year-old children who have not received any doses of the DTP vaccine (%)-Female;51.55555555555556;0.5221522508232717
2632;One-year-old children who have not received any doses of the DTP vaccine (%)-Male;51.55555555555556;0.5221522508232717
2633;One-year-old children who have not received any doses of the DTP vaccine (%);51.55555555555556;-8302.063815893562
2634;Satisfaction with assistive products and related services (%);90.22222222222223;-10748.371323297852
2635;Barriers to accessing assistive products (%);90.22222222222223;-10748.371323297852
2636;Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, crude-Male;13.777777777777771;1.8140452269335228
2637;Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, crude-Both sexes;13.777777777777771;1.9909248938461404
2638;Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, crude;13.777777777777771;-16.537674089807645
2639;Compliance with ban on billboard and outdoor advertising (score);40.888888888888886;-10083.926163139517
2640;Prevalence of anaemia in women of reproductive age (aged 15-49) (%)-nan;13.333333333333329;0
2641;Prevalence of anaemia in women of reproductive age (aged 15-49) (%);13.333333333333329;-16.45777199021143
2642;Reported number of tests performed where results were received by a person (testing volume);56.0;-10105.822500767359
2643;Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension, age-standardized;13.333333333333329;-16.17348841325219
2644;Compliance with ban on advertising in local magazines and newspapers (score);41.77777777777778;-10099.762080448203
2645;Age range of most recent adolescent survey;0.0;
2646;Mean HDL cholesterol, crude-Male;15.111111111111114;0.3448257147270275
2647;Mean HDL cholesterol, crude-Female;15.111111111111114;0.38674074670067116
2648;Mean HDL cholesterol, crude-Both sexes;15.111111111111114;0.3521575887179602
2649;Mean HDL cholesterol, crude;15.111111111111114;-97.84301125576164
2650;Compliance with smoke-free education facilities except universities law (score);47.111111111111114;-10135.455039406388
2651;Title of most recent survey of adults;0.0;
2652;Existence of national radon map;0.0;
2653;Total population pushed   further  below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (millions);0.0;
2654;Travel distance to obtain assistive products (%);90.22222222222223;-10748.371323297852
2655;Institutional Births (birth taken place in a facility) (%);22.66666666666667;-5175.052844214818
2656;Population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%);35.55555555555556;-7198.499996677058
2657;Number of women of reproductive age (aged 15-49 years) with anaemia (thousands)-nan;13.333333333333329;0
2658;Number of women of reproductive age (aged 15-49 years) with anaemia (thousands);13.333333333333329;-15.68384700897845
2659;Estimate of current cigarette smoking prevalence (%) (age-standardized rate)-Both sexes;26.66666666666667;0.14968387883496392
2660;Estimate of current cigarette smoking prevalence (%) (age-standardized rate)-Male;26.66666666666667;0.14715506752318008
2661;Estimate of current cigarette smoking prevalence (%) (age-standardized rate)-Female;26.66666666666667;0.12624507357080983
2662;Estimate of current cigarette smoking prevalence (%) (age-standardized rate);26.66666666666667;-9909.749180312825
2663;Proportion of bloodstream infection due Escherichia coli resistant to 3rd-generation cephalosporin, median (%);61.77777777777778;-9600.319006394677
2664;Women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (%)-Female;40.888888888888886;0.5630074114218524
2665;Women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (%);40.888888888888886;-7926.947382118335
2666;Compliance with ban on free distribution in mail or through other means (score);50.22222222222222;-10167.570218785915
2667;Prevalence of daily tobacco smoking among adolescents (%)-Male;96.44444444444444;0.0031781472799243815
2668;Prevalence of daily tobacco smoking among adolescents (%)-Both sexes;96.44444444444444;0.0031781472799243815
2669;Prevalence of daily tobacco smoking among adolescents (%)-Female;96.44444444444444;0.0031781472799243815
2670;Prevalence of daily tobacco smoking among adolescents (%);96.44444444444444;-10730.972699330589
2671;Low birth weight (in thousands);35.111111111111114;-1720.8401505073075
2672;Low birth weight, prevalence (%);35.111111111111114;-1721.4606680827794
2673;Prevalence of need of assistive products (%)-nan;90.22222222222223;0
2674;Prevalence of need of assistive products (%)-Both sexes;90.22222222222223;0.004986605785878062
2675;Prevalence of need of assistive products (%)-Male;90.22222222222223;0.004986605785878062
2676;Prevalence of need of assistive products (%)-Female;90.22222222222223;0.004986605785878062
2677;Prevalence of need of assistive products (%);90.22222222222223;-10748.371323297852
2678;Existence of national policy instruments for occupational health and safety for health workers;0.0;
2679;Total population pushed further below the $1.90 a day poverty line by household health expenditures (%);0.0;
2680;Total population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (millions);0.0;
2681;Number of surveillance sites reporting to GLASS: In- and outpatient facilities;0.0;
2682;Total population pushed  further  below the $3.20 a day poverty line by household health expenditures (%);0.0;
2683;Indicator 16.2.1: Proportion of children aged 1-17 years who experienced any physical punishment and/or psychological aggression by caregivers in the past month;62.22222222222222;-10199.079714112006
2684;Proportion of isolates with decreased susceptibility or resistance (DS/R) to extended-spectrum cephalosporins reported to WHO-GASP;60.888888888888886;-8508.639267111235
2685;Process evaluation was employed to assess implementation of the campaign;0.0;
2686;Proportion of isolates with resistance to ciprofloxacin reported to WHO-GASP;61.77777777777778;-8440.026126625677
2687;Number of malaria cases treated with artemisinin-based combination therapies (ACTs);62.666666666666664;-9010.921078084924
2688;Number of children aged 6–59 months with anaemia (thousands)-nan;13.333333333333329;0
2689;Number of children aged 6–59 months with anaemia (thousands);13.333333333333329;-15.682835484453737
2690;Number of reported cases of poliomyelitis by wild poliovirus (WPV);18.66666666666667;-6288.758752414678
2691;Prevalence of current tobacco smoking among adults (%)-Male;36.44444444444444;0.10817986998476536
2692;Prevalence of current tobacco smoking among adults (%)-Female;36.44444444444444;0.09756274626459316
2693;Prevalence of current tobacco smoking among adults (%)-Both sexes;36.44444444444444;0.09208405523063634
2694;Prevalence of current tobacco smoking among adults (%);36.44444444444444;-10102.352190255206
2695;Number of malaria positive cases by microscopy;56.0;-4366.331278720625
2696;Prevalence of current smokeless tobacco use among adolescents (%)-Both sexes;44.888888888888886;0.11490897518216725
2697;Prevalence of current smokeless tobacco use among adolescents (%)-Male;44.888888888888886;0.11689035017061933
2698;Prevalence of current smokeless tobacco use among adolescents (%)-Female;44.888888888888886;0.11368129975894714
2699;Prevalence of current smokeless tobacco use among adolescents (%);44.888888888888886;-10053.092040880003
2700;Compliance with smoke-free pubs and bars law (score);71.55555555555556;-10398.775551072487
2701;Prevalence of current cigarette smoking among adults (%)-Male;58.22222222222222;0.11032288366375509
2702;Prevalence of current cigarette smoking among adults (%)-Female;58.22222222222222;0.09700910103551541
2703;Prevalence of current cigarette smoking among adults (%)-Both sexes;58.22222222222222;0.06314111834012825
2704;Prevalence of current cigarette smoking among adults (%);58.22222222222222;-10160.888728896709
2705;Girls aged 15 years old that received the recommended doses of HPV vaccine (%);57.33333333333333;-8317.933583965803
2706;Prevalence of daily cigarette smoking among adolescents (%)-Male;92.88888888888889;0.012697788892745532
2707;Prevalence of daily cigarette smoking among adolescents (%)-Female;92.88888888888889;0.012697788892745532
2708;Prevalence of daily cigarette smoking among adolescents (%)-Both sexes;92.88888888888889;0.012192026630388764
2709;Prevalence of daily cigarette smoking among adolescents (%);92.88888888888889;-10689.270741000677
2710;Existence of responsible ministry/authority on assistive technology;0.0;
2711;Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP;61.333333333333336;-8676.14825485187
2712;Representation of latest youth prevalence survey (nonsmoked);0.0;
2713;Number of pregnant women (aged 15-49 years) with anaemia (thousands)-nan;13.333333333333329;0
2714;Number of pregnant women (aged 15-49 years) with anaemia (thousands);13.333333333333329;-15.687893107077304
2715;Amount of water- and sanitation-related official development assistance that is part of a government-coordinated spending plan (current US$ millions);39.55555555555556;-9898.365907748348
2716;Year of most recent adolescent survey;0.0;
2717;Health Service Provision;14.222222222222229;-8080.7587168271075
2718;Prevalence of current tobacco use among adults (%)-Male;58.666666666666664;0.09710754854931425
2719;Prevalence of current tobacco use among adults (%)-Female;58.666666666666664;0.09704929704636722
2720;Prevalence of current tobacco use among adults (%)-Both sexes;58.666666666666664;0.06415606980720856
2721;Prevalence of current tobacco use among adults (%);58.666666666666664;-10194.678756461279
2722;Existence of legislation on access to assistive technology;0.0;
2723;Proportion of isolates with resistance to azithromycin reported to WHO-GASP;69.33333333333334;-9111.721528605582
2724;Prevalence of daily e-cigarette use among adolescents (%)-Male;96.88888888888889;0.004415623285979553
2725;Prevalence of daily e-cigarette use among adolescents (%)-Female;96.88888888888889;0.004415623285979553
2726;Prevalence of daily e-cigarette use among adolescents (%)-Both sexes;96.88888888888889;0.004415623285979553
2727;Prevalence of daily e-cigarette use among adolescents (%);96.88888888888889;-10727.586964978702
2728;Total number of surveillance sites reporting to GLASS;0.0;
2729;Ban on tobacco companies/the tobacco industry publicizing their CSR activities;0.0;
2730;Subnational smoking bans - at least one jurisdiction has a comprehensive ban in place;0.0;
2731;Increase in poverty gap due to household health expenditures, expressed as a proportion of a relative poverty line (60% of median daily per capita consumption or income) (%);36.0;-7244.618861798077
2732;Prevalence of anaemia in children aged 6–59 months (%)-nan;13.333333333333329;0
2733;Prevalence of anaemia in children aged 6–59 months (%);13.333333333333329;-16.319393003076968
2734;Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension, crude;13.777777777777771;-16.17818719454409
2735;Existence of national policies on trans-fatty acid elimination;0.0;
2736;Ban on entities other than tobacco companies/the tobacco industry publicizing the CSR activities of the tobacco companies/industry;0.0;
2737;Cheapest brand of cigarettes - price in US$ at official exchange rates;24.0;-9889.570514925867
2738;Mean Non-HDL cholesterol, crude-Male;15.111111111111114;0.8800113401778913
2739;Mean Non-HDL cholesterol, crude-Female;15.111111111111114;0.7853202352568043
2740;Mean Non-HDL cholesterol, crude-Both sexes;15.111111111111114;0.8447890139943981
2741;Mean Non-HDL cholesterol, crude;15.111111111111114;-97.34455133341557
2742;Coverage of people in need of assistive technology by legislation;0.0;
2743;Compliance with ban on sponsorship (contributions and/or publicity of contributions) (score);63.111111111111114;-10344.030301284227
2744;Compliance with ban on advertising on national television and radio (score);37.33333333333333;-10034.615973232003
2745;Cytisine - cost covered;13.333333333333329;-9743.918840708055
2746;ICD-11 implementation progress level;56.44444444444445;-10228.499892299697
2747;Reference level for workplaces (Bq/m3);99.55555555555556;-10759.301872830627
2748;Compliance with smoke-free public transport law (score);55.55555555555556;-10223.133860453792
2749;Nursing personnel (%)-Female;35.111111111111114;0.5274516828233646
2750;Nursing personnel (%)-Male;35.111111111111114;0.5279574450857214
2751;Nursing personnel (%);35.111111111111114;-8083.132847022485
2752;Mean total cholesterol,  age-standardized-Male;15.111111111111114;0.8157535859245715
2753;Mean total cholesterol,  age-standardized-Female;15.111111111111114;0.7621572221074309
2754;Mean total cholesterol,  age-standardized-Both sexes;15.111111111111114;0.8077116931362212
2755;Mean total cholesterol,  age-standardized;15.111111111111114;-97.29737321277695
2756;Subnational bans on advertising, promotion and sponsorship - at least one jurisdiction has a comprehensive ban in place;0.0;
2757;Year the law was enacted (latest revision);0.0;
2758;Number of malaria positive cases by rapid diagnostic test (RDT);60.0;-5583.854200888383
2759;Most sold brand of cigarettes - price in US$ at official exchange rates;13.333333333333329;-4956.355383605819
2760;Total population pushed  further below the $1.90 a day poverty line by household health expenditures (millions);0.0;
2761;Proportion of population with primary reliance on polluting fuels and technologies for cooking (%);15.555555555555557;-31.285436964528984
2762;Tax stamps, fiscal marks, banderole or other types of marking are applied on cigarettes;0.0;
2763;Households pushed below or further below a relative poverty line (reflecting basic needs: food, housing, utilities) by out-of-pocket payments (%);85.77777777777777;-10216.361474211915
2764;Prevalence of previous diagnosis of hypertension among adults aged 30-79 with hypertension, crude;13.777777777777771;-16.145686855259
2765;Compliance with ban on appearance of tobacco brands in TV and/or films (score);53.77777777777778;-10239.769658446547
2766;Number of malaria cases treated with any first  line tx courses (including artemisinin-based combination therapies (ACTs));61.333333333333336;-8976.81574019928
2767;Mean hemoglobin level of women of reproductive age (aged 15-49 years);13.333333333333329;-18.590370216357325
2768;Name of latest adult prevalence survey (nonsmoked);0.0;
2769;SDG 6.3.1 Proportion of safely treated domestic wastewater flows (%);48.88888888888889;-10225.281482237835
2770;Availability of government/registered services for assistive technology;0.0;
2771;Number of confirmed yaws cases reported;90.22222222222223;-10426.034121278592
2772;Full immunization coverage among one-year-olds (%)-nan;52.44444444444444;0
2773;Full immunization coverage among one-year-olds (%)-Female;52.44444444444444;0.5100307695418165
2774;Full immunization coverage among one-year-olds (%)-Male;52.44444444444444;0.5100307695418165
2775;Full immunization coverage among one-year-olds (%);52.44444444444444;-8367.041507528056
2776;Population pushed further below the $1.90 a day poverty line by household health expenditures (%);36.44444444444444;-7272.80941596271
2777;Population with primary reliance on clean fuels and technologies for cooking (in millions);15.555555555555557;-30.775691837206168
2778;Medical doctors (%)-Female;43.111111111111114;0.5243036692546159
2779;Medical doctors (%)-Male;43.111111111111114;0.5237979069922591
2780;Medical doctors (%);43.111111111111114;-7568.179569890604
2781;Estimated malaria mortality rate (per 100 000 population);52.44444444444444;-471.0001901658271
2782;Prevalence of current tobacco use among adolescents (%)-Male;40.0;0.14142594205490688
2783;Prevalence of current tobacco use among adolescents (%)-Female;40.0;0.13908802754858263
2784;Prevalence of current tobacco use among adolescents (%)-Both sexes;40.0;0.13570344676789148
2785;Prevalence of current tobacco use among adolescents (%);40.0;-9975.857012992574
2786;Affordability – category of change 2010-2020 (Yes (less affordable), No (more affordable), No change).;0.0;
2787;Age range of latest youth prevalence survey (nonsmoked);0.0;
2788;Obesity prevalence in non-pregnant women aged 15-49 years, BMI >= 30 (%);70.22222222222223;-9472.069187001594
2789;Severe wasting prevalence in children aged < 5 years (%)-nan;54.22222222222222;0
2790;Severe wasting prevalence in children aged < 5 years (%)-Female;54.22222222222222;0.43010238119361865
2791;Severe wasting prevalence in children aged < 5 years (%)-Male;54.22222222222222;0.4296162094214706
2792;Severe wasting prevalence in children aged < 5 years (%);54.22222222222222;-8709.725364320902
2793;Availability of public funding for assistive technology;0.0;
2794;Funding for assistive products (%);90.22222222222223;-10748.371323297852
2795;Year of most recent survey of adults;0.0;
2796;Number of isolates tested for ciprofloxacin;61.77777777777778;-8440.04679147283
2797;Prevalence of current tobacco smoking among adolescents (%)-Male;56.44444444444445;0.0830777332988828
2798;Prevalence of current tobacco smoking among adolescents (%)-Female;56.44444444444445;0.08257197103652603
2799;Prevalence of current tobacco smoking among adolescents (%)-Both sexes;56.44444444444445;0.08194224012273166
2800;Prevalence of current tobacco smoking among adolescents (%);56.44444444444445;-10263.353843802724
2801;Tax stamps, fiscal marks, banderole or other types of marking are applied on other tobacco products;0.0;
2802;Pregnant women attending antenatal care  at least once and receiving at least 3 doses of Intermittent Preventive Treatment of Malaria for Pregnant Women (IPTp3) (%);85.33333333333333;-7492.723754329631
2803;Measles immunization coverage among one-year-olds (%)-nan;51.55555555555556;0
2804;Measles immunization coverage among one-year-olds (%)-Female;51.55555555555556;0.5185271807741056
2805;Measles immunization coverage among one-year-olds (%)-Male;51.55555555555556;0.5185271807741056
2806;Measles immunization coverage among one-year-olds (%);51.55555555555556;-8315.5512720613
2807;Reported number of tests performed where results were received by a person (testing volume), reporting period;0.0;
2808;Number of presumed malaria cases;56.0;-4293.004357499158
2809;Total population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%);0.0;
2810;Title of most recent adolescent survey;0.0;
2811;Mean Non-HDL cholesterol, age-standardized-Male;15.111111111111114;0.8387350280916741
2812;Mean Non-HDL cholesterol, age-standardized-Female;15.111111111111114;0.7966399104615585
2813;Mean Non-HDL cholesterol, age-standardized-Both sexes;15.111111111111114;0.8069051959293954
2814;Mean Non-HDL cholesterol, age-standardized;15.111111111111114;-97.36773675409982
2815;Number of suspected yaws cases reported;87.55555555555556;-9659.97050071215
2816;Demand for family planning satisfied - use of modern methods (%);52.88888888888889;-8486.619181262105
2817;Number of isolates tested for azithromycin;69.33333333333334;-9111.694339927624
2818;Prevalence of daily cigarette smoking among adults (%)-Male;70.66666666666667;0.0631333433119905
2819;Prevalence of daily cigarette smoking among adults (%)-Female;70.66666666666667;0.04991163597965498
2820;Prevalence of daily cigarette smoking among adults (%)-Both sexes;70.66666666666667;0.04913594307058533
2821;Prevalence of daily cigarette smoking among adults (%);70.66666666666667;-10395.775563840838
2822;Existence of regulations/standards/guidelines/protocols on assistive technology;0.0;
2823;Estimate of current tobacco use prevalence (%) (age-standardized rate)-Both sexes;27.111111111111114;0.8578035327813684
2824;Estimate of current tobacco use prevalence (%) (age-standardized rate)-Male;27.111111111111114;0.897317253073703
2825;Estimate of current tobacco use prevalence (%) (age-standardized rate)-Female;27.111111111111114;0.7556334966793625
2826;Estimate of current tobacco use prevalence (%) (age-standardized rate);27.111111111111114;-5536.654128600415
2827;Number of non-pregnant women (aged 15-49 years) with anaemia (thousands)-nan;13.333333333333329;0
2828;Number of non-pregnant women (aged 15-49 years) with anaemia (thousands);13.333333333333329;-15.683341246716093
2829;Total population pushed  further  below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%);0.0;
2830;Ban on advertising at point of sale;0.0;
2831;Households with out-of-pocket payments greater than 40% of capacity to pay for health care (food, housing and utilities approach - developed by WHO/Europe) (%);85.77777777777777;-10216.36248573644
2832;Prevalence of current e-cigarette use among adolescents (%)-Male;60.888888888888886;0.053378854702908374
2833;Prevalence of current e-cigarette use among adolescents (%)-Female;60.888888888888886;0.053378854702908374
2834;Prevalence of current e-cigarette use among adolescents (%)-Both sexes;60.888888888888886;0.05658865856050044
2835;Prevalence of current e-cigarette use among adolescents (%);60.888888888888886;-10394.99622031915
2836;Prevalence of daily tobacco smoking among adults (%)-Male;43.111111111111114;0.09366674730950875
2837;Prevalence of daily tobacco smoking among adults (%)-Female;43.111111111111114;0.07236583679609687
2838;Prevalence of daily tobacco smoking among adults (%)-Both sexes;43.111111111111114;0.08359356496960979
2839;Prevalence of daily tobacco smoking among adults (%);43.111111111111114;-10167.535531208689
2840;Number of people protected from malaria by indoor residual spraying (IRS);69.33333333333334;-9422.316804928441
2841;Ban on sale of duty-free or excise-free cigarettes;0.0;
2842;Representativeness of most recent adolescent survey;0.0;
2843;Prevalence of anaemia in pregnant women (aged 15-49) (%)-nan;13.333333333333329;0
2844;Prevalence of anaemia in pregnant women (aged 15-49) (%);13.333333333333329;-16.45722071381742
2845;A minimum price policy is implemented;0.0;
2846;Average of 13 International Health Regulations core capacity scores, SPAR version, 1st edition;14.666666666666657;-8086.061438632001
2847;Compliance with smoke-free universities law (score);52.88888888888889;-10173.681243974064
2848;Polio immunization coverage among one-year-olds (%)-nan;51.55555555555556;0
2849;Polio immunization coverage among one-year-olds (%)-Male;51.55555555555556;0.8461300627432764
2850;Polio immunization coverage among one-year-olds (%)-Female;51.55555555555556;0.8456640814454208
2851;Polio immunization coverage among one-year-olds (%);51.55555555555556;-8321.808917069317
2852;Mean hemoglobin level of non-pregnant women (aged 15-49 years);13.333333333333329;-18.60352121371496
2853;Law requires fines for violations of advertising bans;0.0;
2854;Proportion of population with primary reliance on fuels and technologies for cooking, by fuel type (%);42.22222222222223;-320.3395867620846
2855;Compliance with ban on use of brand name of non-tobacco product for tobacco product (score);58.22222222222222;-10280.932963212314
2856;Law requires fines for violations of promotion and sponsorship bans;0.0;
2857;Food Safety (SPAR);14.222222222222229;-8080.827921234087
2858;DTP3 immunization coverage among one-year-olds (%)-nan;51.55555555555556;0
2859;DTP3 immunization coverage among one-year-olds (%)-Female;51.55555555555556;0.5149621344279867
2860;DTP3 immunization coverage among one-year-olds (%)-Male;51.55555555555556;0.5149621344279867
2861;DTP3 immunization coverage among one-year-olds (%);51.55555555555556;-8334.488921313763
2862;New leprosy child case detection rate (less than 15 years of age) per 1 000 000 child population;16.0;-5405.9413146371335
2863;Number of isolates tested for extended-spectrum cephalosporins;60.888888888888886;-8508.47000365097
2864;Number of isolates tested for ceftriaxone;61.333333333333336;-8675.963752375479
2865;Prevalence of use of assistive products (%)-nan;90.22222222222223;0
2866;Prevalence of use of assistive products (%)-Both sexes;90.22222222222223;0.004986605785878062
2867;Prevalence of use of assistive products (%)-Male;90.22222222222223;0.004986605785878062
2868;Prevalence of use of assistive products (%)-Female;90.22222222222223;0.004986605785878062
2869;Prevalence of use of assistive products (%);90.22222222222223;-10748.371323297852
2870;Prevalence of daily tobacco use among adults (%)-Male;77.33333333333334;0.03556062326751164
2871;Prevalence of daily tobacco use among adults (%)-Female;77.33333333333334;0.035981505743230446
2872;Prevalence of daily tobacco use among adults (%)-Both sexes;77.33333333333334;0.036500902125026435
2873;Prevalence of daily tobacco use among adults (%);77.33333333333334;-10531.061719509122
2874;Age range of most recent survey of adults;0.0;
2875;Total number of  malaria cases (presumed + confirmed cases);55.55555555555556;-3937.1077680910767
2876;Persistence to last grade of primary (% of cohort)-Male;28.0;0.8414923312753251
2877;Persistence to last grade of primary (% of cohort)-Female;28.0;0.8414923312753251
2878;Persistence to last grade of primary (% of cohort)-Both sexes;28.0;0.8951133124494604
2879;Persistence to last grade of primary (% of cohort);28.0;-6444.3698171345395
2880;Existence of national radon action plan - Years covered;0.0;
2881;Estimate of current tobacco smoking prevalence (%) (age-standardized rate)-Both sexes;27.111111111111114;0.8412292065462954
2882;Estimate of current tobacco smoking prevalence (%) (age-standardized rate)-Male;27.111111111111114;0.8892603798815069
2883;Estimate of current tobacco smoking prevalence (%) (age-standardized rate)-Female;27.111111111111114;0.697969276785662
2884;Estimate of current tobacco smoking prevalence (%) (age-standardized rate);27.111111111111114;-5536.658575213907
2885;Year of latest adult prevalence survey (nonsmoked);0.0;
2886;Prevalence of daily e-cigarette use among adults (%)-Male;95.55555555555556;0.0034480239433287707
2887;Prevalence of daily e-cigarette use among adults (%)-Female;95.55555555555556;0.0034480239433287707
2888;Prevalence of daily e-cigarette use among adults (%)-Both sexes;95.55555555555556;0.0034480239433287707
2889;Prevalence of daily e-cigarette use among adults (%);95.55555555555556;-10734.157621264265
2890;Overall compliance with regulations on smoke-free environments (score);40.888888888888886;-10097.684921895716
2891;Number of isolates tested for cefixime;70.66666666666667;-9632.44254704678
2892;Best-practice policy implemented for industrially produced trans-fatty acids (TFA) (Y/N);42.22222222222223;-2820.7117874259884
2893;nMx - age-specific death rate between ages x and x+n-Female;76.16716867469879;
2894;nMx - nMx - age-specific death rate between ages x and x+n-Both sexes;75.71536144578313
2895;nMx - age-specific death rate between ages x and x+n-Male;76.16716867469879;
